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1.1. Significance of natural sterols  
Sterols are omnipresent in living nature, whereby the most abundant sterols are cholesterol in 
mammals, β-sitosterol in plants and ergosterol in fungi (Figure 1a) [1]. 
 
Figure 1 a: Structures of cholesterol, β-sitosterol and ergosterol, b: Numbering and ring letters of steroids 
according to IUPAC [2]  
These sterols are synthesized de novo in most organisms starting from acetyl-CoA (coenzyme 
A) and isoprenoids, but they can also be acquired from diet [3]. The latter was shown for 
invertebrates like insects that lack an own de novo biosynthesis, but are able to synthesize the 
required sterols from dietary precursors [4]. The fact that sterols are vital for so many different 
species and that the enzyme squalene monooxygenase, which performs the initial step for 
sterol biosynthesis, has several conserved motifs throughout the different species [5, 6] gives 
a hint to the importance of sterols for early eukaryotic evolution. It has been suggested, see 
e.g. [6, 7], that sterols played an important role in the evolution from prokaryotes to eukaryotes. 
This evolutionary step is characterized by the development of cell compartments and the 
differentiation of cell organelles as well as the endocytosis and exocytosis [5]. All these 
processes involve rapid deformation of cell membranes, and sterols play a crucial role for 
membrane fluidity and function [5]. Due to their amphiphilic properties they are stored in 
between the phospholipids in the cell membranes. Cholesterol, for example, is oriented 
perpendicular to the membrane plane and causes an increase of the membrane’s stability [8]. 
Hence, sterols are essential building materials and a prerequisite for the function of every cell. 
Despite of their important physical properties, sterols like cholesterol act as precursors for 
further essential steroids or bile acids [3, 9]. The focus of this work is the mammalian sterol 
cholesterol and its biosynthesis and metabolism. 
1. Introduction 
2 
1.2. Steroid biosynthetic pathways 
1.2.1. Cholesterol 
Cholesterol de novo biosynthesis in mammals generally can take place in every tissue. 
However, the majority is synthesized in the liver [9, 10]. It is then distributed throughout the 
body via the blood circulation, when bound to specific transport proteins as very low density 
lipoprotein (VLDL) and low density lipoprotein (LDL) [9-11]. In the form of LDL, cholesterol is 
taken up into cells by LDL receptor mediated endocytosis, and excess cholesterol can be 
redistributed to the liver in the form of high density lipoprotein (HDL) [9, 11]. One exception to 
this cholesterol dissemination is the central nervous system (CNS). Almost all CNS cholesterol 
is synthesized de novo within the brain and it is remarkable that the CNS, which accounts for 
about 2% of the body mass, accounts for about one quarter of the whole unesterified 
cholesterol [11]. Cholesterol biosynthesis can be divided into pre- and post-squalene pathway. 
In Figure 2 the pre-squalene section and the involved enzymes and intermediates are shown. 
First, HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) (C6) is synthesized from three acetyl CoA 
(C2) building blocks. Following reduction of HMG-CoA leads to mevalonate (C6). After 
activation of mevalonate by conjugation with pyrophosphate and subsequent decarboxylation, 
isopentenyl diphosphate (IPP) (C5) and its isomer dimethylallyl diphosphate (C5) are formed. 
IPP is a central element of terpenoids, a huge group of natural products. Afterwards, farnesyl 
diphosphate (C15) is synthesized from tree IPP building blocks. The final product of this 




Figure 2 Pre-squalene pathway of cholesterol biosynthesis. Involved enzymes: A: acetyl-CoA acetyltransferase B: 
HMG-CoA synthase C: HMG-CoA reductase D: mevalonate kinase E: mevalonate-P kinase F: mevalonate-PP 
decarboxylase G: isopentenyl-PP isomerase H: geranyl-PP synthase I:  farnesyl-PP synthase J: squalene synthase 
[12, 13]. 
The second part of cholesterol biosynthesis starts with the epoxidation and cyclization of 
squalene to form lanosterol. The core pathway from lanosterol to cholesterol involves nine 
different enzymes that are integral membrane-bound proteins of the endoplasmic reticulum 
[13]. These steps can proceed via C24–C25 unsaturated intermediates (Bloch pathway), or 
via the corresponding C24–C25 saturated intermediates (Kandutsch-Russell pathway) [13]. 
Both pathways begin with C14 demethylation followed by elimination of both C3 methyl groups. 




Figure 3 Post-squalene pathway of cholesterol biosynthesis and involved enzymes. A: squalene epoxygenase B: 
2,3-oxidosqualene cyclase C: sterol C14-demethylase D: sterol C14-reductase E: methylsterol monooxygenase F: 
sterol 4α-carboxylate-3-dehydrogenase G: 3-keto steroid reductase H: sterol Δ8-Δ7-isomerase I: sterol Δ5-




Several congenital diseases are associated with malfunctions in cholesterol biosynthesis or 
cholesterol distribution. The most common disorder is the Smith-Lemli-Opitz syndrome (SLOS) 
which is caused by a defect of sterol Δ7-reductase (Figure 3, J) [12, 16, 17]. This enzyme 
catalyzes the reduction of 7-dehydrocholesterol to cholesterol as final step of cholesterol 
biosynthesis which leads to an accumulation of 7-dehydrocholesterol in the Kandutsch-Russell 
pathway [12, 16, 17]. This disease is characterized by growth retardation, malformations and 
intellectual deficiencies [16]. Further examples for cholesterol biosynthesis associated 
diseases are Antley-Bixler-syndrome, CHILD-syndrome (Congenital Hemidysplasia with 
Ichthyosiform nevus and Limb Defects) and desmosterolosis [17]. An example for a disease 
associated with cholesterol distribution is Niemann-Pick type C disease (NPC). NPC is a 
severe neurodegenerative disease and is characterized by an accumulation of cholesterol and 
other lipids in endosomes [18]. This is due to a mutation of the NPC protein 1, which is 




Oxysterols are phase 1 metabolites of cholesterol which are formed by hydroxylation of the 
ring structure or the side chain. Oxysterols are products of enzymatic hydroxylation and/or 
cholesterol autoxidation [19]. For example, 25-hydroxycholesterol is an autoxidation product 
of cholesterol, as well as a product of enzymatic hydroxylation (Figure 4) [19]. Oxysterols are 
formed by different CYP enzymes. One exception is cholesterol 25-hydroxylase, which is a 
member of a small enzyme class that uses diiron cofactors and is not a CYP enzyme [19-21]. 
The expression of the different enzymes and their corresponding oxysterols depends on the 
tissue. For example, cholesterol 24-hydroxylase is mainly expressed in neurons and sparsely 
in liver, while cholesterol 7α-hydroxylase is only expressed in liver [21]. In contrast cholesterol 
25-hydroxylase and cholesterol 27-hydroxylase can be found in many tissues [19, 21]. 
Especially sterol 27-hydroxylase has a broad substrate specificity and can form different 
oxysterols and plays a key role in steroid acid formation (Chapter 1.2.3) [19]. The major 
oxysterols and the respective enzymes of their biosynthesis are shown in Figure 4. Further 




Figure 4 Oxysterol biosynthesis starting from cholesterol and the respective enzymesl, A: cholesterol 7α-
hydroxylase (CYP 7A1) B: sterol 27-hydroxylase (CYP27A1) C: cholesterol 24-hydroxylase (CYP46A1) D: 
cholesterol 25-hydroxylase [O]: autoxidation [22]. 
Oxysterols have specific biological functions, like cholesterol, they are localized in the cell 
membrane but with different orientation and seem to have a destabilizing effect on the 
membrane [8]. Furthermore, oxysterols are ligands of nuclear receptors like liver X receptor 
(LXR) [8, 24]. Due to this interaction they affect lipid homeostasis and show immunomodulatory 
effects [8, 24, 25]. A known malfunction in oxysterol genesis is, for example, 7α-hydroxylase 
deficiency, leading to higher cholesterol levels in serum and liver and a decrease of bile acid 
formation [21]. Sterol 27-hydroxylase deficiency is the cause of cerebrotendinous 
xanthomatosis (CTX), due to the key role of 27-hydroxylase in bile acid formation. This disease 
is characterized by a decrease of bile acid formation and elevated cholesterol and cholestanol 
levels in blood and tissues like the CNS, which can lead to progressive neurological 
dysfunction [21, 26]. 
 
1.2.3. Steroid acids 
Oxysterols are further processed to bile acids by hydroxylation of the ring structure and side 
chain modifications. The involved enzymes have a broad substrate specificity so the order of 
the different reaction steps may vary [21]. The possible pathways can be roughly divided into 
acidic, 24-hydroxylase-, 25-hydroxylase- and neutral pathway (Figure 5) [21]. In the acidic 
pathway, the side chain is first oxidized to form the carboxylic acid, and the ring structure 
modifications are performed afterwards. In the other pathways, the ring structure is modified 
first, followed by the side chain oxidation. About 75% of the metabolized cholesterol is 
processed via the neutral pathway, also known as classic pathway, and about 25% are 
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processed following the acidic pathway [21]. The first bile acids that are formed along these 
pathways are known as primary bile acids. Examples are cholic acid and chenodeoxycholic 
acid [21]. It is remarkable that the structure of the primary bile acids can vary between different 
mammalian species, like muricholic acid which can only be found in mice, and ursodeoxycholic 
acid which is characteristic for bears [21]. Bile acids play an important role in digestion. They 
are excreted by the liver into the gut and can solubilize hydrophobic dietary components like 
fat-soluble vitamins and enable their absorption [27]. The primary bile acids can be further 
processed by bacteria in the gut to form the so-called secondary bile acids, for example, 
lithocholic acid and deoxycholic acid [21, 27]. Most bile acids excreted from the liver are bile 
acids conjugated to glycine or taurine, which are more amphiphilic [21]. So, the bile acid pool 
of an organism consists of a variety of diverse bile acids and is noticeably different between 
the species. A lack of bile acids, for example due to 3β-hydroxy-Δ5-C27-steroid oxidoreductase 
(Figure 5, D) deficiency, leads to neonatal jaundice, liver enlargement and malabsorption of 





Figure 5 Possible pathways of bile acid synthesis and the involved enzymes. grey: Structure variations arising from 
24- or 25-hydroxylase pathway. A: sterol 27-hydroxylase B: oxysterol 7α-hydroxylase (CYP 7B1) C: oxysterol 7α-
hydroxylase (CYP 39A1) D: 3β-hydroxy-Δ5-C27-steroid oxidoreductase E: sterol 12α-hydroxylase F: Δ4-3-
oxosteroid-5β-reductase G: 3α-hydroxysteroid dehydrogenase H: bile acid CoA ligase I: 2-methylacyl-CoA 
racemase J: branched-chain acyl-CoA oxidase K: D-bifunctional protein L: peroxisomal thiolase 2 M: 6β-




Cholesterol side chain hydroxylation at C20 and C22 by cholesterol monooxygenase leads to 
side chain cleavage and the formation of the C21 steroid pregnenolone (Figure 6). 
Pregnenolone is the precursor for several classes of steroid hormones like progestagens, 
mineralocorticoids, glucocorticoids, androgens and estrogens.  
 
 
Figure 6 Neurosteroid biosynthesis starting from cholesterol and involved enzymes. A: cholesterol monooxygenase 
B: 3β-hydroxysteroid dehydrogenase C: steroid-17α-hydroxylase-17,20-lyase D: oxysterol-7α-hydroxylase E: 20α-
hydroxysteroid dehydrogenase F: steroid-5α-reductase G: 3α-hydroxysteroid dehydrogenase H: steroid-5β-
reductase I: 3β-hydroxysteroid dehydrogenase [31-34]. 
As hormones, these steroids can bind to intracellular steroid hormone receptors and thereby 
modulate the transcription of distinct genes. In this way they can unfold huge effects even at 
low endogenous levels. The term “neurosteroids” originally referred to steroids that were 
synthesized within the nervous system [35, 36]. Later, this term was also used to describe the 
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neuromodulatory function of neurosteroids [37] and the additional term “neurosterols” was 
introduced to describe C27 neurosteroids [38]. In this work, the term “neurosteroids” refers to 
C19 and C20 steroids with focus on progestagens and androgens. These steroids do not only 
take effect via steroid hormone receptors, but can also bind to neurotransmitter receptors like 
γ-aminobutyric acid (GABAA) receptors [22, 35, 37, 39], N-methyl-D-aspartate (NMDA) 
receptors [22, 35] or sigma receptors [35]. They are known to play an important role in brain 
development, neuronal growth and plasticity [35]. In addition, they show neuroprotective 
effects, for example, after injuries or ischemia [35] and alterations in neurosteroids genesis are 
associated with neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease 
and multiple sclerosis [40].   
 
1.2.5. Sterol sulfates 
The hydroxyl group of sterols can be sulfo-conjugated by sulfotranferases [41]. Two different 
human hydroxysteroid sulfotransferases, SULT2A1 and SULT2B1, see Figure 7, are known 
[41]. The most important substrate of SULT2A1 is dehydroepiandrosterone with its 3β-hydroxyl 
group, but also steroids with 3α-, 17β- or phenolic hydroxyl groups can serve as substrate for 
SULT2A1 [41]. The enzyme SULT2B1 and especially the subtype SULT2B1b selectively 
sulfonates C3-hydroxy groups of C27 sterols [41, 42]. 
 
Figure 7 Biosynthesis of sterol sulfates. A: sulfotransferase (SULT2A1) B: sulfotransferase (SULT2B1b) [31, 41-
43]. 
In general, sterol sulfates cannot bind to intracellular steroid hormone receptors as the 
respective unconjugated sterols [44], but they still have inherent biological activities [45]. So, 
the sulfo-conjugates of the aforementioned neurosteroids are known to modulate GABAA 
receptors [46], NMDA receptors [46, 47] and melastatin-like transient receptor potential 
channels (TRPM1 and TRPM3) [46]. Sterol sulfates contribute significantly to reproduction [48] 
and cognitive performance [49]. Alterations in SULT activities are also associated with 
Alzheimer’s disease [50]. Cholesterol sulfate as C27 sterol sulfate is, beside 
dehydroepiandrosterone sulfate, the most abundant sterol sulfate in humans [42]. It modifies 
cell membrane stability and modulates the function of blood platelets [42, 51].  
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1.3. Steroids and Alzheimer’s disease 
At the “Deutsches Zentrum für neurodegenerative Erkrankungen” (DZNE), the research 
interest of the group of Prof. Dr. Harald Steiner is the enzyme γ-secretase, an enzyme 
associated with Alzheimer’s disease (AD) [52]. The amyloid precursor protein (APP) is a 
transmembrane glycoprotein and is amongst others cleaved by β-secretase and γ-secretase 
to form amyloid β (Aβ) peptides [52]. Depending on the length of the Aβ fragment, these 
peptides could aggregate and form extracellular plaques, which are characteristic for AD. The 
major species Aβ 1-40 and some shorter Aβ fragments aggregate less likely as the longer 
species Aβ 42 [53, 54]. So, the specific cleavage site of the γ-secretase is responsible for 
plaque formation and the factors which modulate the γ-secretase activity are therefore under 
investigation [53, 55]. In the group of Prof. Dr. Steiner, the impact of different steroids on γ-
secretase activity is investigated. They observed that free sterols and their corresponding 
sulfates can show contrary activities. Also Vaňková et al. [31] showed different concentrations 
of sterols and sterol sulfates in women with AD compared to healthy women. But not only 
neurosteroids and sterol sulfates are known to affect the γ-secretase, also steroid acids [29], 
cholesterol precursors [56, 57] and oxysterols [58] are under investigation. It remains unclear 
if γ-secretase is modulated via direct binding sites for steroids, or if an altered steroid 
composition in the membrane can influence γ-secretase activity because of the modified 
microenvironment. Effects of cholesterol binding to APP [59], membrane thickness [60] and 
the formation of lipid rafts [61] were already demonstrated. 
 
1.4. Steroid analysis 
The example of Alzheimer’s disease illustrates the multiple ways steroids are involved in the 
development of diseases. To learn more about these mechanisms a broad view on all the 
steroid classes in specific tissues or experimental cell lines is necessary. This kind of steroid 
analysis is hampered by the very similar structures within the single classes, for example 
pregnanolone and allopregnanolone, and the great differences in concentration which can vary 
by a factor of about 100,000 like cholesterol (~ 10 µg/mg) versus pregnenolone (< 0.1 ng/mg) 
in brain tissue (see Chapter 4). Some of the first analytical procedures, that are still used today, 
are radioimmunoassays (RIA). These play an important role in clinical diagnosis but show 
limited sensitivity and specificity, as cross-reactivities to similar steroids cannot be excluded 
[62-64]. In addition, these assays are not capable of giving information about the presence of 
possibly unexpected accumulating steroids. Such pitfalls can be avoided by mass 
spectrometry (MS) combined with chromatographic systems like gas chromatography-mass 
spectrometry (GC-MS) [62], liquid chromatography-mass spectrometry (LC-MS) [62] and even 
supercritical fluid chromatography-mass spectrometry (SFC-MS) [65]. The most popular 
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systems are LC-MS and GC-MS which have their own specific strengths. The “older” 
technology GC impresses with its huge separation power and, therefore, significant specificity 
even for isobaric steroids [66]. GC-MS systems usually apply electron ionization which is 
especially effective for lipophilic analytes and results in characteristic and highly reproducible 
mass spectra [64, 67]. This enables identification of unexpected compounds using MS-spectra 
libraries [64, 66]. But not every steroidal compound can by analyzed with GC because they 
need to be vaporable without decomposition. Thus, steroids are usually derivatized before GC-
MS analysis, and conjugated steroids, for example, steroid sulfates, also need to be cleaved 
before GC-MS analysis [64]. This makes sample preparation time-consuming and fault prone. 
LC-MS has its strengths in shorter run times and faster sample preparation [62, 64]. However, 
the shorter run time leads to a limited chromatographic resolution [62], so separation of very 
similar compounds cannot always be accomplished. In addition, the ionization of the usually 
applied electro spray procedure is not very effective for lipophilic steroids [64, 67]. Therefore, 
derivatization is also often used in LC-MS procedures [68]. On the other hand the more polar 
analytes like steroid acids or sterol sulfates are easily detected with LC-MS and can be 






Topic of this work was the development of a GC-MS based analytical procedure, to analyze 
the steroidome in tissue and cell samples. The term steroidome covers the whole set of 
steroids found in an organism or tissue [69]. Information about the steroidome is necessary to 
get a better understanding of the underlying pathomechanisms of diseases like, for example, 
Alzheimer’s disease. Hence, a comprehensive analytical method, that gives an as broad as 
possible view on the sterolome, is needed. Nevertheless, there was a focus on some steroids 
of special interest. Those steroids were defined by the group of Prof. Dr. Steiner at DZNE, 
based on their previous experimental results. Consequently, the method ought to include 
specific neurosteroids, oxysterols, sterol sulfates, steroid acids, but should still provide 
information about accumulating unexpected steroidal compounds. The method should be 
applied on biological samples like mouse brain or cultured cells. In order to achieve this goal 
some problems needed to be solved. As mentioned before the sterol sulfates are not vaporable 
without decomposition, so for GC-MS analysis a suitable method for deconjugation was 
required. In addition, the sterol sulfates needed to be separated from unconjugated sterols 
before deconjugation. But also unconjugated steroids needed some additional sample 
preparation before GC-MS analysis. To improve the peak shape and the sensitivity, hydrophilic 
functional hydroxyl groups are frequently derivatized to trimethylsilyl (TMS) ethers using a 
mixture of N-methyl-N-trimethylsilyl acetamide (MSTFA) and trimethylsilyl imidazole (TSIM). 
But this well-established procedure [14, 70, 71] was not sufficient for all steroids of interest, 
especially those with keto groups were subject to artefact formation [72]. So, an additional 
derivatization of the keto groups was necessary. For bile acid analysis an appropriate sample 
preparation procedure including carboxylate derivatization was needed, too. In addition, these 
different steroid classes had to be extracted from the tissue and separated from each other 
before derivatization. The main task of this work was the development of a suitable sample 
preparation procedure which ensured all these requirements. As mentioned before, the 
endogenous levels of some steroids of interest are very low (e.g. pregnenolone < 0.1 ng/mg). 
The well-established measurement in scan mode on an ion trap- (IT-) MS system [14, 66, 70, 
71] could not provide the required sensitivity and therefore, the development of an additional 
method in dynamic multiple reaction monitoring (dMRM) mode on a triple quadrupole- (QqQ-) 
MS system was also part of this work. 
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3. Sterol sulfate analysis 
 
J. Junker, I. Chong, F. Kamp, H. Steiner, M. Giera, C. Müller, F. Bracher, Comparison of 
strategies for the determination of sterol sulfates via GC-MS leading to a novel 
deconjugation-derivatization protocol, Molecules, 24 (2019) 2353 
 
3.1. Summary 
The impact of steroids and sterol sulfates on the γ-secretase activity is of special interest in 
the group of Prof. Dr. Steiner at DZNE. In their in vitro assays sterol sulfates have shown 
contrary effects compared to their unconjugated counterparts. These findings, in addition to 
reports of divergent sulfotransferase activity in AD patients [31, 50], show the necessity of an 
analytical method which enables the analysis of steroids as well as sterol sulfates in biological 
samples. As mentioned in Chapter 1.4, GC-MS is the analytical method of choice especially 
for untargeted “screening” analysis. However, the analysis of sterol sulfates with GC-MS is 
challenging, because these sterol conjugates are not vaporable without decomposition. For 
this reason, the sterol sulfates need to be cleaved and the free sterol must be derivatized to 
achieve sufficient sensitivity and reproducibility. In the following article we compared and 
discussed different strategies for deconjugation and derivatization of sterol sulfates on the 
basis of eight exemplary sterol sulfates. Therefore, “older” literature methods [73, 74] for 
chemical sulfate cleavage were adapted and modified for the analysis of smaller sample 
amounts. Also, an enzymatic procedure was investigated as a possible alternative to the 
chemical cleavage. The resulting free sterols were then converted into TMS or MO-TMS 
(methyloxime-trimethylsilyl) derivatives (Figure 8). Additionally, the direct derivatization using 
trifluoroacetic anhydride (TFAA) and the resulting trifluoroacetyl (TFA) derivatives were 
examined. I was also able to identify another direct derivatization procedure that was not 
previously reported. This novel deconjugation-derivatization protocol utilized the reagent O-
methylhydroxylamine hydrochloride (2% in pyridine). This reagent is usually used for 
derivatization of the keto groups and has shown to lead simultaneously to the cleavage of the 
sulfate esters. This could be explained with the relatively high nucleophilic properties of O-
methylhydroxylamine due to the so called α-effect. This new method was optimized and 
compared to the solvolysis and MO-TMS derivatization procedure (both well-established). All 
these strategies and the associated advantages and limitations were discussed in detail. 
Especially the discovery of the direct MO-TMS derivatization could simplify future sterol sulfate 
analysis with GC-MS. This method enables the deconjugation of sterol sulfates regardless of 
C5-C6 saturation or C3-configuration. Beside this wide application range, the finally resulting 
MO-TMS derivatives have excellent chromatographic properties and give meaningful mass 
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spectra that are frequently used and therefore can be found in many mass spectral libraries. 
This new method was an important element of the final sample preparation protocol for 
simultaneous analysis of neutral steroids, steroid acids and sterol sulfates (Chapter 4).  
 
Figure 8 Graphical abstract of the original article: Comparison of strategies for the determination of sterol sulfates 
via GC-MS leading to a novel deconjugation-derivatization protocol 
Some preliminary experiments focusing on the sterol sulfate pregnenolone sulfate have 
already been part of my diploma thesis [75]. These experiments included TMS derivatization, 
TFA derivatization, solvolysis with dioxane/acetic acid and enzymatic cleavage. The 
experiments on the other seven exemplary sterol sulfates and the use of O-methyl 
hydroxylamine hydrochloride for derivatization of the keto groups as well as the described 
novel direct deconjugation/derivatization procedure were part of my doctoral thesis.  
 
3.2. Personal contribution 
My contributions to this article were the previous research and conduction of preliminary 
experiments. Also, conceptualization, the final methodology and designs for the reported 
experiments were part of my contribution. The subsequent performance of the experiments, 
as well as the analysis of the measurement data, formal analysis and data curation was done 
by me. Finally, visualization of the experimental results, writing of the original draft as well as 
reviewing and editing were my contribution to this publication. 
The experiments were carried out with support of Isabelle Chong (internship in the Master, 
Pharmaceutical Sciences), who also contributed to the analysis of the measurement data, as 
well as the formal analysis. 
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Prof. Dr. Harald Steiner and Dr. Frits Kamp were involved in the conceptualization of the project 
as well as in granting of resources and acquisition of funding. They further contributed in 
reviewing and editing of the original draft. 
Dr. Martin Giera supported this publication regarding the investigation, formal analysis and 
data curation. He was also involved in reviewing and editing of the original draft. 
 Dr. Christoph Müller contributed in the planning of the experimental design and in the whole 
investigation. He was involved in the formal analysis and curation of the experimental data and 
further supported the visualization of these results. In addition, he contributed in the 
development of the article structure, writing of the original draft as well as reviewing and editing. 
Prof Dr. Franz Bracher supervised this work along with Prof. Dr Harald Steiner and Dr. Martin 
Giera and was involved in the conceptualization of the project. He also supported the 
investigation, formal analysis and curation of the experimental data. Additionally, he provided 
resources and contributed in reviewing and editing of the original draft.  
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3.3. Article  
The following article is printed in the original wording. The formatting may vary slightly 
compared to the original article. 
 molecules        
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Abstract: Sulfoconjugates of sterols play important roles as neurosteroids, neurotransmitters, 
and ion channel ligands in health and disease. In most cases, sterol conjugate analysis is 
performed with liquid chromatography-mass spectrometry. This is a valuable tool for routine 
analytics with the advantage of direct sterol sulfates analysis without previous cleavage 
and/or derivatization. The complementary technique gas chromatography-mass spectrometry 
(GC-MS) is a preeminent discovery tool in the field of sterolomics, but the analysis of sterol 
sulfates is hampered by mandatory deconjugation and derivatization. Despite the difficulties 
in sample workup, GC-MS is an indispensable tool for untargeted analysis and steroid 
profiling. There are no general sample preparation protocols for sterol sulfate analysis using 
GC-MS. In this study we present a reinvestigation and evaluation of different deconjugation 
and derivatization procedures with a set of representative sterol sulfates. The advantages and 
disadvantages of trimethylsilyl (TMS), methyloxime-trimethylsilyl (MO-TMS), and 
trifluoroacetyl (TFA) derivatives were examined. Different published procedures of sterol 
sulfate deconjugation, including enzymatic and chemical cleavage, were reinvestigated and 
examined for diverse sterol sulfates. Finally, we present a new protocol for the chemical 
cleavage of sterol sulfates, allowing for simultaneous deconjugation and derivatization, 
simplifying GC-MS based sterol sulfate analysis. 
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1. Introduction 
The sulfoconjugates of sterols, also called sterol sulfates, are synthesized in vivo by conversion of the 
respective sterols by specific cytosolic sulfotransferase enzymes (SULT) [1,2]. These sterol sulfates are 
much more than just terminal stages of steroid metabolism and reservoir of their free analogues [2,3]. 
Several sterol sulfates are known to activate, modulate and inhibit specific enzymes and ion channels. 
For example, pregnenolone sulfate (6), dehydroepiandrosterone sulfate (2) and epipregnanolone sulfate 
are known to modulate neurotransmitter receptors like the γ-aminobutyric acid type A (GABAA) and 
the N-methyl-d-aspartate (NMDA) receptors [4,5]. Furthermore, epipregnanolone sulfate and 
pregnenolone sulfate (6) are activators of melastatin-like transient receptor potential (TRPM) ion 
channels [3,4]. Steroid sulfates can also bind to membrane-associated G-protein coupled receptors 
(GPCRs) and activate MAP kinase cascade or phospholipase C [6]. Amongst other functions, 
cholesteryl sulfate (7) interferes with blood coagulation by activating Factor XII and inhibiting 
the serine proteases thrombin and plasmin [7,8]. The balance between sulfatation and 
desulfatation is fundamental for the tissue distribution and function of sterols and its 
dysregulation is involved in many diseases [9]. For instance, pregnenolone sulfate (6) and 
dehydroepiandrosterone sulfate (2) have been reported to be decreased in the brains of 
Alzheimer’s disease (AD) patients [10]. Altered levels of pregnenolone sulfate (6) and several 
other sterol conjugates have also been found in the blood female AD patients [11], which might 
be related to an attenuated activity of SULT2A1 in the adrenal zona reticularis [12].  
The analysis of sterol sulfates is hampered by the highly similar chemical structures of the 
sterol sulfates and their low abundance in biological samples. Several methodically different 
approaches are being applied in sterol sulfate analysis, the most common being 
radioimmunoassays (RIA), gas chromatography-mass spectrometry (GC-MS) and liquid 
chromatography-(tandem)mass spectrometry (LC-MS(/MS)). The major concerns about RIA 
are the need for using radioactive material as well as the low selectivity and possible cross-
reactivity of similar analytes in addition to matrix effects [13]. In the last decade LC-MS(/MS) 
was the predominantly-used method for sterol conjugate analysis [14]. In contrast to GC-MS, 
as the gold standard of neutral cholesterol metabolites analysis [15], LC-MS(/MS) provides the 
possibility to analyze the non-volatile sterol conjugates without prior deconjugation [13,16,17]. 
Moreover, faster workup without deconjugation and/or derivatization and shorter run times 
of liquid chromatography makes it a high throughput method for targeted analysis ideally 
suited for clinical purposes [13,14]. Nevertheless, LC-MS(/MS) also has disadvantages such as 
limited chromatographic resolution and detection by electrospray ionization (ESI) mass 
spectra, that contain limited structural information due to low fragmentation rates [13,18]. In 
these aspects GC-MS cannot be replaced by LC-MS, since its high chromatographic resolution 
and the option for recording information-rich electron ionization (EI) mass spectra makes GC-
MS a powerful tool for untargeted analyses and steroid profiling [13,16–19]. In particular, EI 
mass spectra of derivatives like sterol trimethylsilyl (TMS) ethers and methyloxime-
trimethylsilyl (MO-TMS) ethers provide considerable structural information which can help 
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to identify unknown steroidal analytes and can be used for suspected-target screening 
[18,20,21]. 
While these derivatization methods are well established for unconjugated steroids (free 
sterols including keto sterols, Figure 1) [20,22], there is no general procedure for the analysis 
of sterol sulfates using GC-MS. There are many different approaches published for 
deconjugation including enzymatic cleavage using sulfatases or chemical solvolysis, but an 
universally applicable method is lacking [23,24]. We discuss here in detail the most commonly 
used methods for deconjugation and derivatization for the GC-MS based analysis of sterol 
sulfates (Figure 1), and provide a significantly simplified procedure developed in the course 
of our investigations, allowing for simultaneous deconjugation and derivatization. 
  
Figure 1. Strategies for sterol sulfate determination utilizing gas chromatography-mass spectrometry (GC-
MS). “Two step” methods make use of a prior deconjugation step to form the free (unconjugated) sterol and 
a subsequent derivatization of the hydroxyl and, for methyloxime-trimethylsilyl (MO-TMS) derivatives, also 
the keto group. Direct derivatization refers to simultaneous cleavage of the sterol sulfate and derivatization. 
The deconjugation and derivatization strategies are shown with pregnenolone sulfate (6) here. TMS = 
derivatization to pregnenolone trimethylsilyl ether, MO-TMS = deconjugation/derivatization to pregnenolone 
methyloxime-trimethylsilyl ether, TFA = deconjugation/derivatization to pregnenolone trifluoroacetyl ester. 
 
Furthermore, we present a comprehensive re-investigation of published methods 
demonstrating the scope and limitations of different derivatization procedures including 
direct acylation and formation of TMS and MO-TMS ethers. Additionally, we present a new 
protocol which allows the direct formation of MO-TMS derivatives from sterol sulfates, 
effectively combining sulfate ester cleavage and the formation of methyloximes (MO). The 
residual free hydroxyl groups can then be selectively silylated in a second step. The 
experiments were carried out with a representative collection of eight sterol sulfates with 
and without keto groups including 3α- and 3β-sterol sulfates and ∆5-unsaturated and 
saturated sterols. The structures of the model analytes are shown in Figure 2. 
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Figure 2. Overview of the model analytes: 1 androsterone sulfate, 2 dehydroepiandrosterone sulfate, 3 
epiandrosterone sulfate, 4 allopregnanolone sulfate, 5 pregnanolone sulfate, 6 pregnenolone sulfate, 7 cholesterol 
sulfate, 8 25-hydroxycholesterol sulfate, and 9 cholestane (internal standard, IS). 
2. Results 
2.1. Derivatization Strategies for Free Sterols (Deconjugated Sterol Sulfates) 
2.1.1. Trimethylsilyl (TMS) Derivatives 
The most popular derivatization method for sterols is the formation of sterol TMS ethers 
[22,25–30]. For this derivatization free hydroxyl groups are required, so in the case of sterol 
sulfates a prior deconjugation step is mandatory. Available deconjugation procedures are 
subject of Section 2.3. 
For silylation several reagents with different silyl donor abilities are available. To ensure a 
complete derivatization even of sterically hindered tertiary hydroxyl groups, the addition of 
a catalyst like N-trimethylsilylimidazole (TSIM) and trimethyliodosilane and/or an auxiliary 
base like pyridine is necessary [25]. An established silylation mixture for complete 
derivatization of secondary and tertiary hydroxyl groups even at room temperature is N-
methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) with 10% TSIM [20,31]. A known 
difficulty in TMS derivatization is the presence of keto groups, because the formation of 
artifacts (identified as enol TMS ethers) can be observed under these conditions [32]. We 
investigated the extent of the reported artifact formation for the exemplary keto sterol 
pregnenolone. The observed total ion chromatogram (TIC) in Figure 3 shows one peak (I) for 
pregnenolone with only one TMS ether (silylated 3-OH) and three (II–IV) artifacts 
corresponding to pregnenolone derivatives with an additional enol TMS ether. The plausible 
structures of these derivatives are shown in Figure 3c [33]. 
One attempt to avoid the formation of mixtures of mono- and bis-silylated products has 
been the application of a stronger silylating reagent which should enhance the enol TMS 
formation. For this purpose trimethyliodosilane can be used. This reactive reagent is generated 
in situ in a mixture of MSTFA and ammonium iodide. A reducing agent such as 
mercaptoethanol is further added in order to avoid undesired side reactions resulting from 
accidentally formed iodine [33–38]. This method requires much effort for optimization 
depending on the analytes of interest [36]. In addition also with this procedure artifacts can be 
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observed, resulting from incorporation of mercaptoethanol [34,35]. In conclusion, silylation of 
keto sterols is cumbersome in most cases. 
2.1.2. Methyloxime-Trimethylsilyl (MO-TMS) Derivatives 
The problematic (and frequently inevitable) enol TMS ether formation of keto sterols can 
be avoided with a two-step derivatization protocol. In this approach the keto groups are 
converted into methoxylamine (synonym: oxime methyl ether; MO) derivatives first, typically 
using 2% O-methylhydroxylamine hydrochloride (m/v) in pyridine (Scheme 1). In a second 
step the hydroxyl groups can be selectively transformed into TMS ethers using the methods 
described in Section 2.1.1 [20,32,34,39]. 
However, with this method two isomeric MO derivatives (syn, anti) can be formed, which 
are partially or fully separated by GC giving two peaks with the same fragmentation patterns 
[32,40,41]. We were able to convert all exemplary keto sterol sulfates into their respective MO-
TMS derivatives after solvolysis (see Section 2.3). The acquired chromatogram in Figure 4a 
shows only one peak for each sterol derivative and no additional peaks or peak shoulders due 
to syn-/anti-isomers of the MO residues were observed. With this procedure keto sterols 
(derived from sulfates 1–6) and sterols without keto groups (derived from 7, 8) can be analyzed 
likewise. 
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Figure 3. (a) Total ion chromatogram (TIC) of pregnenolone-TMS derivatives (containing cholestane (IS)). (b) Mass 
spectra of resulting pregenolone TMS ethers peaks (I)–(IV) after derivatization with N-methyl-N-
trimethylsilyltrifluoroacetamide (MSTFA)/N-trimethylsilylimidazole (TSIM) (9:1). (c) Structures of pregnenolone-
mono-TMS ether (I) and pregnenolone-bis-TMS ethers (II–IV) [33]; for chromatographic and mass spectral 
characteristics see Supplementary Table S1. 
 
 





Figure 4. (a) Total ion chromatogram (TIC) of the eight sterol (MO-)TMS ethers and internal standard (IS). Analyzed 
sterols: 1 androsterone sulfate, 2 dehydroepiandrosterone sulfate, 3 epiandrosterone sulfate, 4 allopregnanolone 
sulfate, 5 pregnanolone sulfate, 6 pregnenolone sulfate, 7 cholesterol sulfate, 8 25-hydroxycholesterol sulfate, and 
9 cholestane (IS). * Impurity of silylating reagent; (b) mass spectrum of pregnenolone MO-TMS ether; (c) mass 
spectrum of cholesterol-TMS ether; (d) proposed fragmentations of pregnenolone MO-TMS ether according to 
literature [29]. For chromatographic and mass spectral characteristics see Supplementary Table S1. 
The mass spectra of these derivatives provide much structural information. They show the 
molecular ion peaks and characteristic fragmentations, which can be seen in Figure 4b,c. As 
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exemplarily shown for pregnenolone MO-TMS ether in Figure 4d the molecular ion [M]+ is 
observable, and the base peak m/z [M − 15 − 16]+ clearly indicates the fragmentation of the MO 
moiety. The ion m/z [M − 90]+ is typical for the loss of trimethylsilanol and the ions m/z [M − 
129]+ as well as m/z 129 are characteristic for ∆5-sterol TMS ethers referring to the loss of 
trimethylsilanol from C-3 together with C-1, C-2 and C-3 [42]. 
2.2. Direct Deconjugation/Derivatization of Sterol Sulfates to Give Trifluoroacetyl (TFA) Derivatives 
The problematic deconjugation step of sterol sulfates (for details see Section 2.3) can in 
certain cases be avoided if O-perfluoroacylation is chosen instead of TMS derivatization. The 
formation of perfluoroacyl derivatives is a fast and easy way to obtain volatile derivatives 
directly from sterol sulfates in one single operation. This method was first described by 
Touchstone and Dobbins [43] who used heptafluorobutyric anhydride (HFBA) in benzene to 
form the 3-O-acylated products directly from estriol sulfate and dehydroepiandrosterone 
sulfate (2). Also, Liere et al. [44] and Schumacher et al. [5] used successfully HFBA for the 
direct derivatization of 2 and 6 without prior sulfate deconjugation in one single step. 
Further investigations with different anhydrides, sterol sulfates and reaction conditions 
were performed by Murray and Baille [45], who observed that this direct derivatization 
protocol is limited to sulfates derived from ∆5-sterols and estrogens. They also showed that 
there is no need for using additional solvents like benzene, and demonstrated that the 
supplement of the auxiliary base pyridine, which is normally used to enhance the esterification 
of free sterols, even inhibits the reaction with sterol sulfates [45]. Complete derivatization of 
the ∆5-sterol sulfate dehydroepiandrosterone sulfate (2) was further obtained using 
trifluoroacetic anhydride (TFAA) without additional solvent reacted at 70 ◦C for 30 min. The 
authors [45] proposed an acid-catalyzed reaction which is shown in Scheme 2. 
  
Scheme 2. Mechanism for the acid-catalyzed reaction of ∆5-sterol sulfates with trifluoroacetic anhydride 
according to Murray and Baille [45]. 
We examined the scope of this direct derivatization protocol with the eight exemplary 
sterol sulfates shown in Figure 2. The results of this experiment are shown in Figure 5 and 
confirm the previously claimed limitation of this method to ∆5-sterol sulfates. The ∆5-
unsaturated sterol sulfates 2, 6, and 7 showed good results while the saturated sterol sulfates 
1, 3, 4, and 5 did not undergo noteworthy conversion. An exception is the ∆5-unsaturated 25-
hydroxycholesterol sulfate (8) whose TFA derivative was detected only in trace amounts 
(Figure 5a). The peak of analyte 8 in the chromatogram (Figure 5b) shows a peak shoulder and 
the corresponding mass spectra indicate an incomplete derivatization. The addition of 
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pyridine is not useful in this case because it would inhibit the deconjugation of the sulfated 
hydroxyl group at C-3 at the same time [45]. 
 
Figure 5. (a) Bar chart with mean base peak areas and standard deviations (n = 6) of the sterol TFA esters 
obtained by treatment of sterol sulfates 1–8 with trifluoroacetic anhydride. (b) Total ion chromatogram (TIC) 
of the eight sterol TFA esters and the internal standard, derived from: 1 androsterone sulfate, 2 
dehydroepiandrosterone sulfate, 3 epiandrosterone sulfate, 4 allopregnanolone sulfate, 5 pregnanolone 
sulfate, 6 pregnenolone sulfate, 7 cholesterol sulfate, 8 25-hydroxycholesterol sulfate, and 9 cholestane (IS). 
(c) Mass spectrum of pregnenolone TFA ester ([M]+ m/z 412). (d) Mass spectrum of cholesterol TFA ester ([M]+ 
m/z 482). For chromatographic and mass spectral characteristics see Supplementary Table S1. 
Another weakness of this approach is the missing molecular ion of ∆5-sterol acyl derivatives 
[26,42,46,47] which is evident from the mass spectra shown in Figure 5c,d. This fact may lead 
to difficulties in identification of unknown compounds. Besides the missing molecular ion 
peak and the incomplete derivatization for some sterols, the residual TFA amounts in the 
samples lead to column bleeding and a shorter shelf life of the GC capillary column. 
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2.3. Strategies for Sterol Sulfate Deconjugation 
2.3.1. Enzymatic Cleavage of Sterol Sulfates 
For the analysis of sterol sulfates as their corresponding TMS derivatives by GC-MS free 
hydroxyl groups of the unconjugated sterols are mandatory. Hence, an additional step for 
deconjugation is required. The enzymatic cleavage of sterol conjugates is a frequently used 
procedure especially in analysis of anabolic androgenic steroids in urine samples [23,24,48]. 
For glucuronides enzymatic cleavage utilizing the highly specific E. coli β-glucuronidase is the 
gold standard for steroid analysis in urine samples [23]. For the cleavage of sterol sulfates 
enzyme preparations from molluscs are commonly used, because these contain sulfatase 
activity beside β-glucuronidase activity. The most common preparations are from Helix 
pomatia, but also Patella vulgata, Haliotis spp. and Ampullaria are current sources [24]. These 
sulfatases are known to hydrolyze sulfates of 3β-hydroxy-∆5-sterols, 3β-hydroxy-5α-sterols, 
and 3α-hydroxy-5β-sterols, but fail to cleave 3α-hydroxy-5α-sterol sulfates [39,49]. Another 
known problem is the conversion and degradation of sterols especially by Helix pomatia 
preparations, which contain additional enzymes with various activities [24,25,28]. Due to these 
limitations there is no general procedure available for enzymatic cleavage of sterol sulfates. 
Gomes et al. [24] present several published procedures utilizing different enzymes, buffers 
and reaction conditions. We adopted the method described by Xu. et al. [50] with the 
difference that we used an aqueous solution of the sterol sulfates instead of a urinary sample. 
Under the described conditions (Section 5.3.4) we obtained only partial hydrolysis of 
dehydroepiandrosterone sulfate (2), a 3β-hydroxy-∆5-sterol sulfate, and epiandrosterone 
sulfate (3), a 3β-hydroxy-5α-sterol sulfate, with poor reproducibility. The other sterol sulfates 
in the experiment did not show any measurable hydrolysis. Variations of the buffer system 
(acetate buffer pH 7, phosphate buffer pH 5, 7, and 8) and reaction conditions (35 ◦C for 4 h 
and 20 h, 55 ◦C for 4 h and 20 h) did not improve our results. Hence, as optimization of the 
hydrolysis conditions is rather complex [48] and many sulfate conjugates (e.g., androsterone 
(1), a 3α-hydroxy-5α-sterol sulfate) are known to be resistant to enzymatic hydrolysis [39,49], 
this method seems not to be suitable for the untargeted analysis of sterol sulfates. 
2.3.2. Chemical Cleavage of Sterol Sulfates 
An alternative to the enzymatic hydrolysis is the chemical hydrolysis or solvolysis. 
Traditionally acidic hydrolysis at elevated temperatures was used for deconjugation of sterol 
sulfates. But the drastic conditions that are required for this hydrolysis includinghigh amounts 
of mineral acid and refluxing, can lead to degradation or transformation of some sterols [51–
53]. In turn, solvolysis under mild conditions is preferred and can be achieved by extracting 
the sterol sulfates from an acidified (with sulfuric acid) aqueous sample with ethyl acetate and 
storing this moist organic phase for 24 h at 39 ◦C [54] or with trimethylchlorosilane in methanol 
(methanolysis) [30]. The ability of oxygen-containing solvents, especially ethers, to cleave 
sterol sulfates in presence of minor amounts of water and acid was investigated in 1958 by 
Burstein and Lieberman [55]. They proposed an acid-catalyzed mechanism for the solvolysis 
(Scheme 3) in oxygen containing solvents, like 1,4-dioxane [55]. Having examined several 
published protocols, we found the solvolysis in 1,4-dioxane to be a particularly effective and 
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mild method. It is applicable for both 3α- and 3β-sterol sulfates as well as for sulfates derived 
from saturated and unsaturated sterols [55,56]. 
To examine the scope of solvolysis we modified a method published by Hutchins and 
Kaplanis [57] who applied 1% acetic acid in 1,4-dioxane under reflux overnight (here: ≤6 h, 100 
◦C; see Section 5.3.5.1). This solvolysis worked for every sterol sulfate in this experiment 
regardless of the configuration at C3 and presence of a ∆5-double bond. The experiments 
revealed the best reaction time for solvolysis was 3 h for the entire set of tested sterol sulfates. 
The optimum reaction times for solvolysis for individual sterol sulfates, shown in Figure 6a 
and Supplementary Table S2, vary between 3 h and 4 h. The solvolyzed sterol sulfates were 
measured as their MO-TMS derivatives (two-step derivatization as described in Section 2.1.2). 
 
Scheme 3. Mechanism of the acid-catalyzed solvolysis of sterol sulfates in 1,4-dioxane proposed by 
Burstein and Lieberman [55]  
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Figure 6. Determination of (keto-)sterol sulfates 1–8 as (MO-)TMS derivatives (a) with and (b) without 
previous sulfate solvolysis step (with 1% acetic acid in 1,4-dioxane). The indicated time refers to the duration 
of solvolysis prior to MO-TMS derivatization (for ”Solvolysis and derivatization”, (a)) or to the incubation 
with O-methylhydroxylamine solution (for ”Simultaneous deconjugation/MO derivatization”, (b)). The 
results obtained for each individual sterol sulfate under the different conditions are shown as relative peak 
areas [%] ± standard deviation (n = 6); the mean value of all steroids for every time point is shown in the 
background (grey), the best conditions for all tested sterol sulfates are marked as “Best condition”. The 
maximum recorded peak area for each sterol derivative within this experiment was set as 100%. Analyzed 
sterols: 1 androsterone sulfate, 2 dehydroepiandrosterone sulfate, 3 epiandrosterone sulfate, 4 
allopregnanolone sulfate, 5 pregnanolone sulfate, 6 pregnenolone sulfate, 7 cholesterol sulfate, and 8 25-
hydroxycholesterol sulfate. 
 
Further experiments surprisingly revealed a possibly new form of chemical cleavage. Sterol 
sulfate deconjugation was found to be a side effect of the first derivatization step, the 
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methyloxime (MO) formation of the keto groups. We examined scope and efficiency of this 
new method for simultaneous cleavage and MO derivatization of sterol sulfates in additional 
experiments. To this end, eight sterol sulfates 1–8 (Figure 2) were incubated with O-
methylhydroxylamine solution for different times (0.5 h–6 h; see Section 5.3.5.2) without 
previous solvolysis, then silylated, and the results were compared with the results of the 
solvolysis approach. This comparison is shown in Figure 6b, and Supplementary Table S2. In 
conclusion, we found that the acidic solvolysis step is dispensable for all investigated sterol 
sulfates. Optimal results for all analytes under investigation, using our new simultaneous 
deconjugation/MO derivatization protocol, were obtained after 4 h incubation with O-
methylhydroxylamine solution. The optimum conditions of this simultaneous 
deconjugation/MO derivatization method for each individual sterol sulfate, shown in Figure 
6b and Supplementary Table S2, vary between 3 h and 6 h. Two criteria were employed for 
evaluation of optimal conditions, on the one hand the relative peak area was taken as indicator 
for the degree of deconjugation, on the other hand the standard deviation (SD) should be as 
small as possible. 
Figure 6a shows that solvolysis is a reliable method which achieves the best results for most 
of the tested sterol sulfates (100% is the best result achieved for individual sterols, not the 
recovery). The disadvantage of solvolysis is the additional workup step, because 
derivatization including methyloxime formation for 0.5 h, if keto sterols are analyzed, and 
silylation has to be performed in addition to the solvolysis step. This extra deconjugation 
procedure can be avoided in the approach with simultaneous deconjugation/MO 
derivatization. In this case, incubation for 4 h achieves the best results for most of the tested 
sterol sulfates. The peak areas achieved under these conditions are similar to those obtained 
with solvolysis with the advantage of less workup efforts. 
Which method should be preferred is dependent on the target analytes. If sterols without 
keto groups are analyzed solely, a simplified approach with solvolysis and subsequent 
silylation is advisable. If keto sterols are determined it depends on the particular sterols, for 
example for dehydroepiandrosterone sulfate (2) better results can be achieved with the 
simultaneous deconjugation/MO derivatization protocol, whereas allopregnanolone sulfate 
(4) can be cleaved with solvolysis more effectively. 
3. Discussion 
We investigated the scope and limitations of most of the commonly used procedures including 
direct acylation and formation of TMS and MO-TMS ethers. The advantages and 
disadvantages of these methods are summarized in Table 1. 
Surprisingly, we found that in the course of the methoximation of keto sterol sulfates, 
originally intended only to protect their keto groups as MO derivatives for avoiding undesired 
enol silylation in the subsequent silylation of the 3-hydroxy groups (see Section 2.1.2), that 
sterol sulfates were as well cleaved upon treatment with the O-methylhydroxylamine reagent. 
To the best of our knowledge, this reaction has not yet been utilized in the analysis of sterol 
sulfates before. Only scarce evidence on this type of organosulfate cleavage has been 
published before, and previous investigations were performed only with aryl [58] and methyl 
sulfates [59,60]. Most likely, this exceptional reactivity of methoxylamine is due to the so-called 
α-effect [59,61], leading to strongly enhanced nucleophilicity of the NH2 group, even enabling 
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this reagent to cleave organosulfates under uncommon nucleophilic attack at the S-atom. This 
novel sample pretreatment allows for an unprecedented, short and easy-to-perform 
derivatization of keto sterol sulfates involving both organosulfate deconjugation and ketone 
methoximation under relatively mild reaction conditions. Subsequent silylation of liberated 
hydroxyl groups provides suitable derivatives for GC-MS analysis. Hence, this new 
deconjugation/derivatization protocol represents a considerable progress in the analysis of 
keto sterol sulfates. Our present investigations on the chemical behavior of sterol sulfates 
provided further useful evidence for the analysis of sterol sulfates. 
Table 1. Overview of derivatization methods for analysis of sterol sulfates. 
 
4. Conclusions 
The aim of the present work was to find the best deconjugation/derivatization strategy for 
the analysis of sterol sulfates by GC-MS. As expected, there is no single best method for 
deconjunction and derivatization of sterol sulfates. Depending on the nature of the analyte of 
interest, the methods have individual strengths and weaknesses (Section 2.3.2, Table 1). For 
the targeted determination of known (∆5-)sterol sulfates an especially fast workup employing 
direct perfluoroacylation can be the method of choice. But one of the biggest advantages of 
GC-MS is its strength as discovery tool for unexpected sterols. For this untargeted approach 
workup procedures are necessary, that are not limited to a subset of sterol sulfates. In addition, 
these workup procedures should form derivatives with characteristic mass spectra. Both our 
new protocol for simultaneous deconjugation/MO-derivatization followed by TMS 
derivatization and the protocol for acidic solvolysis followed by MO-TMS derivatization meet 
these requirements. 
5. Materials and Methods 
5.1. Materials and Reagents 
All consumables were from VWR (Ismaning, Germany). Derivatization reagents 
trifluoroacetic anhydride (TFAA), 1-(trimethylsilyl)imidazole (TSIM), and N-methyl-N-
trimethylsilyltrifluoroacetamide (MSTFA) were from Macherey-Nagel (Düren, Germany). 
Deionized water was prepared with an in-house ion-exchanger. 1,4-Dioxane and methyl tert-
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butyl ether (MtBE) were distilled before use. β-Glucuronidase/sulfatase from Helix pomatia 
type HP-2, 5α-cholestane (≥97%), pregnenolone (>98%), pregnenolone sulfate sodium salt 
(>98%), and cholesteryl sulfate sodium salt (>99%) were purchased from Sigma-Aldrich 
(Schnelldorf, Germany). Dehydroepiandrosterone sulfate sodium salt (>99%) and 25-
hydroxycholesteryl sulfate sodium salt (>99%) were from Avanti Polar Lipids (Alabaster, AL, 
USA). All other sterol sulfate sodium salts were from Steraloids (Newport, RI, USA). All other 
reagents and solvents were purchased in HPLC grade or in pro analysis quality from Sigma-
Aldrich (Schnelldorf, Germany). 
5.2. Instruments and Equipment 
Gas chromatography (GC) was performed on a Varian 3800 gas chromatograph coupled to 
a Saturn 2200 ion trap from Varian (Darmstadt, Germany). The autosampler was from CTC 
Analytics (Zwingen, Switzerland) and the split/splitless injector was a Varian 1177 
(Darmstadt, Germany). Instrument control and data analysis were carried out with Varian 
Workstation 6.9 SP1 software (Darmstadt, Germany) and Agilent MassHunter Workstation 
Software package B.08.00 (Santa Clara, CA, USA). An Agilent HP-5-ms capillary column 
(Santa Clara, CA, USA) of 30 m length, 0.25 mm i.d., and 0.25 µm film thickness was used at 
a constant flow rate of 1.4 mL/min. Carrier gas was helium 99.999% from Air Liquide 
(Düsseldorf, Germany). The inlet temperature was kept at 300 ◦C and injection volume was 1 
µL with splitless time 1.0 min. The initial column temperature was 50 ◦C and was held for 1.0 
min. Then temperature was ramped up to 250 ◦C with 50 ◦C/min. Then the sterols were eluted 
at a rate of 5 ◦C/min until 310 ◦C (hold time 3 min). Total run time was 20 min. Transfer line 
temperature was 300 ◦C and the ion trap temperature was 150 ◦C. The ion trap was operated 
with electron ionization (EI) at 70 eV in scan mode (m/z 50–650) with a solvent delay of 6.3 
min. 
5.3. Methods 
A stock solution containing androsterone sulfate (1), dehydroepiandrosterone sulfate (2), 
epiandrosterone sulfate (3), allopregnanolone sulfate (4), pregnanolone sulfate (5), 
pregnenolone sulfate (6), cholesterol sulfate (7), 25-hydroxycholesterol sulfate (8), and 
cholestane (9) as internal standard (IS) with a concentration of 10 µM of each analyte in ethyl 
acetate was prepared. Substance structures are shown in Figure 1. 
5.3.1. TMS Derivatives by Direct Silylation 
Pregnenolone (2 µg) and cholestane (1 µg, IS) was silylated with 50 µL of a mixture of MSTFA 
and TSIM (9:1) at room temperature for 30 min. After the addition of 950 µL methyl tert-butyl 
ether (MtBE) the sample was analyzed as described above by GC-MS. 
5.3.2. Acidic Deconjugation and Formation of MO-TMS Derivatives 
An aliquot of the stock solution containing 10 nmol of each sterol sulfate and IS was 
transferred into an autosampler vial and the solvent (ethyl acetate) was evaporated under a 
stream of nitrogen. Deconjugation was performed in 1,4-dioxane with 1% acetic acid (v/v) for 
3 h (see Section 5.3.5.1). Subsequently, the sample was evaporated to dryness under a stream 
of nitrogen. The dry residue was derivatized with 100 µL 2% O-methylhydroxylamine 
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hydrochloride in pyridine (m/v) at 80 ◦C for 30 min. This reaction time is sufficient for a 
complete derivatization of the keto groups. Then the sample was diluted with 400 µL water 
and the sterols were extracted with 2 × 1000 µL MtBE. The combined organic phases were 
transferred into a new autosampler vial and evaporated to dryness under a stream of nitrogen. 
Then the residue was silylated with 50 µL of a mixture of MSTFA and TSIM (9:1) at room 
temperature for 30 min. After addition of 950 µL MtBE the sample was analyzed by GC-MS. 
5.3.3. TFA Derivatives by Direct Deconjugation/Derivatization 
An aliquot of the stock solution containing 10 nmol of each sterol sulfate and IS was 
transferred into an autosampler vial (n = 6) and evaporated to dryness under a stream of 
nitrogen. Fifty microliters of trifluoroacetic anhydride (TFAA) was added to the residue. The 
vial was closed and stored at 70 ◦C for 30 min, then the volatiles were evaporated under a 
stream of nitrogen. The residue was dissolved in 1000 µL MtBE and analyzed by GC-MS. 
5.3.4. Enzymatic Cleavage of Sulfates and Derivatization 
An aliquot of the stock solution containing 10 nmol of each sterol sulfate and IS was 
transferred into an autosampler vial (n = 6) and was evaporated to dryness under a stream of 
nitrogen. The residue was diluted in 0.5 mL water and 0.5 mL buffer containing β-
glucuronidase/sulfatase from Helix pomatia type HP-2 was added [50]. The closed vial was 
stored at 37 ◦C for 20 h. Then the sample was extracted with 2 × 1000 µL MtBE. The combined 
organic phases were transferred into a new autosampler vial and evaporated to dryness under 
a stream of nitrogen. The residue was silylated with 50 µL of a mixture of MSTFA and TSIM 
(9:1) at room temperature for 30 min. After addition of 950 µL MtBE the sample was analyzed 
by GC-MS. The acquired peak area for each sterol was compared to the area obtained by 
solvolysis (see Section 5.3.5.1) followed by TMS derivatization. The obtained data are listed in 
Table 1. 
5.3.5. Chemical Cleavage of Sulfates and Derivatization 
5.3.5.1. With Acidic Deconjugation (Solvolysis) 
An aliquot of the stock solution containing 10 nmol of each sterol sulfate and IS was 
transferred into an autosampler vial (n = 6) and the solvent (ethyl acetate) was evaporated 
under a stream of nitrogen. For solvolysis 500 µL of 1,4-dioxane with 1% acetic acid (v/v) was 
added and the vial was closed tightly. The mixture was stored at 100 ◦C for different periods 
of time (0.5–6 h, Figure 6 and Supplementary Table S2). Then the sample was evaporated to 
dryness under a stream of nitrogen. The residue was derivatized with 100 µL 2% O-
methylhydroxylamine hydrochloride in pyridine (m/v) at 80 ◦C for 30 min. Then the sample 
was diluted with 400 µL water and the sterols were extracted with 2 × 1000 µL MtBE. The 
combined organic phases were transferred into a new autosampler vial and evaporated to 
dryness under a stream of nitrogen. Then the residue was silylated with 50 µL of a mixture of 
MSTFA and TSIM (9:1) at room temperature for 30 min. After addition of 950 µL MtBE the 
sample was analyzed by GC-MS. 
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5.3.5.2. With Deconjugation/Methoximation with O-Methylhydroxylamine 
An aliquot of the stock solution containing 10 nmol of each sterol sulfate and IS was 
transferred into an autosampler vial (n = 6) and the solvent (ethyl acetate) was evaporated 
under a stream of nitrogen. Simultaneous deconjugation/MO derivatization was achieved by 
addition of 100 µL 2% O-methylhydroxylamine hydrochloride in pyridine (m/v) directly to the 
neat sterol sulfates (n = 6). The vial was stored at 80 ◦C for different periods of time (0.5–6 h, 
Figure 6 and Supplementary Table S2). Then the sample was diluted with 400 µL water and 
the sterols were extracted with 2 × 1000 µL MtBE. The combined organic phases were 
transferred into a new autosampler vial and evaporated to dryness under a stream of nitrogen. 
Then the residue was silylated with 50 µL of a mixture of MSTFA and TSIM (9:1) at room 
temperature for 30 min. After addition of 950 µL MtBE the sample was analyzed by GC-MS. 
Supplementary Materials: Table S1: Gas chromatography-mass spectrometry data for the eight model sterol 
sulfates. Table S2: Determination of sterol sulfates as MO-TMS derivatives with and without solvolysis. 
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3.4. Supplementary material 
 
Table S1. Gas chromatography-mass spectrometry (GC-MS) data for the derivatives obtained from the 
eight model sterol sulfates 1 – 8 using different deconjugation/derivatization protocols; chemical 
formulae of the sterol sulfates; TFA: trifluoroacetyl ester; TMS: trimethylsilyl ether; MO-TMS: 
methyloxime-trimethylsilyl ether; relative retention times (RRT) related to internal standard cholestane 
(9); bold m/z value: base peak; * predominantly (2 × TFA); a analyzed as TMS ether (since no keto group 
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Table S2. Determination of (keto-)sterol sulfates 1 - 8 as (MO-)TMS derivatives with and without 
previous sulfate solvolysis step (with 1% acetic acid in 1,4-dioxane). The indicated time refers to the 
duration of solvolysis prior to derivatization (MO-TMS) (upper row “Solv. + Deriv.”) or to the duration 
of the simultaneous deconjugation/MO derivatization (lower row “Deconjug./MO”). The results 
obtained for each individual sterol sulfate under the different conditions are shown as relative peak areas 
[%] ± standard deviation (n = 6); optimum conditions for all  tested sterol sulfates are shown in the last 
two rows Ø 1 – 8; in bold: the best conditions for each sterol sulfate; in red: optimum method for all 
tested sterol sulfates. The maximum recorded peak area for each sterol derivative within this experiment 
was set as 100% (Note: The values presented here are not revoveries). Analyzed sterols: 1 androsterone 
sulfate, 2 dehydroepiandrosterone sulfate, 3 epiandrosterone sulfate, 4 allopregnanolone sulfate, 5 





0.5 h 1 h 2 h 3 h 4 h 5 h 6 h 
1 
Solv. + Deriv. 34 ± 4 47 ± 19 39 ± 9 89 ± 27 100 ± 14 90 ± 5 60 ± 9 
Deconjug./MO 0 ± 0 8 ± 1 17 ± 2 88 ± 45 92 ± 31 41 ± 4 44 ± 3 
2 
Solv. + Deriv. 24 ± 4 31 ± 12 23 ± 4 51 ± 18 60 ± 4 32 ± 5 34 ± 5 
Deconjug./MO. 3 ± 1 12 ± 1 24 ± 5 100 ± 48 92 ± 23 38 ± 4 35 ± 2 
3 
Solv. + Deriv. 44 ± 4 68 ± 17 71 ± 12 98 ± 5 94 ± 5 100 ± 3 92 ± 2 
Deconjug./MO. 8 ± 2 31 ± 2 56 ± 2 82 ± 5 87 ± 5 84 ± 5 86 ± 3 
4 
Solv. + Deriv. 46 ± 4 69 ± 15 68 ± 13 100 ± 5 97 ± 6 98 ± 5 90 ±7 
Deconjug./MO 3 ± 1 12 ± 1 27 ± 2 52 ± 8 61 ± 6 60 ± 4 64 ± 2 
5 
Solv. + Deriv. 53 ± 5 73 ± 16 79 ± 13 99 ± 4 98 ± 5 100 ± 5 96 ± 2 
Deconjug./MO 14 ± 2 36 ± 2 57 ± 4 81 ± 6 90 ± 7 86 ± 6 88 ± 4 
6 
Solv. + Deriv. 58 ± 4 79 ± 15 74 ± 10 100 ± 4 96 ± 5 98 ± 4 93 ± 3 
Deconjug./MO 13 ± 2 38 ± 3 62 ± 6 92 ± 5 100 ± 9 93 ± 5 95 ± 2 
7 
Solv. + Deriv. 71 ± 6 88 ± 9 94 ± 21 99 ± 4 92 ± 4 97 ± 2 100 ± 11 
Deconjug./MO 16 ± 1 33 ± 5 58 ± 3 82 ± 15 83 ± 5 90 ± 6 92 ± 4 
8 
Solv. + Deriv. 48 ± 6 66 ± 14 75 ± 8 100 ± 4 92 ± 4 96 ± 6 92 ± 3 
Deconjug./MO 7 ± 1 23 ± 4 46 ± 4 87 ± 6 99 ± 9 85 ± 8 91 ± 4 
Ø 1 - 8 
Solv. + Deriv. 47 ± 4 65 ± 15 65 ± 11 92 ± 9 91 ± 6 85 ± 4 82 ± 5 
Deconjug./MO 8 ± 1 24 ± 2 43 ± 3 83 ± 17 88 ± 12 72 ± 5 74 ± 3 
  
 




4. Analysis of neutral steroids, steroid acids and sterol 
sulfates 
 
The article “Effective sample preparation procedure for the analysis of neutral steroids, 
steroid acids and sterol sulfates in different tissues by GC-MS” was submitted to the Journal 
of Steroid Biochemistry and Molecular Biology. 
A revised version of the manuscript has been submitted to the editor. This manuscript is 
presented here.  
 
4.1. Summary 
The γ-secretase research of the group of Prof. Dr. Steiner does not only focus on neurosteroids 
and sterol sulfates, but this group is also interested in oxysterols and steroid acids. These 
analytes were reported by others to affect the γ-secretase [29, 76-78], and the aim of this work 
was to develop an analytical method for the analysis of these compounds. Also, cholesterol 
precursors, like desmosterol were reported to play a role in AD [56, 57] and their level is 
presumably altered in mouse models like the frequently used NPC knockout mice. Hence, an 
inclusion of this steroid class to the new method was desired and straightforward, as we 
already had much experience in the analysis of cholesterol precursors from earlier work 
(Chapter 4). In the end, the method was validated for nine cholesterol precursors, five 
oxysterols, nine neurosteroids, seven sterol sulfates and seven steroid acids. These analytes 
were measured using GC-MS/MS (tandem MS) in dMRM mode with high sensitivity and 
additionally using GC/MS in scan mode in an untargeted approach. With this untargeted 
screening method further steroids could be identified (e.g. phytosterols). Hence, this method 
enabled the analysis of unexpected occurring steroids as well as the analysis of steroids 
occurring at trace levels. So, this method provides a broader overview on the sterolome as 
other published methods and could therefore help to get a better understanding of sterol 
associated diseases like AD. To accomplish analysis of this wide spectrum of analytes an 
effective sample preparation procedure was developed. As shown in Figure 9 it consists of the 
lipid extraction from the tissue, the steroid group separation and subsequent GC-MS(/MS) 









Figure 9 Graphical abstract of the article showing the lipid extraction from liver and brain tissue and the principle 
of steroid group separation on the SPE cartridge with subsequent GC-MS analysis. 
First the samples (brain/liver tissue or cultured cells) were homogenized using a bead mill and 
subjected to liquid-liquid extraction using an optimized solvent mixture. The organic phase 
containing the analytes of interest was then further processed on a solid phase extraction 
(SPE) cartridge containing a weak anion exchange sorbent. This enabled the separation of 
neutral steroids (neurosteroids, oxysterols and cholesterol precursors) from steroid acids and 
steroid sulfates using specific eluents. These steroid groups could then be derivatized and 
measured separately. This method was validated for liver and brain tissue and was applied on 
different samples (mice 10 months /three weeks old, cultured cells). Overall, 45 steroids were 
identified and the endogenous concentrations higher than the limit of quantification (> LOQ) 
were reported. 
 
4.2. Personal contribution 
My contribution to this work were the conceptualization, investigation and method 
development. The latter included optimization of lipid extraction and SPE, concerning the 
choice of solvents, sorbents and eluents. Also, the implementation of the GC-MS procedure 
especially optimization of mass transitions and collision energies for dMRM mode was part of 
the method development. Method validation and application on biological samples were also 
part of my contribution. This included the planning and execution of necessary experiments as 
well as the formal analysis and curation of the measurement data. In addition, the visualization 
of the obtained results as well as writing of the original draft were done by me.  
Prof. Dr. Harald Steiner and Dr. Frits Kamp supported this project by providing resources like 
analytical standards and biological samples. They also designated the steroids of special 
interest for this project. Additionally, they contributed by acquisition of funding.  




Further biological samples were provided by Edith Winkler, who also performed preliminary 
experiments to determine steroids of interest for this project. 
Prof. Dr. Franz Bracher contributed to this project by providing the necessary resources and 
acquisition of funding. He was also involved in reviewing and editing of the original draft. 
Dr. Christoph Müller was involved in the conceptualization of the project and supported the 
determination of the final experimental design and methodology. He further contributed in the 
formal analysis of the obtained data and especially in reviewing and editing of the original draft. 
 
4.3. Article 
The following article was submitted to the Journal of Steroid Biochemistry and Molecular 
Biology. It is printed in the original wording of the revised manuscript, that was submitted to 
the editor in February 2021.  
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Abstract 
Steroids play an important role in cell regulation and homeostasis. Many diseases like Alzheimer’s 
disease or Smith-Lemli-Opitz syndrome are known to be associated with deviations in the steroid 
profile. Most published methods only allow the analysis of small subgroups of steroids and cannot give 
an overview of the total steroid profile. We developed and validated a method that allows the analysis 
of neutral steroids, including intermediates of cholesterol biosynthesis, oxysterols, C19 and C21 steroids, 
steroid acids, including bile acids, and sterol sulfates using gas chromatography-mass spectrometry. 
Samples were analyzed in scan mode for screening purposes and in dynamic multiple reaction 
monitoring mode for highly sensitive quantitative analysis. The method was validated for mouse brain 
and liver tissue and consists of sample homogenization, lipid extraction, steroid group separation, 
deconjugation, derivatization and gas chromatography-mass spectrometry analysis. We applied the 
method on brain and liver samples of mice (10 months and 3 weeks old) and cultured N2a cells and 
report the endogenous concentrations of 29 physiological steroids. 
Keywords 
Screening method, bile acids, group separation, steroid profiling, deconjugation, gas chromatography-
mass spectrometry 
1. Introduction 
Steroids are a very large and versatile class of biomolecules. Versatile by means of structure, 
occurrence and by means of biological activity. They act as important cell-building material and as 
signaling molecules on different intracellular and membrane-bound receptors. The set of all steroids of 
a cell or organism is called steroidome and its qualitative and quantitative analysis is known by the term 
steroidomics [1]. In the last decades, steroidomics were used to investigate changes of the steroidome 
in the context of different diseases like congenital adrenal hyperplasia (CAH) [2-5], cerebrotendinous 
xanthomatosis (CTX) [6], Alzheimer’s disease (AD) [7-9], Smith-Lemli-Opitz syndrome (SLOS) [10] 
and more [11, 12]. A change in steroid metabolism leads to an accumulation or reduction of certain 
steroids and this change in the steroid pattern can affect the whole organism in various ways. A change 
of the sterol composition in cell membranes, for example, can alter membrane structure and thickness 
[13, 14], in turn this can modulate the activity of membrane-bound enzymes like γ-secretase [15], an 
enzyme involved in AD. Oxysterols like 27-hydroxycholesterol (23, Table 2) can take effect via nuclear 
receptors like liver X receptor (LXR) and therefore interfere with cellular lipid homeostasis [16, 17]. 
Some oxysterols also reveal immunomodulatory actions, like the Epstein-Barr virus-induced G-protein 




coupled receptor 2 (EBI2) ligand 7α,25-dihydroxycholesterol (25) [18, 19] and other oxysterols, which 
are involved in neuroinflammation in AD patients [7]. A further important steroid class are 
neurosteroids, like pregnenolone (26), dehydroepiandrosterone (31), allopregnanolone (38) and their 
respective sulfates, which are synthesized and/or take action in the central and peripheral nervous system 
[20-23]. Their biological targets are neurotransmitter receptors like γ-aminobutyric acid type A 
(GABAA) and N-methyl-D-aspartate (NMDA) receptors in brain, and they effect cognitive performance 
[20, 24, 25]. In addition, they have all been investigated in context of AD [8, 9, 26-28]. These 
neurosteroids further interfere with cholesterol biosynthesis, for example pregnenolone (26), 17α-
hydroxypregnenolone (28) and progesterone (29) are supposed to be inhibitors of 24-dehydrocholesterol 
reductase (DHCR24) and lead to an accumulation of desmosterol (13) [29]. Desmosterol (13), other 
cholesterol precursors [30-32] and also cholesterol (10) [33, 34] itself are known to play a role in AD 
pathogenesis. Also, the class of steroid acids do not only play an important role in cholesterol 
homeostasis in liver as bile acids, they also occur in brain and are connected to neurodegenerative 
disorders like AD as well [35-37]. All these different steroidal compounds play their own important 
roles in cell development and homeostasis and are connected to each other by biosynthesis.  
In order to understand the mechanism behind pathological changes in the steroidome, all these different 
steroids need to be analyzed qualitatively and quantitatively. A universal method covering all possible 
steroidal compounds and their conjugates is still far away, but there are already methods published 
covering large numbers of analytes (Table 1). Neurosteroids and conjugates can be analyzed using gas 
chromatography-(tandem) mass spectrometry (GC-MS(/MS)) [2-5, 38-41], liquid chromatography-
tandem mass spectrometry (LC-MS/MS) [42-46], supercritical fluid chromatography-(tandem) mass 
spectrometry (SFC-MS(/MS)) [47] and also with radioimmunoassays (RIA) [48, 49]. Other methods 
cover oxysterols [50-52] and steroid acids [52-58]. Representative validated analytical methods are 
shown in Table 1. However, for most published methods no validation data are provided. The challenge 
in method validation often is a lack of authentic standards or appropriate blank matrix. Hence, most 
methods are qualitative or semi-quantitative, which seems sufficient for most biological studies, in 
which solely variations between different experimental groups are examined.  
  










Type of analytes Biological matrix 
Additional 
information 
Dzeletovic et al. 1995 [59] GC-MS 9 oxysterols plasma  
Liere et al. 2000 [41] GC-MS 6 
C19/C21 steroids + 
conjugates 
brain  
Acimovic et al. 2009 [60] GC-MS 11 
cholesterol precursors 
+ plant sterols 
cultured cells  
Hill et al. 2010 [38] GC-MS 44 C19/C20/C21 steroids serum/amniotic fluid 6 separate runs 




Tsai et al 2011 [61] GC-MS 8 steroid acids liver/ kidney  
Schött et al. 2015 [50] GC-MS 13 oxysterols serum  
Matysik et al. 2015 [62] GC-MS 4 C19/C21 steroids plasma  
Hill et al. 2019 [40] GC-MS 100 
C19/C20 /C2 steroids + 
conjugates 
serum 3 separate runs 
Müller et al. 2019 [63] GC-MS 12 cholesterol precursors cultured cells  




C19/C21 steroids + 
conjugates 
brain runtime 155 min 




Rustichelli et al. 2013 [46] LC-MS 3 
C19/C21 steroids + 
conjugates 
brain  
Sánchez-Guijo et al. 2015 
[64] 
LC-MS 11 
C19/C21 sterol sulfates 
+ cholesterol sulfate 
serum  




Matysik et al. 2017 [66] LC-MS 8 C19/C21 steroids serum  




Gomez-Gomez et al. 2020 
[68] 
LC-MS 28/15/12 
C19/C21 steroids + 
glucuronides 




steroids are not 
distinguished 
 
As shown in Table 1, most methods which enable the analysis of multiple compounds are GC-MS- 
based. This is due to the higher separation efficiencies for the highly similar steroidal compounds 
compared to LC-MS methods [69]. An often-named advantage of LC-MS is the simple sample work up 
without need for derivatization, as it is mandatory for GC-MS analysis. Even though derivatization with 
Girard`s P reagent (1-(hydrazinocarbonylmethyl)pyridinium chloride) or similar reagents is common in 
LC-MS analysis of oxosteroids and of 3β-hydroxysteroids after enzymatic oxidation, in order to enhance 
sensitivity and improve identification [44, 56]. Careful sample preparation is also important to reduce 
matrix effects, which play a role in both analytical systems, although LC-MS is more susceptible to 
matrix effects [69, 70]. The main disadvantage of GC-MS is the tedious determination of steroid 
conjugates (e.g. glucuronides, sulfates) which must be separated completely from their unconjugated 
counterparts first and cleaved afterwards. A direct measurement of these conjugates can be achieved by 
LC-MS and mistaken identification can therefore be avoided [64]. The same applies to the analysis of 
the even more complex conjugated steroid acids and bile acids. Although GC-MS is the recommended 
method for the analysis of complex mixtures of unconjugated bile acids [71] the analysis of the 
conjugated bile acids is cumbersome. Various groups of different conjugated bile acids are known, 
including but not limited to taurine-, glycine- and sulfo-conjugates [71]. Procedures for bile acid 
extraction and group separation have been discussed in detail by Sjövall and Setchell [72]. Using a 
combination of different reverse phase and ion exchange columns, for example, allowed the separation 
and detailed analysis of the bile acid profile in faeces [73, 74]. Nevertheless, for most conjugated bile 
acids deconjugation before GC-MS analysis is mandatory [72], similar to the process for sterol sulfates. 
This deconjugation is rather difficult as acid hydrolysis leads to a deconstruction of the nuclear structure, 
while alkaline hydrolysis does not work for all bile acids [72]. For example, C27 bile acids need more 
harsh conditions than C24 bile acids and a quantitative cleavage and prevention of artifact formation is 




not guaranteed [72]. For this reason, the direct analysis without deconjugation using LC-MS after group 
separation, as demonstrated by Yang et al. [75], seems to be a more promising approach for the analysis 
of conjugated bile acids. For this reason, the scope of our method was limited to unconjugated steroid 
acids.  
Based on these previously published methods, a method was developed and validated which enables 
the analysis of differed groups of steroidal compounds including cholesterol precursors, oxysterols, 
neurosteroids, unconjugated steroid acids and sterol sulfates. We used GC-MS with its high separation 
efficiency as analytical system. The samples were first analyzed on a gas chromatograph-ion trap-mass 
spectrometer (GC-IT-MS) system in scan mode for untargeted analysis of unexpected compounds 
(screening method). Additionally, for targeted analysis a gas chromatograph-tandem mass spectrometer 
(GC-MS/MS) was used to obtain higher sensitivity. Most of the methods shown in Table 1 were 
developed for one specific biological matrix, mainly serum or brain. Especially for neutral steroids only 
one method for liver microsomes [45] and one for cultured hepatocytes [60] were published, but no 
method for neutral steroids or sterol sulfates is described in literature for liver tissue. Therefore, the 
steroid content in liver had to be measured until now with methods for serum or brain that were applied 
to liver tissue [76, 77]. In this work we present our validated and optimized sample preparation 
procedure consisting of lipid extraction from murine brain and liver tissues, steroid group separation on 




2.1 Chemicals, reagents and materials 
 
C19/C21 steroids: Pregnenolone (>98%), progesterone (>99%), allopregnanolone (>98%) and 
pregnanolone (>98%) were purchased from Sigma-Aldrich (Schnelldorf, Germany). 
Dehydroepiandrosterone (>99%) was from Avanti Polar Lipids (Alabaster, AL, USA). Etiocholanolone, 
epietiocholanolone, 17-hydroxyprogesterone, 20-hydroxyprogesterone and 17-hydroxypregnenolone 
were acquired from Steraloids (Newport, RI, USA). Epipregnenolone was synthesized by us and will be 
published elsewhere. Neutral steroids and precursors: Cholesterol (>99%), cholestanol (>99%), 
squalene (>98%), squalene epoxide (>92%), 8-dehydrocholesterol (>99%), and 7-dehydrocholesterol 
(>99%) were purchased from Sigma-Aldrich (Schnelldorf, Germany). Zymosterol (>99%), lathosterol 
(>99%), lanosterol (>99%), dihydrolanosterol (>99%), cholesta-8,14-dien-3β-ol (>99%), 4,4-
dimethylcholesta-5,7-dien-3β-ol (>99%), and 4,4-dimethylcholesta-8,14-dien-3β-ol (>99%) were from 
Avanti Polar Lipids (Alabaster, AL, USA). Desmosterol was purchased from Santa Cruz Biotechnology 
(Dallas, TX, USA) and 4,4-dimethylcholest-8-en-3β-ol was synthesized according to literature [78]. 
Oxysterols: 24(S)-Hydroxycholesterol (>99%), 7α-hydroxycholesterol (>99%), 7β-hydroxycholesterol 
(>99%) and (25R)-27-hydroxycholesterol (>99%) were from Avanti Polar Lipids (Alabaster, AL, USA). 
7α,25-Dihydroxycholesterol was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). 7-
Ketocholesterol and trihydroxycoprostane were acquired from Steraloids (Newport, RI, USA). Sterol 
sulfates: Cholesterol sulfate sodium salt (>99%) and pregnenolone sulfate sodium salt (>98%) were 
purchased from Sigma-Aldrich (Schnelldorf, Germany). Dehydroepiandrosterone sulfate sodium salt 
(>99%) and 25-hydroxycholesterol sulfate sodium salt (>99%) were from Avanti Polar Lipids 
(Alabaster, AL, USA). Allopregnanolone sulfate sodium salt, pregnanolone sulfate sodium salt, 
androsterone sulfate sodium salt and epiandrosterone sulfate sodium salt were acquired from Steraloids 
(Newport, RI, USA). Steroid acids: 5β-Cholanic acid (>99%), cholic acid (>98%), deoxycholic acid 
(>98%) and lithocholic acid (>98%) were purchased from Sigma-Aldrich (Schnelldorf, Germany). 
Cholestenoic acid (>99%), 7α-hydroxycholestenoic acid (>99%) and 3α,7α,12α-trihydroxycholestanoic 
acid (>99%) were from Avanti Polar Lipids (Alabaster, AL, USA). Chenodeoxycholic acid was from 
Santa Cruz Biotechnology (Dallas, TX, USA). Standards: 5α-Cholestane (>97%), pregnenolone-
20,21-13C2-16,16-d2 (>98%), and pregnenolone-20,21-13C2-16,16-d2 sulfate sodium salt (>98%) were 
purchased from Sigma-Aldrich (Schnelldorf, Germany). Cholesterol-25,26,26,26,27,27,27-d7 (>99%) 




and desmosterol-26,26,26,27,27,27-d6 (>99%) was purchased from Avanti Polar Lipids (Alabaster, AL, 
USA). Fernholtz acid was acquired from Steraloids (Newport, RI, USA).  
Derivatization reagents N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) and 1-
(trimethylsilyl)imidazole (TSIM) were from Macherey-Nagel (Düren, Germany). Deionized water was 
prepared with an in-house ion-exchanger. Iso-hexane and methyl tert-butyl ether (MtBE) were distilled 
before use. All other reagents and solvents were purchased in HPLC grade or in pro analysis quality 
from Sigma-Aldrich (Schnelldorf, Germany). All solvent mixtures were mixed by (v/v). We used the 
following solid-phase extraction cartridges: Chromabond HR-XAW 45 µm, 3 mL/200 mg from 
Macherey-Nagel (Düren, Germany) and Bond Elut C18 40 µm, 1 mL/100 mg from Agilent Technologies 
(Santa Clara, CA, USA). For tissue homogenization we used an IKA (Staufen, Germany) Ultra Turrax 
Tube Drive with BMT-20S Tubes for grinding with stainless steel beads (5.0 mm) or a vortexer equipped 
with a bead tube holder from a Macherey-Nagel (Düren, Germany) and 2 mL microcentrifuge tubes 
containing glass beads (2.0 mm and 3.0 mm). All other consumables were from VWR (Ismaning, 
Germany). 
 
2.2 Stock solutions 
 
Stock solutions of each analyte (1 mg/mL) were prepared in ethanol (EtOH) or ethyl acetate (EtOAc) 
and stored at 4 °C. Mixtures for each experiment were prepared right before use in the necessary 
concentration.  
 
2.3 Biological samples 
 
For method development, optimization and validation pig brain and bovine liver from local markets 
were used. For the data presented, whole brains and livers were taken from wild-type mice (C57BL/6J, 
3 male mice were sacrificed after 3 weeks and 3 female mice were sacrificed at 10 months of age). 
Additionally, mouse neuroblastoma (N2a) cells were taken for analysis. These tissues were stored at -
20 °C before analysis. 
 
2.4 Gas chromatography - mass spectrometry 
 
Samples were analyzed with two different gas chromatography - mass spectrometry (GC-MS) systems. 
An ion trap-mass spectrometer (IT-MS) was used for the screening method (non-targeted screening) and 
a tandem mass spectrometer (MS/MS) was used for highly sensitive and selective analysis (targeted 
screening). 
 
2.4.1 GC-IT-MS (screening method) 
 
Gas chromatography (GC) was performed on a Varian 3800 gas chromatograph coupled to a Saturn 
2200 ion trap from Varian (Darmstadt, Germany). The autosampler was from CTC Analytics (Zwingen, 
Switzerland) and the split/splitless injector was a Varian 1177 (Darmstadt, Germany). Instrument 
control and data analysis were carried out with Varian Workstation 6.9 SP1 software (Darmstadt, 
Germany) and Agilent MassHunter Workstation Software package B.08.00 (Santa Clara, CA, USA). 
An Agilent VF-5ms capillary column of 30 m length with 10 m EZ-Guard, 0.25 mm i.d. and 0.25 µm 
film thickness was used at a constant flow rate of 1.4 mL/min. Carrier gas was helium 99.999% from 
Air Liquide (Düsseldorf, Germany). The inlet temperature was kept at 300 °C and injection volume was 
1 µL. The different steroid groups were analyzed with different split ratios. Neutral steroids (cholesterol 
biosynthesis intermediates, oxysterols and C19/C21 steroids) were measured with split 1:5, steroid acids 
with split 1:2 and sterol sulfates were measured splitless. The initial column temperature was 50 °C and 
was held for 1.0 min. Then the temperature was ramped up to 250 °C with 50 °C/min. The steroids were 
eluted at a rate of 5 °C/min until 310 °C (hold time 3 min). The total run time was 20 min. The transfer 




line temperature was 300 °C and the ion trap temperature was 150 °C. The ion trap was operated with 
electron ionization (EI) at 70 eV in scan mode (m/z 50–650) with a solvent delay of 9.0 min. For 
measurement of neutral steroids (except cholesterol) an additional time segment (15.35 min -15.70 min) 
without ionization was added.  
The analysis of cholesterol was performed on the above-mentioned chromatographic system with a 
shorter run time (15.4 min). The inlet temperature was kept at 300 °C and injection volume was 1 µL. 
Cholesterol was measured splitless for liver tissue or with split (1:10) for brain tissue. The initial column 
temperature was 50 °C and was held for 1.0 min. Then the temperature was ramped up to 270 °C with 
50 °C/min. Then cholesterol was eluted at a rate of 5 °C/min until 310 °C (hold time 2 min). 
2.4.2 GC-MS/MS (targeted analysis) 
 
An Agilent Technologies 7890B gas chromatograph (Santa Clara, CA, USA) with an Agilent 
Technologies Multimode Inlet (MMI) was coupled to an Agilent Technologies 7010B triple quadrupole 
detector with a high efficiency source (HES) and a Pal3 RSI autosampler from CTC Analytics (Zwingen, 
Switzerland). Two connected 15 m Agilent J&W HP-5ms ultra inert capillary columns with 0.25 mm 
i.d. and 0.25 µm film thickness were used at a flow rate of 1.0 mL/min on the first column and 1.2 
mL/min on the second column. Carrier gas was helium 99.999% from Air Liquide (Düsseldorf, 
Germany). The inlet was utilized in solvent vent mode with a start temperature of 70 °C and vent flow 
of 100 mL/min for 0.01 min, then temperature was raised at a rate of 600 °C/min to 300 °C and was 
held for 5.0 min. During post run and backflush the inlet temperature was elevated to 310 °C. The 
injection volume was 5 µL. Initial oven temperature was 50 °C and was held for 5.0 min. Then 
temperature was ramped up to 250 °C with 50 °C/min. Then the steroids were eluted at a rate of 5 °C/min 
until 310 °C (hold time 3 min). Total runtime was 20 min and additional 4 min post run with backflush 
of the first column at 310 °C. Instrument control and data analysis were carried out with Agilent 
MassHunter Workstation Software package B.08.00 (Santa Clara, CA, USA). The triple quadrupole 
(MS/MS) was operated with electron ionization (EI) at 70 eV in dynamic multiple reaction monitoring 
mode (dMRM) with collision gas argon 99.995% from Air Liquide (Düsseldorf, Germany) with a flow 
rate of 0.9 mL/min. Source temperature was 230 °C. The multiplier operated with gain factor 10. Solvent 
delay was 8.0 min. The transitions and collision energies were optimized using MassHunter MRM 
optimizations software and authentic standards and are given in Table 2. 
 




Table 2 Analytical details of the analyzed steroidal compounds. dMRM transitions were only determined for compounds of interest that were available in sufficient purity. Some compounds were 
identified by comparison with literature data: 1 [79], 2 [80], 3 [63], 4 [81], 5 [82]. *: Relative retention time (RRT) is referring to the highest peak in case of double peaks; n.d.: not determined. The 
unknown muricholic acids 52 and 53 are likely β- and ω-muricholic acid. In bold: quantifier ions/transitions. In brackets: collision energy. Sterol sulfates were measured as their unconjugated 
counterpart and are marked in the text with an additional “S” to the compound number.  
Analytes Scan (IT-MS system) dMRM (MS/MS system) 





121, 81, 69 0.943 163→107(5), 121→93(5), 121→51(40) 0.958 




143, 107, 69 1.085 n.d. n.d. 
3 Lanosterol Lanosta-8,24-dien-3β-ol 498, 393, 241 1.385 498→393(5), 483→393(0), 393→95(20) 1.401 
4 Dihydrolanosterol 5α-Lanost-8-en-3β-ol 485, 395, 229 1.350 500→395(5), 485→395(0), 395→55(45) 1.362 
5 4,4-Dimethylcholesta-8,14-dienol 4,4-Dimethylcholesta-8,14-dien-3β-ol 484, 379, 351 1.361 484→379(10), 379→251(20), 379→223(20) 1.380 
6 4,4-Dimethylcholest-8-enol 4,4-Dimethyl-5α-cholest-8-en-3β-ol 486, 396, 381 1.375 n.d. n.d. 
7 Zymostenol 5α-Cholest-8-en-3β-ol 458, 353, 213 1.247 458→213(10), 458→81(35), 443→353(5) 1.257 
8 Lathosterol Cholest-7-en-3β-ol 458, 353, 255 1.279 458→229(5), 458→213(15), 458→147(5) 1.290 
9 7-Dehydrocholesterol Cholesta-5,7-dien-3β-ol 366, 351, 325 1.269 456→143(35), 351→143(15), 325→119(15) 1.273 
10 Cholesterol Cholest-5-en-3β-ol 458, 368, 329 1.226 458→145(2), 368→145(20), 329→91(45) 1.239 
10d Cholesterol-d7 Cholesterol-25,26,26,26,27,27,27-d7 465, 375, 336 1.208 n.d. n.d. 
11 Cholestanol 5α-Cholestan-3β-ol 455, 355, 215 1.232 460→215(10), 445→75(25), 215→91(35) 1.239 
12 Zymosterol 5α-Cholesta-8,24-dien-3β-ol 441, 351, 213 1.284 456→105(45), 372→357(5) 1.290 




462, 372, 357 1.255 462→372(5), 462→357(10) 1.263 
14 Cholesta-8,14-dienol Cholesta-8,14-dien-3β-ol 456, 351, 182 1.240 456→351(10), 351→238(10), 182→45(35) 1.250 
15 4,4-Dimethylcholesta-5,7-dienol 4,4-Dimethylcholesta-5,7-dien-3β-ol 379, 353, 325 1.381 379→171(15), 379→156(35), 172→157(5) 1.386 
16 8-Dehydrocholesterol Cholesta-5,8-dien-3β-ol 456, 351, 325 1.234 456→325(10), 351→143(15), 351→128(45) 1.246 
17 4,4-Dimethylcholest-8(14)-enol 4,4-Dimethyl-5α-cholest-8(14)-en-3β-ol 486, 396, 381 1.357 n.d. n.d. 
18 7-Ketocholesterol 7-Oxocholest-5-en-3β-ol 486, 470, 380 1.427 501→197(25), 501→95(40), 486→81(30) 1.455 
19 7β-Hydroxycholesterol Cholest-5-en-3β,7β-diol 456, (442, 351) 1.300 456→233(15), 456→73(40) 1.318 
20 7α-Hydroxycholesterol Cholest-5-en-3β,7α-diol 456, (443, 129) 1.185 456→233(15), 456→73(45) 1.212 




21 Trihydroxycoprostan 5β-Cholestane-3α,7α,12α-triol 456, 366, 253 1.193 366→281(5), 343→253(5), 253→128(40) 1.228 
22 24S-Hydroxycholesterol Cholest-5-en-3β,24(S)-diol 456, 413, 323 1.440 413→323(0), 413→159(5), 323→91(45) 1.463 
23 27-Hydroxycholesterol Cholest-(25R)-5-en-3β,26-diol 546, 456, 417 1.514 456→145(25), 456→105(45) 1.536 
24 25-Hydroxycholesterol Cholest-5-en-3β,25-diol 546, 456, 131 1.458 131→73(5), 131→58(30) 1.479 
25 7α,25-Dihydroxycholesterol Cholest-5-en-3β,7α,25-triol 544, 454, 131 1.392 544→73(45), 454→73(45), 131→73(5) 1.440 




406, 390, 316 0.967 406→316(0), 406→241(5) 0.989 
27 Epipregnenolone 3α-Hydroxypregn-5-en-20-one 402, 386, 312 0.799 n.d. n.d. 
28 17-Hydroxypregnenolone 3β,17α-Dihydroxypregn-5-en-20-one 505, 474, 384 1.012 474→105(40), 474→73(40), 474→384(5) 1.032 
29 Progesterone Pregn-4-ene-3,20-dione 372, 341, 386 1.067 372→341(5), 286→126(15), 153→95(10) 1.067* 
30 17-Hydroxyprogesterone 17-Hydroxypregn-4-ene-3,20-dione 460, 429, 339 1.095 460→429(5), 429→370(10), 429→73(45) 1.107* 
31 Dehydroepiandrosterone 3β-Hydroxyandrost-5-en-17-one 374, 358, 268 0.827 358→84(10), 358→268(5) 0.849 
32 7α-Hydroxydehydroepiandrosterone 3β,7α-Dihydroxyandrost-5-en-17-one 387, 357, 266 0.826 387→356(5), 387→73(40) 0.858 
33 Androsterone 3α-Hydroxy-5α-androstan-17-one 376, 360, 270 0.784 360→270(5), 270→213(5), 270→91(35) 0.798 
34 Epiandrosterone 3β-Hydroxy-5α-androstan-17-one 376, 360, 270 0.837 360→270(5), 270→91(35), 270→84(10) 0.857 
35 Etiocholanolone 3α-Hydroxy-5β-androstan-17-one 376, 360, 270 0.794 360→270(5), 270→105(25), 270→91(35) 0,802 
36 Epietiocholanolone 3β-Hydroxy-5β-androstan-17-one 376, 360, 270 0.774 360→270(5), 270→213(15), 270→84(5) 0,794 
37 20-Hydroxyprogesterone 20-Hydroxypregn-4-en-3-one 417, 286, 117 1.069 417→117(10), 417→73(35), 117→73(5) 1.086 * 
38 Allopregnanolone 3α-Hydroxy-5α-pregnane-20-one 388, 298, 100 0.915 388→70(25), 100→68(5), 100→54(20) 0.929 
39 Pregnanolone 3α-Hydroxy-5β-pregnan-20-one 388, 298, 100 0.925 388→70(25), 100→68(5), 100→54(15) 0.933 
40 Cholestenoic acid 3β-Hydroxycholest-5-en-26-oic acid 502, 412, 373 1.514 412→145(20), 412→105(45), 255→159(10) 1.540 
41 3β,7α-Dihydroxycholestenoic acid 3β,7α-Dihydroxycholest-5-en-26-oic acid 410, 211, 158 1.420 410→211(5), 158→143(10), 158→128(20) 1.413 
42 7α-Hydroxy-3-oxo-4-cholestenoic acid 
7α-Hydroxy-3-oxocholest-4-en-26-oic 
acid 
498, 483, 470 1.573 269→133(10), 269→105(30), 133→105(10) 1.706 
43 Trihydroxycoprostanoic acid 
3α,7α,12α-Trihydroxy-5β-cholestan-26-
oic acid 
410, 343, 253 1.458 410→281(10), 253→143(15), 253→128(40) 1.511 
44 Cholic acid 
3α,7α,12α-Trihydroxy-5β-cholan-24-oic 
acid 
458, 368, 252 1.272 458→368(5), 368→253(5), 253→143(15) 1.313 
45 Chenodeoxycholic acid 3α,7α-Dihydroxy-5β-cholan-24-oic acid 370, 355, 255 1.284 370→105(45), 370→91(45), 213→157(10) 1.306 
46 Deoxycholic acid 3α,12α-Dihydroxy-5β-cholan-24-oic acid 535, 370, 255 1.251 370→255(5), 255→105(25), 255→91(40) 1.288 
47 Lithocholic acid 3α-Hydroxy-5β-cholan-24-oic acid 372, 357, 215 1.242 372→215(5), 215→105(20), 215→91(35) 1.241 
48 Cholestane 5α-Cholestane 372, 357, 217 1.000 372→217(5), 217→121(5), 217→67(25) 1.000 




49 5β-Cholanic acid 5β-Cholan-24-oic acid 374, 359, 217 1.043 n.d. n.d. 
50 Fernholtz acid 23,24-Bisnor-5-cholenic acid-3β-ol 342, 303, 215 1.069 342→105(40), 215→159(10), 215→91(35) 1.087 
51 -Murcholic acid 
3α,6α,7β-Trihydroxy-5β-cholan-24-oic 
acid 
458, 443, 195 1, 2 1.254   
52 unknown-Muricholic acid 1 unknown-Muricholic acid 1 195, 285, 369 1, 2 1.453   
53 unknown-Muricholic acid 2 unknown-Muricholic acid 2 195, 285, 361 1, 2 1.462   
54 T-MAS 4,4-Dimethylcholesta-8,24-dien-3β-ol 394, 379, 135 3 1.407   
55 Sitosterol 24S-Stigmast-5-en-3β-ol 486, 396, 357 4 1.387   
56 Campesterol Ergost-5-en-3β-ol 382, 343, 129 5 1.316   
57 Cholesta-7,24-dienol Cholesta-7,24-dien-3β-ol 456, 441, 343 3 1.315   
58 Lophenol 4α-Methylcholest-7-en-3β-ol 472, 382, 367 3 1.320   
59 4-Methylcholesta-7,24-dienol 4α-Methylcholesta-7,24-dien-3β-ol 470, 455, 365 3 1.352   




2.5 Sample preparation 
 
2.5.1 Lipid extraction procedure 
 
Lipid extraction was performed in 15 mL grinding tubes or 2 mL microcentrifuge tubes depending on 
the available sample amount.  
Mouse brain and liver tissues of 250 - 1,500 mg were homogenized in grinding tubes containing 10 
steel beads. The samples were homogenized without additional solvent at 6,000 rpm for 2 min. Then 2 
mL EtOH containing 5 mg/mL butylated hydroxytoluene (BHT) as antioxidant and 8 mL EtOAc 
containing internal standards as described in Chapter 2.8.1 were added. The samples were mixed one 
more time at 6,000 rpm for 2 min. Then 4 mL of 0.2 M HCl with 25% (m/v) aqueous KCl solution and 
4 mL EtOAc were added to the mixture. The samples were homogenized for another 2 min. Then the 
whole content of the grinding tubes was transferred into 50 mL centrifuge tubes and the samples were 
centrifuged for 5 min at 3,300 g. The organic layer was collected, and the aqueous phase was extracted 
two more times by addition of 10 mL EtOAc, shaking for 1 min and subsequent centrifugation. The 
organic phases were combined.  
Smaller amounts (50 mg – 250 mg) of tissue or cell samples were extracted in 2 mL microcentrifuge 
tubes containing 3 big and 3 small glass beads on a tube shaker (see Chapter 2.1). The samples were 
homogenized without additional solvent at 3,200 rpm for 10 min. Then 200 µL EtOH containing 5 
mg/mL BHT and 800 µL EtOAc containing internal standards as described in Chapter 2.8.1 were added. 
The samples were mixed one more time at 3,200 rpm for 10 min. Then 400 µL of 0.2 M HCl with 25% 
(m/v) aqueous KCl solution and 400 µL EtOAc were added to the microcentrifuge tubes. The samples 
were homogenized for another 10 min at maximum speed. Then the samples were centrifuged for 5 min 
at 12,000 g. The organic layer was collected, and the aqueous phase was extracted two more times by 
addition of 1000 µL EtOAc, mixed for 1 min and centrifuged for 5 min at 12,000 g. The organic phases 
were combined.  
Aliquots (n=3) of these lipid extracts corresponding to 1 mg liver tissue or 0.4 mg brain tissue were 
used for cholesterol determination. For solid-phase extraction and determination of the other steroids, 
aliquots (n=3) corresponding to 250 mg liver tissue or 100 mg brain tissue were used. The aliquots were 
transferred into glass vials (5 mL) and concentrated to dryness under a gentle stream of nitrogen. 
 
2.5.2 Steroid group separation 
 
After extraction the lipids were separated in different groups: neutral steroids, steroid acids and sterol 
sulfates. Therefore, a mixed mode solid-phase extraction (SPE) cartridge with reversed-phase (RP) and 
weak anion exchange abilities was used. All steps were carried out without additional pressure or 
vacuum, exceptions are mentioned explicitly. First, possible lipophilic contaminations from 
manufacturing were removed from the column by washing with 2 mL MtBE. Then the sorbent was 
conditioned with 4 mL MeOH and 4 mL of MeOH/H2O (3:7). Care was taken that the sorbent was 
always wetted. The dried lipid extracts were reconstituted in 600 µL MeOH and then diluted with 1400 
µL H2O. The final pH was spot-checked and ranged between 5 and 7. The sample solution was loaded 
on the column. After the whole solvent had run through, the cartridge was dried by through-flow of 
nitrogen for 1 h. Steroid groups were eluted in the following order: neutral steroids, steroid acids, and 
sterol sulfates. After every elution step, the cartridges were dried for 5 min by through-flow of nitrogen. 
Each eluate was evaporated to dryness under a stream of nitrogen (exception sterol sulfates, see below) 
and was stored at -20 °C prior to further analysis. Different solvents were tested for elutions to find the 
most suitable mixture for every single steroid group. For this purpose, lipid extracts of 50 mg brain 
tissue were spiked with several representative steroidal compounds at concentrations of 1 µg/50 mg 
tissue each, which exceeds the unneglectable endogenous concentration of most steroidal compounds. 
In case of desmosterol, which occurs in a higher concentration in brain, we used desmosterol-d6 (13d). 




Optimization was performed in separate experiments for each steroid group and each experiment was 
performed in triplicate. 
Starting with neutral steroids, desmosterol-d6 (13d), pregnenolone (26), 17-hydroxypregnenolone 
(28), 17-hydroxyprogesterone (30), androsterone (33), 20-hydroxyprogesterone (37), allopregnanolone 
(38) and pregnanolone (39) were used as model analytes. The steroid acid lithocholic acid (47) was used 
as negative control here, and the following solvents were tested: MeOH, iso-hexane/iso-propanol (7:3), 
CHCl3/MtBE (9:1) and dichloromethane (DCM)/MtBE (9:1). Neutral steroids were eluted with 3 × 3 
mL solvent and the internal standard (IS) cholestane (48) (10 µL of 100 µg/mL stock solution) was 
added to each eluate. The eluates were evaporated under a stream of nitrogen and the dry residue of each 
sample was derivatized following the protocol for neutral and sulfated steroids (Chapter 2.6.2). After 
derivatization the samples were analyzed with GC-IT-MS (Chapter 2.4.1). In the case of CHCl3/MtBE 
(9:1) additional fractions of 2 × 3 mL were analyzed to monitor the elution of the huge amount of 
cholesterol occurring in the brain extracts. Recovery was calculated by comparison to the spiked steroids 
measured without SPE in solvent.  
The solvent for elution of steroid acids was optimized using the model compounds cholic acid (44), 
chenodeoxycholic acid (45), lithocholic acid (47), cholanic acid (49), and Fernholtz acid (50). After 
elution of neutral steroids with 3 × 3 mL CHCl3/MtBE (9:1), steroid acids were eluted using the 
following solvents, each with addition of 5% trifluoroacetic acid (TFA): MeOH, iso-hexane/iso-
propanol (7:3), CHCl3/MtBE (9:1), EtOH/EtOAc (2:8) and CH3CN/acetone (2.5:7.5). Analytes were 
eluted with 2 × 1.5 mL solvent and cholestane (1 µg, IS) was added to each eluate. The eluates were 
evaporated under a stream of nitrogen and the dry residue of each sample was derivatized following the 
protocol for steroid acids (Chapter 2.6.3). The derivatized samples were analyzed with GC-IT-MS 
(Chapter 2.4.1). Recovery was calculated by comparison to the spiked steroids measured without SPE 
in solvent. 
Optimization of sterol sulfate elution was performed using cholesterol sulfate (10S), 25-
hydroxycholesterol sulfate (24S), pregnenolone sulfate (26S), dehydroepiandrosterone sulfate (31S), 
androsterone sulfate (33S), epiandrosterone sulfate (34S), allopregnanolone sulfate (38S), and 
pregnanolone sulfate (39S) as model sterol sulfates. Elution of sterol sulfates was investigated after 
elution of neutral steroids (with 3 × 3 mL CHCl3/MtBE (9:1) and steroid acids (with 2 × 1.5 mL 
EtOH/EtOAc (2:8) + 5% TFA) with 2 × 1.5 mL of the following solvents CHCl3/MeOH (1:1), 
MeOH/H2O (1:1), MeOH/H2O (8:2), MeOH/H2O (9:1) and acetone. To each solvent mixture 5% 
triethylamine (TEA) was added for mixed mode SPE. The consecutive use of TFA and TEA leads to 
the formation of small amounts of TEA-TFA salt in the fractions of sterol sulfates. For the removal of 
this contamination an additional C18 SPE was necessary. For this purpose, the sterol sulfate eluate of 
mixed mode SPE was evaporated to almost dryness under a stream of nitrogen and the residue dissolved 
in 1 mL of 0.1 M HCl/MeOH (7:3). Cholesterol-d7 (10d) (10 µL of 100 µg/mL stock solution) was 
added to each sample to examine the behavior of probably co-eluting traces of cholesterol (cross-
contamination). The C18 sorbent was conditioned with 2 mL MtBE, then 2 mL MeOH and 2 mL of 0.1 
M HCl/MeOH (7:3) and was kept wetted for the whole time. Samples were loaded on the conditioned 
SPE cartridge and contaminants of TEA-TFA salt were removed by washing with 1 mL H2O/MeOH 
(7:3). Sterol sulfates were subsequently eluted with 1 mL of the same solvent as used before for mixed 
mode SPE, but this time without the addition of TEA. Cholestane (10 µL of 100 µg/mL stock solution) 
was added to each eluate. Solvents were removed under a stream of nitrogen at 50 °C and the dry residue 
of each sample was derivatized following the protocol for neutral and sulfated steroids (Chapter 2.6.2). 
The derivatized samples were analyzed with GC-IT-MS (Chapter 2.4.1). Recovery was calculated by 
comparison to the spiked steroids measured without SPE in solvent. 
  








Cholesterol was measured as trimethylsilyl ether (TMS ether). Fifty microliters of MSTFA/TSIM 
(10:1) was added and the sample was kept for 30 min at RT. Finally, 950 µL of MtBE was added and 
the sample was ready for GC-IT-MS analysis (Chapter 2.4.1). 
 
2.6.2 Neutral steroids and sterol sulfates 
 
Neutral steroids and sterol sulfates were measured as their respective O-methyloxime-trimethylsilyl 
ethers (MO-TMS). Sterol sulfates were deconjugated and derivatized in the same step as described 
previously [83]. For this purpose, 200 µL of a solution of O-methylhydroxylamine hydrochloride in 
pyridine 2% (m/v) was added to the dry lipids and kept for 4 h at 80 °C in a 4 mL glass vial. Then the 
sample was transferred into a 2 mL microcentrifuge tube and 400 µl H2O and 1000 µL MtBE were 
added. Liquid-liquid extraction (LLE) was performed by shaking manually for 1 min and centrifugation 
at 10,000 g for 5 min. The organic layer was separated and transferred into an autosampler vial and the 
aqueous phase was extracted one more time with 1000 µL MtBE. The organic phases were combined 
and evaporated to dryness under a stream of nitrogen. Then 50 µL of MSTFA/TSIM (10:1) was added 
and the sample was kept for 30 min at RT. Finally, 940 µL of MtBE and 10 µL internal standard (IS) 
cholestane (48, 1 µg/mL in MtBE) were added before analysis. 
 
2.6.3 Steroid acids 
 
Steroid acids were measured as methyl ester-trimethylsilyl ethers (Me-TMS). To the dry lipids 200 µL 
MeOH and 50 µL HCl conc. were added and the mixture was kept at 80 °C for 30 min. The sample was 
then brought to dryness under a stream of nitrogen at 50 °C. Then 50 µL of MSTFA/TSIM (10:1) was 
added and the sample was kept at RT for 30 min. Finally, 940 µL of MtBE and 10 µL internal standard 
(IS) cholestane (48, 1 µg/mL in MtBE) were added before analysis. 
 
2.7 Investigation of matrix effects 
 
Matrix effects were determined by comparison of the measured peak areas analyzed with and without 
addition of matrix. Therefore, mouse brain samples (50 mg, n=3) were extracted and group separation 
with optimized solvents was performed (see Chapter 2.8.1). The eluates of each class of analytes (neutral 
sterols, steroid acids, and sterol sulfates) were used as matrix. Steroid standards were added to matrix in 
a concentration of 1 µg/50 mg brain tissue, which exceeds the neglectable endogenous concentrations 
of most steroidal compounds in the brain extracts. In case of desmosterol (13) we used desmosterol-d6 
(13d). Solvent samples were prepared with the same steroid standards and concentration. Samples were 
derivatized as described in Chapters 2.6.2 and 2.6.3 and were analyzed with GC-IT-MS (Chapter 2.4.1). 
The ratios of the obtained peak areas with and without matrix were determined for 11 neutral steroids 
(23, 24, 26d, 28, 29-32, and 37-39), 6 steroid acids (40, 44-47, and 50) and 8 sterol sulfates (10S, 24S, 
26S, 31S, 33S, 34S, 38S and 39S). 
2.8 Final method and validation 
 
2.8.1  Final sample preparation protocol 
 
The optimized sample preparation procedure is shown in Figure 1. Tissues (250 -1,500 mg) were 
extracted in grinding tubes, smaller amounts of tissues were extracted in 2 mL microcentrifuge tubes as 
described in 2.5.1. The internal standards were added. For cholesterol precursors desmosterol-d6 (13d) 
(100 ng/250 mg liver; 1000 ng/100 mg brain) was used as internal standard. Pregnenolone-20,21-13C2-




16,16-d2 (26d) (10 ng/250 mg liver; 10 ng/ 100 mg brain) was used as internal standard for the other 
neutral steroids. Pregnenolone-20,21-13C2-16,16-d2 sulfate (26Sd) (10 ng/250 mg liver; 10 ng/100 mg 
brain) was used as internal standard for sterol sulfates. Fernholtz acid (50) (500 ng/250 mg liver; 50 
ng/100 mg brain) was used as internal standard for steroid acids. After addition of these standards, a 
small aliquot of the extract corresponding to 1 mg liver or 0.4 mg brain tissue was diverted for 
cholesterol analysis. For cholesterol analysis cholestane (48) (10 µL of 100 µg/mL stock solution) was 
added to the aliquot and solvent was evaporated to dryness under a stream of nitrogen. Derivatization 
was performed as described in Chapter 2.6.1. and cholesterol samples were analyzed with GC-IT-MS 
(Chapter 2.4.1.). Aliquots for group separation referring to 100 mg brain tissue or 250 mg liver tissue 
were used for SPE. The extracts were dried under a stream of nitrogen and stored at -20 °C before 
analysis. Conditioning and loading of the weak anion exchange cartridge was performed as described in 
Chapter 2.5.2. The best elution solvent for neutral steroids was CHCl3/MtBE (9:1) 3 × 3 mL, for steroid 
acids EtOH/EtOAc (2:8) + 5% TFA 2 × 1.5 mL and for sterol sulfates MeOH/H2O (9:1) + 5% TEA 2 × 
1.5 mL and MeOH/H2O (9:1) 1 mL. Every sample was derivatized (Chapters 2.6.2 an 2.6.3) and 
analyzed with GC-IT-MS and/or GC-MS/MS (Chapters 2.4.1 and 2.4.2).  
 
Figure 10 Final Sample preparation protocol 
 
 
2.8.2  Identification of steroids 
 
Steroidal compounds were identified using their respective relative retention time (RRT) relating to 
the internal standard cholestane (48) and, in the case of scan data, on basis of the obtained mass spectra. 
The spectra were compared to those obtained for authentic standards or mass spectra previously 
published by us and others [63, 79, 81, 82] (Table 2). In case of dMRM data steroidal compounds were 
identified using their respective relative retention time (RRT) relating to the internal standard cholestane 
(48) and on basis of one or two qualifier and one quantifier transitions (Table 2) [84]. The transitions 
for each compound were chosen under consideration of co-eluting similar compounds and matrix 




components. Collision energies were optimized using MassHunter MRM optimizations software and 




Quantification was performed using an external calibration. The calibration standards were measured 
in 6 different concentrations with a consistent concentration of internal standard. This concentration was 
100 ng/mL for liver and 1000 ng/mL for brain samples desmosterol-d6 (13d) for cholesterol precursors 
and 10 ng/mL pregnenolone-20,21-13C2-16,16-d2 (26d) for the other neutral steroids. For the steroid 
acids Fernholtz acid (50) was used as internal standard in a concentration of 500 ng/mL for liver samples 
and 50 ng/mL for brain samples. For sterol sulfates pregnenolone-20,21-13C2-16,16-d2 sulfate (26dS, 10 
ng/mL) was used. For cholesterol (10) determination the internal standard was cholestane (48, 1 µg/mL). 
The calibrators were measured in triplicates using a bracketing procedure and peak area ratios from 
quantifier ions/transitions of the analytes and internal standards were plotted against the corresponding 
concentration. The individual calibration ranges and results of linear regression are given in Tables 7 
and 8. 
 
2.8.4 Determination of LOD and LOQ 
 
Limit of detection (LOD) and limit of quantification (LOQ) were determined using linear regression 
according to DIN 32645 [85]. Authentic standards (3-5, 8-10, 12, 13, 15, 18, 19, 22-24, 24S, 26, 26S, 
28-32, 31S, 33S, 34S, 37-41, 38S, 39S and 43-47) were measured in solvent because no steroid-free 
brain or liver matrix was available and matrix effects have shown to be limited (Chapter 3.2). LOD and 
LOQ values were calculated individually for liver and brain tissue with regards to the different amounts 
of tissue which could be used for analysis (250 mg liver tissue; 100 mg brain tissue). LOD and LOQ for 
the analyzed steroids are given in Tables 7 and 8.  
 
2.8.5 Precision and recovery 
 
Precision and recovery were determined as described by Rustichelli et al. [46], who used three different 
sets of quality control (QCa, QCb and QCc) samples. QCa samples were prepared from 400 mg brain 
(n=3) and 1,000 mg liver (n=3). For this purpose, the respective concentrations of internal standards 
were added, and the samples were prepared as described in Chapter 2.8.1. QCb samples were prepared 
from 400 mg brain (n=6) and 1000 mg liver (n=6). In addition to the respective concentrations of internal 
standards the samples were spiked with authentic standards (3-5, 8, 9, 12, 13, 15, 18, 19, 22-24, 24S, 
26, 26S, 28-32, 31S, 33S, 34S, 37-41, 38S, 39, 39S and 43-47) at two different concentrations (LOQ: 
n=6; 50 × LOQ: n=6). Then the samples were prepared as described in chapter 2.8.1. QCc samples were 
prepared in the same manner as the QCb samples but were spiked with authentic standards (LOQ: n=3; 
50 × LOQ: n=3) after sample preparation, just before the deconjugation/derivatization step. Precision 
was calculated as relative standard deviation (RSD) of the spiked authentic standards in QCb samples 
(n=6). Recovery was calculated by comparing the mean values obtained from QCc-QCa samples with 
those of QCb-QCa.  
 
2.9 Application on biological samples 
 
The method was applied on brain and liver samples of 10 months old female mice and on brain of 3 
weeks old male mice. The whole brains and livers were extracted in grinding tubes and further sample 
preparation and analysis was done in technical triplicates. Furthermore, the method was also applied to 
cultured N2a cells which were extracted using microcentrifuge tubes. Per sample ~ 3 × 107 cells 
corresponding to ~ 200 mg cell mass were used (n = 6).   
  




3. Results and discussion 
 
3.1 Sample preparation 
 
3.1.1 Lipid extraction 
There are various methods published for lipid extraction from biological samples. The most popular 
methods were published by Folch et al. [86] and Bligh and Dyer [87]. Their methods work with varying 
amounts of MeOH, CHCl3 and H2O. These solvents are still frequently used for lipid extraction even if 
the exact procedure may vary [31, 39]. In recent publications some authors tried to substitute these 
solvents by less toxic EtOH and EtOAc [88, 89]. Another possible procedure is saponification with hot 
aqueous NaOH or KOH and then extraction in an organic solvent like diethyl ether, MtBE or hexane 
[63, 90]. Preliminary experiments revealed that a mixture of EtOAc, EtOH and H2O was as effective as 
CHCl3/MeOH mixtures or saponification with hot aqueous NaOH solution for neutral steroid extraction, 
and even superior for steroid acids extraction. The extraction procedure with EtOAc has some more 
advantages, as unlike to CHCl3 the organic phase is the upper layer and can easily be collected without 
contaminations with the aqueous phase. And in contrast to the saponification protocol we do not need 
harsh conditions and elevated temperatures, which is one main reason for cholesterol autoxidation that 
could lead to the formation of artefacts like 7-hydroxy- or 7-oxocholesterol [91]. Without saponification 
free cholesterol can also be distinguished from cholesterol fatty acid esters. Hence, in the final extraction 
protocol the solvent system EtOH, EtOAc and H2O was used. In addition, the antioxidant 
butylhydroxytoluene (BHT) was used to avoid cholesterol autoxidation and hydrochloric acid was used 
for acidification of the aqueous phase to increase extraction of steroidal acids and sterol sulfates. 
Additionally, a high concentration of KCl improved phase separation and lipid recovery.  
3.1.2 Steroid group separation 
 
After extraction the lipids were separated into different groups: neutral steroids, steroid acids and sterol 
sulfates. This separation is necessary to differentiate between sterols and the respective sterol sulfates, 
which were finally also measured in their deconjugated form. Another reason is the derivatization 
procedure for the steroid acids which varies from neutral or sulfated steroids. A separation just basing 
on the polarity of the analytes, as liquid-liquid-extraction (LLE) [40], column chromatography [92] or 
reversed phase SPE [41] was only successful for a smaller group of steroids, for example C19 and C21 
steroids and their corresponding sulfates. Including C27 steroids (cholesterol precursors), whose 
corresponding sulfates could be more lipophilic than unconjugated smaller steroids, the analysis requires 
another separation mechanism. This could be achieved by SPE with an anion exchange sorbent. Griffiths 
et al. [93] presented a universal extraction scheme employing subsequent solid phase extractions on C18, 
cation exchange and anion exchange sorbents. Following this principle including three to five separation 
steps Liu et al. [43] measured neurosteroids (e.g. progesterone, dehydroepiandrosterone and 
pregnenolone) and sterol sulfates in rat brain. Their sample preparation also gave a fraction of weak 
acids that was not further analyzed. We followed this principle using reversed phase (RP) SPE in 
combination with ion exchange sorbents, but instead of subsequent extraction steps on different 
cartridges, we used a mixed mode sorbent with RP and weak anion exchange properties. So, we could 
reduce the number of extraction steps and achieve a robust method with high reproducibility. In the first 
elution step neutral steroids were eluted from the cartridge. Subsequently, steroid acids were eluted in 
their uncharged form from the sorbent under acidic conditions. The more acidic sterol sulfates remained 
on the column under these conditions and were eluted in a last step under alkaline conditions. 
 
3.1.3 Neutral steroids 
 
The results of the optimization experiments for elution of neutral steroids are shown in Table 3. The 
best results were obtained for CHCl3/MtBE (9:1). Under these conditions the highest recoveries for most 
tested steroids were achieved and the relative standard deviations (RSD) were within an acceptable 




range. Steroids were eluted with a final volume of 9 mL (3 × 3 mL). Further experiments with larger 
volumes of CHCl3/MtBE (9:1) were performed and it was determined that 99.9% of the endogenous 
cholesterol is eluted with the first 9 mL. Moreover, lithocholic acid (47) started to elute from the solid 




Mean recovery for various neutral steroids using different solvents (n=3) and respective average relative standard deviations 
(RSD). Log P values (calculated) of analyzed neutral steroids are shown. The final extraction mixture is given in bold letters. 






















































13d Desmosterol-d6 6.7 84 54 90 80 








3.4 29 20 72 57 




3.9 80 84 100 47 
38 Allopregnanolone 4.0 78 73 95 62 
39 Pregnanolone 4.0 80 74 98 62 
 Average recovery [%]  68 60 90 64 
 Average RSD [%]  19 23 19 16 
 
3.1.4 Steroid acids 
 
The results of the optimization experiment for elution of steroid acids are shown in Table 4. The best 
recoveries for most steroid acids were obtained with iso-hexane/iso-propanol (7:3) + 5% TFA and 
EtOH/EtOAc (2:8) + 5% TFA. The recovery of the EtOH/EtOAc (2:8) + 5% TFA protocol was better and 
with lower RSD for the more lipophilic steroid acids. With consideration of further steroid acids that are 
even more lipophilic than lithocholic acid (47), e.g. 3β-hydroxycholestenoic acid (40), and are expected 
to be found only in trace amounts, the mixture of EtOH/EtOAc (2:8) + 5% TFA was chosen. The example 
of 49 shows the limitation of this separation step. This very lipophilic steroidal acid was eluted to a great 
extent in the fraction of neutral steroids. For that reason, we performed an additional experiment for 
cholestenoic acid (40) because it has similar lipophilic properties (Log P 6.1) and confirmed that this 
steroidal acid was indeed eluting in the steroid acid fraction. 
  





Mean recovery in % for various steroid acids using different solvents (n=3) and respective average RSD. Log P values 
(calculated) of analyzed steroid acids are shown. The final extraction mixture is given in bold letters. 











































































































44 Cholic acid 2.5 133 123 15 118 75 
45 Chenodeoxycholic acid 3.7 100 107 113 104 86 
47 Lithocholic acid 5.0 75 89 115 93 75 
49 Cholanic acid 6.5 21 5 4 5 6 
50 Fernholtz acid 4.0 21 106 113 88 93 
 Average recovery [%]  70 86 72 82 67 
 Average RSD [%]  39 10 28 6 33 
 
3.1.5 Sterol sulfates 
 
The results of the optimization experiment for elution of sterol sulfates are shown in Table 5. The best 
results were obtained for MeOH/H2O (9:1) + 5% TEA. Sterol sulfates were eluted under alkaline 
conditions from the SPE sorbent. For this reason, the Log D value (calculated) for the sterol sulfate 
anion is specified. The elution of sterol sulfates from the weak anion exchange sorbent was followed by 
an additional purification step on a C18 SPE cartridge. This is necessary to remove the TFA-TEA salt, 
originating from reaction of TFA from the previous elution step with TEA from the present elution, 
which had shown to disturb the following deconjugation and derivatization steps. In this experiment the 
same mixture was used for both SPEs, but in case of the C18 SPE without the addition of TEA. 
Furthermore, cholesterol-d7 (10d) was added right before C18 SPE to monitor the elution of unconjugated 
cholesterol, which could still be retained in small amounts in the sample and would cause wrong results 
for cholesterol sulfate (10S) measurement. For this reason, solvents which were able to elute 10d were 
excluded. This was the case for acetone and CHCl3/MeOH (1:1). In both cases large amounts of detected 
cholesterol sulfate could be co-eluting with residual free cholesterol.  
  





Mean recovery in % for various sterol sulfates using different solvents (n=3) and respective average RSD. Log D values 
(calculated) of analyzed sterol sulfate anions are shown. *: Solvents which also elute unconjugated cholesterol-d7. The final 
extraction mixture is given in bold letters. 


































































































3.4 76 0 52 79 29 




1.0 96 24 104 111 30 
33S Androsterone sulfate 1.5 87 18 105 106 31 




1.7 83 0 95 105 29 
39S Pregnanolone sulfate 1.7 90 0 94 104 27 
 
Average recovery [%]  106* 8 82 92 45* 
 
Average RSD [%]  15 37 27 13 29 
 
3.2 Investigation of matrix effects 
 
Compared to LC-MS/MS matrix effects in GC-MS are known to be minimal [69], even so it is 
recommended to prepare calibration standards in blank matrix [94]. As no steroid-free matrix for brain 
or liver tissue was available the calibration standards had to be prepared in solvent. For this reason, 
matrix effects for all three groups of steroidal compounds were investigated before method validation. 
Brain tissue was chosen for the experiments due to its large amounts of lipids, which are likely to be co-
extracted with the steroids. The matrix effects for neutral steroids (23, 24, 28, 29, 30, 31, 32, 37, 38 and 
39), steroid acids (40, 44, 45, 46, and 47) and sterol sulfates (10S, 24S, 31S, 33S, 34S, 38S and 39S) 
were investigated using several representative compounds (1 µg/50 mg brain tissue) from each steroid 
group. The matrix effects were determined by comparing the peak areas obtained in matrix with those 
obtained in solvent. The mean value for every steroid group is shown in the first row of Table 6. In the 
second row the effect is given after correction with the respective internal standards. The internal 
standards were isotope-labelled pregnenolone (26d) for neutral steroids, Fernholtz acid (50) for steroid 
acids and isotope-labelled pregnenolone sulfate (26dS) for the sterol sulfates.  
 
Table 6 
Mean ratio of peak areas of steroidal compounds measured in spiked matrix compared to pure solvent.  
 
Neutral steroids Steroid acids Sterol sulfates 
Peak area ratio without 
correction with IS 
1.30 2.32 1.11 
Peak area ratio after 
correction with IS 
1.03 1.06 1.15 
 
 
There was a trend to higher areas with matrix matched standards compared to standards analyzed in 
solvent. This matrix enhancement effect [95] seems to take effect especially on the steroid acids. 
However, this effect was successfully compensated by the used of appropriate internal standards. The 




enhancing effect on sterol sulfates is not as high as for other groups, this is most likely due to the matrix 
composition of this group. In this case the effect of the internal standard is small and does not improve 
the result. Despite of that the internal standard for the sterol sulfates is important regarding the whole 
sample preparation procedure because it compensates losses and variations in sample preparation, which 
includes two critical solid phase extraction steps. The chosen internal standards are acceptable for a huge 
number of steroids in the particular groups (individual values for every tested compound are given in 
Figure 2). Anyway the best internal standard for every analyte would be its isotope-labeled counterpart, 
but these labeled compounds are often not commercially available or very expensive. 
Figure 2 Matrix effects for individual compounds with (green) and without (red) correction using the respective internal 
standards
 
3.3 Method performance 
 
The method performance was investigated for 23 neutral steroids (3-5, 8-10, 12, 13, 15, 18, 19, 22-24, 
26, 28- 32 and 37-39) 7 steroid acids (40, 41 and 43-47) and 7 sterol sulfates (24S, 26S, 31S, 33S, 34S, 
38S and 39S). We determined the selectivity, linearity, precision, recovery, limit of detection (LOD), 
and limit of quantification (LOQ) for each individual analyte in brain and in liver tissue. As no great 
differences between those two matrices were noticed, no further validation experiments for cultured cell 
matrix were necessary. 






Compounds were identified using the RRT relative to cholestane (48) and full scan mass spectra or 
dynamic MRM transitions. In Figure 3 chromatograms of dynamic MRM measurements are shown. The 
chosen transitions were sufficiently distinctive even for compounds with identical retention times, as for 
example 7α-hydroxydehydroepiandrosterone (32) and epiandrosterone (34) (Figure 3D). Other 
compounds could be distinguished because of their different retention times although they have identical 
mass transitions, as for example allopregnanolone (38) and pregnanolone (39) (Figure 3B). It should be 
mentioned that progesterone (29) and its hydroxylated metabolites have asymmetrical peak shapes (29, 
37, and 30) (Figure 3B). This is due to endo- and exo-isomeric MO derivatives. These peaks were 
processed as one single peak. 
  




Figure 3 dMRM chromatograms with selected transitions for several steroidal compounds. Transitions referring to one 
compound are marked in the same color. Numbers in the diagram represent the detected steroids as are given in Table 2. A: 
cholesterol precursors (C27 – C30 steroids); B: C21 steroids C: oxysterols; D: C19 steroids; E: steroid acids.  
 




Cholesterol is, because of its high concentration in most biological samples, not analyzed in the same 
run as the other neutral steroids. But its huge amount, especially in brain samples, could still be 
problematic for the analysis of the other neutral steroids. The high on column concentration on the GC-
MS/MS system and the thereof resulting tailing of the cholesterol peak can lead to an overlap with the 
next eluting steroids like lathosterol (8) or desmosterol (13). In this case these steroids could be 
measured alternatively on the GC-IT-MS system with lower on column cholesterol concentration due 
to the lower injection volume (1 µL instead of 5 µL; see Chapter 2.4). 
3.3.2 LOD, LOQ, linearity, precision and recovery 
  
LOD and LOQ were calculated according to DIN 32645 [85]. This method considered slope, intercept 
and residual standard deviation of a calibration curve over a limited concentration range. The advantage 
of this method is that it reveals the individual values for each compound even if they have large 
differences in their LOD and LOQ (see Tables 7 and 8). The achieved limits enable the measurement of 
most endogenous steroids. Only the 17-hydroxylated compounds 28 and 30 had relatively high LOD 
and LOQ. For verification the method precision (RSD of QCb samples, n=6) was measured at LOQ or 
at the lower end of the working range (e.g. 25 ng lanosterol/100 mg brain tissue). One exception was 
cholesterol that was only analyzed at the endogenous level. In this case the precision was calculated as 
RSD of all QC samples. The obtained precision was <20% for 31 compounds in liver tissue and for 20 
compounds in brain tissue and <30% for 34 (liver) and 30 (brain) compounds. Method precision was 
measured also at a medium level corresponding to the middle concentration of working range (e.g. 1,250 
ng lanosterol/100mg brain tissue) and was <20% for 34 (liver) and 31 (brain) compounds and <30% for 
35 (liver) and 32 (brain) compounds. So, no great differences could be determined between the different 
matrices. Measurement of technical replicates would be useful if a sufficient amount of sample is 
available. Higher concentrations were not tested, because this concentration in combination with the 
endogenous amount would exceed the working range by far for some compounds (e.g. cholesterol 
precursors). Determination of recovery is challenging due to the necessary subtraction of the endogenous 
concentration which can lead to inaccuracies because no steroid-free matrix is available for brain and 
liver tissue. So, the recovery was only estimated at medium concentration because endogenous 
concentration did not affect these values that much. For 30 (liver) and 23 (brain) compounds the recovery 
was >50%. Linearity was measured in a bracketing process and was >0.980 for 26 (liver) and 19 (brain) 
compounds. Some compounds showed just sufficient linearity, for example 7-ketocholesterol (18, R2 
0.932), this problem was already described by other authors [65]. Other compounds show difficulties at 
higher concentrations, like desmosterol (13) or lathosterol (8) measured in dMRM in case of liver 
samples. The steroid acids in general showed a smaller linear range compared to the other compounds. 
Linearity and recovery could be improved when using the respective isotope-labelled internal standard, 
which is recommended if a specific steroid of interest should be quantitated with higher accuracy. 
  




Table 7 Validation data for brain samples. *: Desmosterol-d6 as IS instead of isotope labeled pregnenolone. IT: measured with 
GC-IT-MS; * precision calculated by the analytical data obtained at the endogenous level. 
 
  












3 Lanosterol 0.049 0.247 25 - 2500 0.924 8 27 
4 Dihydrolanosterol 0.016 0.028 1.6 - 160 0.958 8 36 
5 4,4-Dimethyl-5α-cholesta-
8,14-dienol 
0.006 0.016 0.6 - 60 0.960 8 42 
8 Lathosterol 0.006 0.039 50 – 5000 IT 0.997 IT 15 IT 162IT 
10 Cholesterol 0.850 4.700 10 - 100 IT 0.999 IT 9 IT* n.d. 
13 Desmosterol 0.009 0.025 200 – 20000 IT 0.998 IT 16 IT 112 IT 
15 4,4-Dimethylcholesta-5,7-
dienol 
0.018 0.018 1.8 - 180 0.916 7 49 
18 7-Ketocholesterol  0.159 0.251 25 - 2500 0.932 20 42 
22 24S-Hydroxycholesterol 0.013 0.040 50 – 5000 IT * 0.968 IT* 42 IT* 59 IT* 
23 27-Hydroxycholesterol 0.004 0.006 10 - 1000 0.905 10 35 
24 25-Hydroxycholesterol 0.008 0.032 0.80 – 80 0.998 8 50 
24S 25-Hydroxycholesterol sulfate 0.004 0.004 0.41 - 41 0.985 8 35 
26 Pregnenolone 0.002 0.004 0.40 - 40 0.999 26 79 
26S Pregnenolone sulfate 0.004 0.010 1.0 - 100 0.997 4 49 
28 17-Hydroxypregnenolone 0.134 0.383 38 - 3800 0.997 67 102 
29 Progesterone 0.001 0.002 0.08 – 8.0 0.982 4 78 
30 17-Hydroxyprogesterone 0.162 0.487 49 - 4900 0.993 8 75 
31 Dehydroepiandrosterone 0.003 0.005 0.33 - 33 0.999 3 68 
31S Dehydroepiandrosterone 
sulfate 




0.001 0.002 0.04 – 4.0 0.971 16 31 
33S Androsterone sulfate 0.004 0.010 0.99 - 99 0.995 6 65 
34S Epiandrosterone sulfate 0.014 0.030 3.0 - 300 0.988 8 55 
37 20α-Hydroxyprogesterone 0.002 0.002 0.16 - 16 0.983 7 81 
38 Allopregnanolone 0.002 0.002 0.24 - 24 0.972 6 58 
38S Allopregnanolone sulfate 0.001 0.002 0.22 - 22 0.998 13 61 
39 Pregnanolone 0.002 0.010 0.20 - 20 0.987 6 68 
39S Pregnanolone sulfate 0.001 0.002 0.16 - 16 0.998 13 50 
40 Cholestenoic acid 0.016 0.035 3.5 - 350 0.858 8 94 
41 3β,7α-Dihydroxycholestenoic 
acid 
0.006 0.269 26 - 2600 0.923 15 19 
43 Trihydroxycoprostanoic acid 0.006 0.031 3.0 - 300 0.979 5 83 
44 Cholic acid 0.017 0.171 17 - 1700 0.968 13 118 
45 Chenodeoxycholic acid 0.012 0.033 3.3 - 330 0.975 5 96 
46 Deoxycholic acid 0.009 0.028 2.8 - 280 0.994 18 81 
47 Lithocholic acid 0.003 0.013 1.3 - 130 0.961 1 82 




Table 8 Validation data for liver samples. IT: measured with GC-IT-MS; * precision calculated by the analytical data obtained 
at the endogenous level. 
 
  












3 Lanosterol 0.020 0.099 25 - 2500 0.987 5 68 




0.002 0.007 0.6 - 60 0.989 7 62 
8 Lathosterol 0.002 0.016 0.6 - 60 0.902 4 58 
9 7-Dehydrocholesterol 0.008 0.009 15 - 1500 0.916 5 73 
10 Cholesterol 0.340 IT 1.880 IT 1.0 - 10 IT 0.999 IT 9 IT* n.d. 
12 Zymosterol 0.009 0.009 2.2 - 220 0.917 14 97 




0.007 0.007 1.8 - 180 0.989 8 64 
18 7-Ketocholesterol 0.064 0.100 25 - 2500 0.930 7 63 
19 7β-Hydroxycholesterol 0.001 0.001 0.14 - 14 0.996 11 91 
22 24S-Hydroxycholesterol 0.005 0.016 1.3 - 130 0.999 11 61 
23 27-Hydroxycholesterol 0.002 0.003 0.37 - 37 0.979 4 51 




0.002 0.002 0.41 - 41 0.998 18 35 
26 Pregnenolone 0.001 0.002 0.40 - 40 0.989 7 78 
26S Pregnenolone sulfate 0.001 0.004 1.00 - 100 0.999 10 55 
28 17-Hydroxypregnenolone 0.054 0.153 38 - 3800 0.990 9 74 
29 Progesterone 0.001 0.001 0.08 - 8.0 0.984 7 80 
30 17-Hydroxyprogesterone 0.065 0.195 49 - 4900 0.989 12 76 









0.001 0.001 0.04 - 4.0 0.993 9 26 
33S Androsterone sulfate 0.001 0.004 0.99 - 99 0.992 4 56 
34S Epiandrosterone sulfate 0.005 0.012 3.0 - 300 0.994 6 52 
37 20α-Hydroxyprogesterone 0.001 0.001 0.16 - 16 0.997 4 78 
38 Allopregnanolone 0.001 0.002 0.24 - 24 0.988 11 71 
38S Allopregnanolone sulfate 0.001 0.001 0.22 - 22 0.990 50 30 
39 Pregnanolone 0.001 0.004 0.20 - 20 0.985 11 70 
39S Pregnanolone sulfate 0.001 0.001 0.16 - 16 0.999 46 37 








0.002 0.012 3.1 - 310 0.983 8 80 
44 Cholic acid 0.007 0.068 17 - 850 0.992 8 19 
45 Chenodeoxycholic acid 0.005 0.013 15 - 750 0.976 7 61 
46 Deoxycholic acid 0.004 0.011 30 - 1500 0.964 9 68 
47 Lithocholic acid 0.001 0.005 15 - 750 0.995 7 61 




3.4 Application on biological samples 
 
Results of analysis of liver, brain and cell samples are shown in Table 9. The results obtained with this 
method fit in most cases with previously published values. It should be mentioned that published data 
on endogenous steroid concentrations have noticeable variations. Concentrations are also dependent on 
age, gender and diet of the animals. Furthermore the determined concentrations can also vary on the 
used analytical procedure. With this approach cholesterol precursors, oxysterols, neurosteroids, 
unconjugated steroid acids and sterol sulfates can be analyzed. However some sterols (e.g. bile acids) 
are preferably present as taurine- or glycine-conjugates, which cannot be determined by this approach 
(see 1. Introduction). 




Table 9 Identified and quantified steroids of mouse brain and liver tissue and cell samples. The concentrations measured with targeted analysis are given as mean ± SD [ng/mg] (n=3) or < LOQ for 
brain and liver tissue. The concentrations measured with targeted analysis are given as mean ± SD [ng/mg] (n=6) or < LOQ for N2a cells. Steroids only detected with the screening method (scan) 
are marked with +. Steroids that could not be detected are marked with n.d.; The unknown muricholic acids 52 and 53 are likely β- and ω-muricholic acid. Results are compared with published data 
[ng/mg], if available. Cholesterol biosynthesis precursors, oxysterols, C19/C21 steroids and sterol sulfates were measured as MO-TMS derivatives (Chapter 2.6.2). Steroid acids were measured as Me-






No. Trivial name 3 weeks 10 months 10 months  References 
 animal 1 2 3 1 2 3 1 2 3 1  
Cholesterol biosynthesis precursors 






















Liver: 1.3-4.9 (2-5 months) [96] 





















Liver: 0.15-0.5 (2-5 months) [96] 

























6 4,4-Dimethylcholest-8-enol + + + n.d. n.d. n.d. n.d. n.d. n.d. n.d.  






















Brain: 20-30 (16-18 weeks) [76] 
Liver: 1.7-2.1 (2-5 months) [96] 






















Cultured cells: 1.48 [60] 
Liver: 0.5-1 (2-5 months) [96] 






















Brain: 16000 (15 weeks) [97] 
Liver: 1800 (2-5 months) [96] 
Cultured cells: 8608 [60] 
11 Cholestanol + n.d. + n.d. + + n.d. n.d. n.d. n.d.  

























Liver: 0.1-0.7 (19 weeks, high fat diet) 
[98] 






















Brain: 100 (15 weeks) [97] 
Liver: 1.2-1.8 (2-5 months) [96] 



































































Brain: <0.05 (15 weeks) [97] 
20 7α-Hydroxycholesterol + + + + + + n.d. n.d. n.d. + Liver: 0.087 [77] 






















Brain: 27.91±0.73 (15 weeks) [97] 
Liver: 0.009-0.027 (2-5 months) [96], 






















Brain: 3.9-6 (3-18 months) [17] 
Liver: 0.013-0.019 (2-5 months) [96], 
0.083 (8 weeks) [77] 







Brain: <0.05 (15 weeks) [97] 
Liver: 0.015 (8 weeks) [77] 























Brain: 0.00165±0.00023 (8 weeks) 
[99] 
0.00167 (male rat) [100] 
0.015 (female rat) [101] 
28 17-Hydroxypregnenolone n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. Brain: n.d. (rat) [100] 
29 Progesterone < 0.002 n.d. n.d. 
0.003 
± 0.00 
< 0.002 < 0.002 n.d. n.d. n.d. n.d. 
Brain: 0.001-0.02 (rat) [43] 
0.008 (female rat) [101] 
0.0007 (male rat) [100] 


















< 0.002 < 0.002 < 0.002 
0.05 
± 0.01 
Brain: 0.00004-0.00011 (rat) [43] 
0.00027 (male rat) [100] 
0.012 (female rat) [101] 
34 Epiandrosterone n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. Brain: n.d. (male rat) [100] 
37 20-Hydroxyprogesterone n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. Brain: 0.00019 (male rat) [100] 
38 Allopregnanolone n.d. < 0.002 n.d. n.d. n.d. < 0.002 n.d. n.d. n.d. n.d. 
Brain: 0.00402±0.00031 (8 weeks) 
[99] 
0.00042-0.038 (rat) [43] 
39 Pregnanolone n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.-0.00016 (rat) [43] 
Steroid acids 





























Brain: 0.047±0.077 (rat) [102] 
Liver: 20-40 [79] 
8.9-22.7 (rat) [103] 









Brain: 0.630±0.23 [102] 
Liver: 0.98-2.6 (rat) [103] 




















Brain: 0.025±0.020 (rat) [102] 
Liver: 2.7-5.1 (rat) [103] 









Liver 1.5-2.6 (rat) [103] 
Sterol sulfates 
26S Pregnenolone sulfate < 0.010 
0.10 
± 0.07 
< 0.010 < 0.010 < 0.010 < 0.010 < 0.004 < 0.004 < 0.004 
0.01 
± 0.00 
Brain: .n.d.-0.00028 (rat) [39] 
n.d. (male rat) [100] 
Liver: n.d. (rat) [39] 













n.d. n.d. < 0.003 
0.01 
± 0.00 
Brain: n.d. (rat) [39] 
0.00104 (male rat) [100] 
Liver: 0.00041-0.00074 (rat) [39] 
33S Androsterone sulfate n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. < 0.004 n.d.  
























Brain: n.d. (male rat) [100]] 
38S Allopregnanolone sulfate < 0.002 
0.16 
± 0.10 
< 0.002 < 0.002 < 0.002 < 0.002 < 0.001 < 0.001 < 0.001 n.d.  
39S Pregnanolone sulfate < 0.002 
0.14 
± 0.09 
n.d. < 0.002 < 0.002 n.d. < 0.001 < 0.001 < 0.001 < 0.001  













n.d. n.d. < 0.002 n.d.  
others 
51 α-Muricholic acid n.d. n.d. n.d. n.d. n.d. n.d. + + + n.d. Brain: n.d. (rat) [102] 
52 unknown Muricholic acid 1 n.d. n.d. n.d. n.d. n.d. n.d. + + + n.d.  
53 unknown Muricholic acid 2 n.d. n.d. n.d. n.d. n.d. n.d. + + + n.d.  
54 T-MAS + + + + + + n.d. n.d. n.d. + Cultured cells: 1.32 [60] 
55 Sitosterol + + n.d. n.d. n.d. + + + + n.d. Cultured cells: 3.45[60] 
56 Campesterol n.d. n.d. n.d. n.d. n.d. n.d. + + + n.d. Cultured cells: 8.22 [60] 
57 Cholesta-7,24-dienol + + + n.d. n.d. n.d. n.d. n.d. n.d. +  
58 Lophenol + + + n.d. n.d. n.d. n.d. n.d. n.d. n.d.  
59 4-Methylcholesta-7,24-dienol + + + + + + n.d. n.d. n.d. n.d.  
 




Figure 4 Total ion chromatograms from GC-IT-MS (full scan m/z 50 – 650). A: Mouse brain; 10 months old; B: Mouse brain; 3 weeks old; C: Mouse liver, 10 months old; D: N2a cells. Neutral 
steroids: green; steroid acids: red; sterol sulfates: yellow. 10*/10*(S): cholesterol detected in steroid acid and sterol sulfates fractions. Numbers in the diagram represent the detected steroids as are 
given in Table 2. 
 




Scan chromatograms measured with IT-MS are shown in Figure 4. Here some additional compounds 
could be identified by comparing with literature data, for example the phytosterols sitosterol (55) and 
campesterol (56) and murine bile acids. Small amounts of residual cholesterol were detected in the 
steroid acids and sterol sulfate groups, where it could not be distinguished from cholesterol 
sulfate.Cholestanol (11, RRT 1.232), 7α-hydroxycholesterol (20, RRT 1.185), and trihydroxycoprostan 
(21, RRT 1.193) could be clearly identified. But due to the high concentration of cholesterol (10, RRT 
1.226) and their nearly identical relative retention times a reliable quantification of 11, 20, and 21 was 




The described GC-MS method allows the analysis of neutral steroids, steroid acids and sterol sulfates 
from one single sample. This method is suitable for brain and liver tissue and is also applicable on 
cultured cells. The combination of scan and dMRM measurement allows identification of unknown or 
unexpected compounds and quantification of targeted compounds in trace amounts. Especially the peak 
spectra obtained in scan mode can help to identify unexpected compounds by comparing with MS 
databases or literature data. The method has some limitations due to the large amounts of cholesterol in 
most biological samples. A complete elution in the group of neutral steroids is not guaranteed and 
residual cholesterol is then found in the following eluates. This makes an indirect measurement of 
cholesterol sulfate impossible. For this compound direct analysis in presence of cholesterol like LC-MS 
analysis is an alternative [64]. In some cases, the high on column concentration of cholesterol also leads 
to a strong peak tailing which could make the proper analysis of compounds eluting right after 
cholesterol difficult. This is the case for some intermediates of cholesterol biosynthesis, then injection 
of a smaller sample volume, as described for GC-IT-MS analysis, can be a solution, as shown for 
lathosterol (8) and desmosterol (13) in brain samples. There are few methods covering a higher number 
of analytes (Table 1), but we present here the up to our knowledge first method covering this large range 
of different steroid classes including cholesterol precursors, oxysterols, C19 and C21 steroids, steroid 
acids and sterol sulfates. The list of analyzed steroids can certainly be extended with further compounds 
of interest. To improve precision of quantification of certain analytes and to minimize matrix effects, 
the use of the respective isotope-labelled internal standards is recommended for targeted analysis. As 
our method has the potential for untargeted screening and steroid profiling in different tissues it could 
be used for further investigation and comprehension of diseases like AD, CAH, CTX, SLOS and more.  
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5.1. Summary 
Cholesterol biosynthesis is the target of cholesterol lowering drugs, which are frequently used 
in therapy of cardiovascular diseases to decrease morbidity and mortality [66, 79]. The most 
commonly used cholesterol lowering drugs are statins, which interfere at an early stage in pre-
squalene pathway of cholesterol biosynthesis. Other drugs, such as triparanolol (MER-29) [80] 
and AY-9944 [81], which interfere in a later stage of cholesterol biosynthesis have not been 
successfully applied due to severe side effects [82]. Some of these side effects could be 
explained by intrinsic effects of accumulating cholesterol precursors [82]. This accumulation of 
cholesterol precursors was also observed in some congenital diseases, like SLOS [12, 16]. In 
other cases, an accumulation of steroid precursors seems to be beneficial, for example 
desmosterol which exhibits antiphlogistic effects via LXR activation [83, 84], or C8-C9 
unsaturated sterols which could enhance remyelination [85]. It is further known that other 
drugs, e.g. neuroleptics, show off target effects and interfere with cholesterol biosynthesis [86-
88], which is particularly critical in the treatment of pregnant women [86]. It therefore appears 
important to have a method that allows the identification and characterization of potential 
cholesterol biosynthesis inhibitors. However, identification and characterization of inhibitors of 
cholesterol biosynthesis is challenging. The enzymes involved in cholesterol biosynthesis are 
membrane bound enzymes and as such hardly available as isolated enzymes that could be 
used for in vitro binding studies or similar assays [13, 14]. This problem could be circumvented 
by an analytical procedur based on whole cells. This procedure was first developed by Dr. 
Martin Giera in the course of his dissertation [89] and was part of earlier publications [66, 90]. 
With this whole cell assay, possible inhibitors of the post-squalene pathway of cholesterol 
biosynthesis could be identified and IC50 values could be determined [66, 89]. In the article 
presented here a further improved and refined whole cell assay, covering all enzymes of the 
post-squalene pathway of cholesterol biosynthesis, is described in detail. The assay utilized 
HL-60 cells, which were incubated with potential inhibitors for 24 h. Then the cells were 
hydrolyzed with aqueous NaOH and the sterols were extracted with methyl-tert-butyl ether 
(MtBE) using a liquid-liquid extraction. The sterols were then derivatized to the respective 
sterol TMS ethers, which were then analyzed with GC-MS. The sterol TMS ethers were 
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identified using their relative retention times (RRT) based on cholestane and their obtained 
mass spectra. Therefore, a mass spectral library was created which contained 22 cholesterol 
precursors. An observed accumulation of certain sterols indicates the inhibition of the 
corresponding enzymes. For IC50 value determination, the cells were incubated with different 
inhibitor concentrations and 13C labeled acetate. The incorporation of 13C in cholesterol in 
relation to inhibitor concentration can then be analyzed. This protocol is designed to be 
adapted in other laboratories. The necessary digital library for sterol identification is provided 
alongside this protocol and well-known inhibitors as AY-9944 and clotrimazole are described 
and should be used for verification. On basis of this protocol, the integration of the cholesterol 
biosynthesis precursors into the new method for simultaneous determination of neutral 
steroids, steroid acids and sterol sulfates was possible (Chapter 4).  
 
5.2. Personal contribution 
The basic development of this assay was done by Dr. Martin Giera [66, 89, 90] and further 
implementation was carried on by Dr. Christoph Müller [71, 91]. These previous works were 
the prerequisite for this publication of the whole protocol. They contributed in writing of the 
manuscript as well as design and performance of the experiments.  
My contributions to this article were the performance of the experiments concerning the mass 
spectral library and method validation, as well as editing and proof reading of the manuscript. 
I further prepared Figure 2 and Table S8, containing the mass spectral library. Therefore, the 
raw data were deconvoluted and formatted for the printed data sheets, as well as for the digital 
library (NIST) by me. The spectra included in the Supplementary Figures S1, S2 and S3 were 
processed by me in the same manner. I further determined and compiled the analytical data 
for Table S1, as well as the validation data in Table S2, the performance of the necessary 
experiments and formal analysis were also done by me.  
Prof. Dr. Franz Bracher was involved in the initial method development and design of the 
protocol [66, 90]. He also contributed in editing and reviewing of the manuscript.  
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5.3. Article 
The following article is printed in the original wording. The formatting may vary slightly 
compared to the original article. 
 
A gas chromatography–mass spectrometry-
based whole-cell screening assay for target 
identification in distal cholesterol 
biosynthesis 
Christoph Müller1, Julia Junker1, Franz Bracher1 and Martin Giera 1,2* 
Distal cholesterol biosynthesis (CB) has recently taken center stage as a promising drug target in several diseases 
previously not linked to this biochemical pathway, including cardiovascular disease, cancer, multiple sclerosis and 
Alzheimer’s disease. Most enzymes involved in this pathway are hard to isolate, warranting dedicated analytical 
tools for biochemical screening. We describe the use of gas chromatography–electron ionization mass spectrometry 
(GC–MS) in a whole-cell screening assay aimed at monitoring interactions with all enzymes of distal CB in a single 
experiment. Following cell culture and lipid extraction, the trimethylsilyl ethers of sterols are analyzed by GC–MS. 
Analytical data for 23 relevant sterols (intermediates) are provided, allowing their unambiguous identification. 
Sterol pattern analysis reveals the target enzyme on the basis of characteristic marker sterols, whereas 
quantification of 2-13C-acetate incorporation correlates with the inhibitory activity of drug candidates. The protocol 
can be used by both experienced scientists and newcomers to the field, allowing detection and quantification of 
small molecule–enzyme interactions in distal CB. The entire protocol can be carried out within two working days. 
Introduction 
 
Distal CB (Fig. 1; all substance numbers and enzyme letters used hereafter correspond to 
those in Fig. 1, Table 1 and Supplementary Table 1) can be defined as the biosynthetic part 
of CB, starting with the triterpene squalene (1)1. Downstream of the first sterol, lanosterol 
(3), the biosynthesis process is divided into the Bloch and Kandutsch–Russell pathways. 
The Bloch pathway contains the Δ24-unsaturated intermediates and is interconnected with 
the Kandutsch–Russell branch by the actions of the enzyme Δ24-dehydrocholesterol 
reductase (sterol C24-reductase, DHCR24, C) on the respective Δ24 intermediates1. 
Cholesterol (11) has long been recognized as an important storage lipid and a critical 
component of biomembranes, and it plays an essential role during embryonic development. 
Mutations in CB genes have been associated with several inborn disorders that lead to 
severe malformations (Table 2). Most of these defects are linked to decreased cholesterol 
and increased precursor levels (e.g., 7-dehydrocholesterol (10), desmosterol (18)) or the 
formation of abnormal sterols such as 8-dehydrocholesterol (23). However, the 
physiological and biological functions of cholesterol precursors have only recently been 
 
1 Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians University Munich, Munich, Germany. 2Center for Proteomics and 
Metabolomics, Leiden University Medical Center (LUMC), Leiden, The Netherlands. *e-mail: m.a.giera@lumc.nl 
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investigated and described, probably because of the low amounts present under 
physiological conditions as compared to cholesterol. Byskov et al.2 were the first to discover 
critical biological functions of the precursors 4,4-dimethylcholesta-8,14,24-trien3β-ol (FF-
MAS) (12) and 4,4-dimethylcholesta-8,24-dien-3β-ol (T-MAS) (13) as meiosis-activating 
sterols. In the middle of the 20th century, several companies pursued distal CB as a possible 
drug target for lowering blood cholesterol. A series of promising inhibitors were developed, 
e.g., BIBX 79, NB-598 and MER-29 (triparanol). However, the discovery of the statins and 
the detrimental effects seen following AY-9944 administration in animal models3; as well 
as the market retraction of MER29 due to severe side effects4 slowed progress and 
diminished interest in distal CB. Therefore, it is not surprising that critical functions and 
roles of several cholesterol precursors have only recently been investigated and described. 
Important examples include cholesta-5,24-dien-3β-ol (desmosterol) (18) and its 
hydroxylated metabolites as key regulators of liver X receptor (LXR) and sterol response 
element–binding protein (SREBP)5. Another recent example is Δ8(9)-unsaturated sterols, 
which have been found to play a critical role in the remyelination of oligodendrocytes6, an 
important process fundamental to numerous neurological diseases (e.g., multiple sclerosis). 
Moreover, it has recently been discovered that several drug substances, for example, 
neuroleptic drugs (e.g., haloperidol)7–9, the anti-arrhythmic drug amiodarone10, the selective 
estrogen receptor modulator tamoxifen11 and certain antifungals such as fluconazole12, 
interfere with distal CB, possibly explaining certain activities and side effects of these 
drugs. Given the abovementioned birth defects, related to genetic mutations and possibly 
increased cholesterol precursor levels due to inhibition of certain enzymes, monitoring of 
distal CB might be warranted, particularly in pregnant women under treatment with drugs 
suspected to interfere with the biosynthetic pathway13. Taken together, these examples 
underline the critical roles and activities of several cholesterol precursors, sparking 
increased interest in distal CB as a bioactive pathway and possible drug target14–17. 
Technological solutions that allow qualitative and quantitative determination of the 
interaction of (drug) substances with distal CB are of great interest. However, screening for 
inhibitors of distal CB is not a straightforward task. Most of the enzymes involved in the 
transformation of squalene (1) to cholesterol (11) (Fig. 1) are membrane associated and 
hard to isolate and rapidly lose activity after isolation1. Together this renders classic 
biochemical approaches relying on the availability of the isolated enzymes very 
cumbersome, demanding a dedicated assay for each enzyme of the cascade. A solution to 
these pitfalls is the targeted analysis of mammalian sterol patterns after incubation with test 
substances. Monitoring metabolic activity and molecular composition provides insights 
into target enzymes and allows the construction of IC50 curves for test substances
18,19. For 
the targeted identification of sterol intermediates, high chromatographic separation 
efficiency, in combination with a characteristic information-rich detection technique, is 
mandatory due to the high structural similarity of the sterols of interest. GC–MS is a 
technique that fulfills these demands. GC–MS allows for a very high separation efficiency 
in combination with isomer-specific retention behavior. As an example, Fig. 2 shows the 
separation of the isomeric Δ7(8)- and Δ8(9)-sterols, lathosterol (9) and zymostenol (8), giving 
rise to almost identical mass spectra. Electron ionization (EI) mass spectra of the sterol 
trimethylsilyl (TMS) ethers present characteristic fragments that are very meaningful for 
structural elucidation20,21. For identifying the quantitative effects of test substances on CB, 
we found it useful to determine 2-13C-acetate incorporation into the ultimate product of the 
biosynthetic cascade, cholesterol18,22. In this way, multiple enzyme interactions can be 
described in one nominal value, allowing for a more facile comparison, whereas selectivity 
can be investigated using qualitative sterol pattern analysis. Moreover, this approach allows 
the quantification of the overall influence of a substance on CB, even if inhibition takes 
place outside distal CB. We identified HL-60 cells, a human leukemia suspension cell line 
characterized by high growth rates (doubling time 40 h) and active CB, as a suitable 
mammalian source for the study of metabolic activity of distal CB under treatment with test 
substances. We also carried out the procedure with a series of other cell lines, for example 
HEK23 and TR14624 cells, as well as induced pluripotent stem cell (iPSC)-derived neurons25. 
However, the high growth rates in suspension, which make EDTA–trypsin treatment 
unnecessary, plus the robustness of the HL-60 cell line, led us to primarily use this cell line. 
We describe here how GC–MS-based sterol pattern analysis of the unsaponifiable matter 
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obtained from the incubation of test substances with HL-60 cells can be used to identify 
enzyme inhibition in distal CB. In addition, we use 2-13C-acetate and its incorporation into 
cholesterol for the construction of IC50 curves. We present the chromatographic data for 23 
sterol TMS ethers and other relevant intermediates, as well as their characteristic EI mass 
spectra, used for unambiguous substance identification and sterol pattern analysis for target 
identification in distal CB. The protocol can be used to identify and quantify interactions in 
distal CB in various cell types. The protocol is useful in drug-screening campaigns aimed 
at distal CB, as well as for the identification of possible off-target effects. 
Fig. 1 | Main cholesterol biosynthesis pathways. The predominantly observed intermediates are shown. 
Enzymes: A squalene monooxygenase, marker substance for inhibition: squalene (1); B 2,3-oxidosqualene 
cyclase, marker substance for inhibition: squalene epoxide (2); C sterol C24-reductase, marker sterol for 
inhibition: desmosterol (18); D sterol C14-demethylase, marker sterol for inhibition: dihydrolanosterol (4); 
E sterol C14-reductase, marker sterol for inhibition: 4,4-dimethylcholesta-8,14-dien-3β-ol (5); F sterol C4-
demthylase complex (sterol C4-methyl oxidase/ sterol C3-dehydrogenase/sterol C3-keto reductase), 
marker sterol for inhibition: 4,4-dimethylcholest-8-en-3β-ol (6); G sterol C8-isomerase, marker sterol for 
inhibition: zymostenol (8); H sterol C5-desaturase, marker sterol for inhibition: lathosterol (9); I sterol C7-
reductase (10). Marker sterols are shown in red. * *Mass spectrum of the sterol TMS ether is not listed in 
the cholesterol database (Supplementary File S1) or in Supplementary Table 1. For detailed information 
about the enzymes and sterols, see Table 1 and Supplementary Table 1. 
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Table 1 | Classification of enzymes, along with Enzyme Commission (EC) number, established selective inhibitors and marker 
sterols 
 
Letter Enzyme EC no. Established inhibitor Marker sterol for inhibition 
A Squalene monooxygenase (SqMO) 1.14.13.132 NB-59818,82 
TU-207883 
Squalene (1) 
B Oxidosqualene cyclase (OSC) 5.4.99.7 BIBX 7918,84 
Ro 48-807185 
Squalene epoxide (2) 
C Sterol C24-reductase (DHCR24) 1.3.1.72 DMHCA86 
SH-4226 
Desmosterol (18) 
D Sterol C14-demethylase (CYP51) 1.14.13.70 Clotrimazole18,87 Dihydrolanosterol (4) 
E Sterol C14-reductase (DHCR14) 1.3.1.70 Clotrimazole18,87 4,4-Dimethylcholesta-8,14-dien-3β-ol (5) 
F Sterol C4-methyl oxidase 1.14.13.72 Aminotriazole18,88 4,4-Dimethylcholest-8-en-3β-ol (6) 
 Sterol C3-dehydrogenase 1.1.1.170 Aminotriazole18,88  
 Sterol C3-keto reductase 1.1.1.270 Aminotriazole18,88  
G Sterol C8-isomerase (EBP) 5.3.3.5 Aminoindenols29 Zymostenol (8) 
H Sterol C5-desaturase (SC5D) 1.14.21.6 MGI-3919 Lathosterol (9) 
I Sterol C7-reductase (DHCR7) 1.3.1.21 Phenethyltetrahydroisoquinolines22 
BM 1576622,89 
7-Dehydrocholesterol (10) 
Compound numbers refer to Supplementary Table 1. 
 
 
Table 2 | Malformation syndromes caused by disorders of cholesterol biosynthesis 
 
 
Associated disorder Biochemistry References 
 
Name OMIM no. Inheritance 
pattern 
Defective gene Affected enzyme Increased serum or plasma levels 
of marker sterols  









AR CYP51A1 and other 
cytochrome P450 
oxidoreductase genes 








215140 AR DHCR14 and LBR Sterol C14-reductase (E) 





CHILD syndrome (congenital 
hemidysplasia with 
ichthyosiform erythroderma 
and limb defects syndrome) 
also called SC4MOL syndrome 
(sterol-C4 methyloxidase-like) 
308050 XL SC4MOL, NSHDL, 
HSD17B7 
Sterol C4-demthylase 




(NSHDL), sterol C3-keto 
reductase (HSD17B7) 
4,4-Dimethylcholest-8-en-3β-ol 
(6), 4-methylzymostenol (7), 
T-MAS (13), lophenol (21) 
61,68,69,90,91 
CDPX2 syndrome (X-linked 
dominant chondrodysplasia 
punctata) also called Conradi–
Hünermann–Happle syndrome 
302960 XL EBP Sterol C8-isomerase (G) Zymostenol (8), 
8-dehydrocholesterol (23) 
62,90,91 





270400 AR DHCR7 Sterol C7-reductase (I) 7-Dehydrocholesterol (10), 
8-dehydrocholesterol (23) 
9,58,63,64,90,91,95 
AR, autosomal recessive; OMIM, Online Mendelian Inheritance in Man; XL, X-linked dominant. aNot dependent only on affected enzyme. bNot characterized here; see Hill et al.55 for GC–MS data. 
 
Development of the protocol 
When we started our work in the field of distal CB, we wanted an assay that would allow 
us to interrogate all enzymes of the pathway to help us to rationally design our synthetic 
efforts26–31 and determine the target enzyme, selectivity and inhibitory efficiency. Owing to 
the aforementioned pitfalls concerning isolation and stability of the enzymes involved in 
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the pathway, we quickly realized that isolation and testing of single enzymes or mixtures 





Fig. 2 | Separation of Δ7- and Δ8-sterol isomers. a–c, Although the isomeric pair zymostenol (8)/lathosterol 
(9) present very similar EI mass spectra (b and c, respectively), with a base peak of m/z 458 and a 
characteristic fragment at m/z 255, GC-based separation (a) allows for their facile separation and hence 
unambiguous identification. 
that monitoring enzyme inhibition at the metabolic level in a whole-cell assay would be a 
much more straightforward and meaningful approach. We therefore sought to adapt our 
concept of whole-cell incubation and metabolic sterol pattern analysis—which we had 
developed for the screening of antifungal drugs21,32—to a mammalian cell system. Initially 
we adapted parts of the HPLC scintillation-based method described by Fernández et al.33. 
In their assay, the authors incorporate 14 C-acetate into cholesterol and its precursors, 
followed by reverse-phase chromatographic separation and scintillation counting. 
Although this is a highly sensitive and useful assay, we wished for faster run times, higher 
throughput and the possibility of identifying unknown sterols accumulating due to 
(multiple) enzyme inhibition. In addition, the use of radioactively labeled materials, which 
is possible only in specialized laboratories and with permission, would limit flexibility. In 
turn, we adapted the cell culture conditions described by Fernández et al.33 and combined 
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these with GC–MS analysis and the incorporation of non-radioactive 2-13C-acetate for 
isotope labeling18. Many intermediates of distal CB are, chemically speaking, highly 
similar, being positional double-bond isomers or they 
 
Table 3 | Sources of established cholesterol biosynthesis inhibitors 
 




Aminotriazole 61-82-5 Sigma-Aldrich A8053 
AY-9944 366-93-8 Cayman Chemicals 14611 
BIBX 79 ExI Ref. 84 ExI 
BM 15766 86621-94-5 Sigma-Aldrich B8685 
Clotrimazole 23593-75-1 Sigma-Aldrich C6019 
DMHCA 79066-03-8 Sigma-Aldrich 700125P 
Haloperidol 52-86-8 Sigma-Aldrich H1512 
MGI-39 ExI Ref. 19 ExI 
NB-598 131060-14-5 AdooQ Bioscience A14131 
Phenethyltetrahydroisoquinolines ExI Ref. 22 ExI 
Ro 48-8071 161582-11-2 Cayman Chemicals 10006415 
SH-42 ExI Ref. 26 ExI 
Tamoxifen 10540-29-1 Sigma-Aldrich T5648 
TU-2078 ExI Ref. 83 ExI 
ExI, experimental inhibitor. 
 
present differential degrees of unsaturation and/or methylation (at C4 and C14). From an 
analytical perspective, this favored the use of GC–MS in combination with EI, tailor-made 
for the intermediates of distal CB. In comparison with HPLC, GC usually allows for higher 
separation efficiencies, as Eddy diffusion in the gas phase is limited, and EI-MS facilitates 
the ionization of neutral molecules and the generation of highly informative mass spectra 
(after derivatization) for substance identification34,35. Initially, we developed a six-well 
screening assay based on liquid/liquid extraction (LLE) of neutral lipids after saponification 
using iso-hexane. We adapted this assay to create a 24-well assay that makes use of methyl 
tert-butyl ether (MtBE), as this solvent has superior solubilizing properties for sterols. The 
recovery for the surrogate analytes (squalene (1), dihydrolanosterol (4), lathosterol (9)) was 
tested with this solvent and found to be >80%18,36. We also determined the linear regression, 
limit of quantification (LOQ) and limit of detection (LOD) for 15 relevant sterols 
(Supplementary Table 2). The detector response, expressed as the slope of the regression 
line of each sterol, was quite similar, with a somewhat lower value found for the Δ24-
unsaturated sterol, desmosterol (18) and a higher value found for cholesta-8,14-dien-3β-ol 
(19) (Supplementary Table 2; ref. 35). The LOD in scan mode ranged between 0.01 and 
0.10 µg/ml and the LOQ ranged between 0.02 and 0.40 µg/ml. Compared to a specific 
liquid chromatography–tandem mass spectrometry (LC–MS/MS) approach, the LODs for 
GC–MS-based analysis are ~20-fold higher (20 pg versus 1 pg on column)37. We 
circumvented the classic lipid extraction protocols of Folch38 and Bligh and Dyer39, which 
make use of chlorinated solvents, thus causing the organic extract to be the lower phase 
during LLE, rendering recovery of the organic extract rather tedious. Instead, we used a 
facile LLE with MtBE, which has a lower density compared to water, thus being the upper 
organic phase for collection. Moreover, as we focused our efforts toward distal CB, we 
carried out a saponification step, allowing investigation of the total sterol pool. When we 
started to work on our protocol, numerous intermediates of distal CB were not 
commercially available; therefore, we carried out organic synthesis for several cholesterol 
precursors of the Kandutsch–Russell pathway and identified members of the Bloch pathway 
using inhibitor combinations and characteristic retention time shifts caused by the Δ24-
unsaturation in combination with the evaluation of EI mass spectra18–20. For details about 
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all identified sterols, see Supplementary Table 1. To validate our system, we utilized well-
described inhibitors of several enzymes of distal CB (Table 3) and recorded the observed 
changes in sterol patterns upon incubation with the respective inhibitors, thereby allowing 
the identification of marker sterols characteristic of specific enzyme inhibition. Later on, 
we developed numerous novel experimental inhibitors to cover the remaining gaps in the 
pathway (see below). However, care must be taken, as several marketed inhibitors of distal 
CB are claimed to be selective, but when used in a whole-cell assay and depending on the 
applied concentrations, multiple enzyme inhibitions were observed. Striking examples are 
AY-9944 and MER-29 (triparanol)40 (see Supplementary Table 3 for non-selective 
inhibitors). 
 
Applications of the protocol 
We have listed several example applications of the protocol below. 
Drug screening approaches aimed at elucidating target enzymes in distal CB 
Test substances can be evaluated for their activity in distal CB using GC–MS analysis 
followed by sterol pattern analysis. In addition, the described quantitative workflow allows 
for the generation of IC50 values. Together these permit medicinal chemistry efforts to be 
steered in terms of selectivity and inhibitory activity. Using our approach, we have 
successfully characterized novel inhibitors of hitherto underexplored enzymes in distal CB, 
including the development of inhibitors of lathosterol oxidase (sterol C5-desaturase, H)6,19, 
selective inhibitors of sterol C8-isomerase (G)29, and selective, in vivo active inhibitors of 
DHCR24 (C)26. 
Evaluation of interactions of drugs with distal CB 
We and others have used the described protocol for evaluating the effects of well-known, 
registered drugs, such as neuroleptics, on CB. Considering the recent interest in distal CB, 
this is an upcoming field of research with several topical contributions41,42. However, the 
concept is not limited to neuroleptics, but can also be expanded to other substance classes 
and diseases43,44. Identification of such previously unknown effects enables drug 
repurposing as an attractive new option for the fast generation of therapeutics for novel 
drug targets. 
Diagnosis of inherited disorders in CB 
The presented analytical data and approach could also be useful for the diagnosis of 
malformation syndromes such as the Smith–Lemli–Opitz syndrome (SLOS) and CHILD 
syndrome (congenital hemidysplasia with ichthyosiform erythroderma and limb defects 
syndrome) (Table 2), as such diseases are characterized by a substantial accumulation of 
cholesterol precursors in patient-derived blood20,26, feces45, tissues45 or other matrices. The 
presented MS data (Supplementary Table 1) allow for the identification of 16 biosynthetic 
precursors of cholesterol; several non-physiological marker sterols (19–21, 23), indicative 
of some malformation syndromes, can also be detected. 
Experimental design 
A detailed depiction of the Procedure can be found in Fig. 3. Experimentally, some steps 
could be modified or carried out in an alternative manner; however, in our experience, the 
described Procedure is the most practical and facile approach. Below we will use Fig. 3 as 
a guideline for the step-by-step description of the entire protocol. 
Cell lysis and extraction of the unsaponifiable matter 
As we focused our attention on distal CB, we opted for alkaline hydrolysis using sodium 
hydroxide, followed by the extraction of the unsaponifiable matter (neutral lipids). This 
procedure has the advantages that (i) no measures have to be taken in order to break the 
cell membrane, and (ii) no dedicated lipid extraction protocol such as those published by 
Bligh and Dyer39 or Folch38 must be applied. A point of attention is the facile autoxidation 
of Δ5,7-sterols, in particular; hence, samples should be flooded with nitrogen or argon gas 
before being heated. The detection of oxysterols, e.g., 7-ketocholesterol, can be indicative 
of sample autoxidation46. If autoxidation is observed, the addition of antioxidants such as 
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butylated hydroxytoluene and triphenylphosphine should be considered. For more 
information about peroxidation of sterols, see Lamberson et al.47. In addition, alkaline 
hydrolysis should be performed in glass vessels, as heating of aqueous suspensions of 
neutral lipids (sterols) in plastic vessels may result in the loss of these analytes, probably 
due to diffusion into the plastic. Moreover, extraction of leachables and extractables from 
polymers can occur, causing pollution of the analytical system. For extraction, we advise 
use of MtBE, as it is an excellent solvent for neutral lipids, and sterols in particular, and its 
low boiling point allows facile removal. Moreover, compared to chlorinated organic 
solvents, waste management is less problematic. To correct for fluctuations of sample 
preparation, cholestane (26), a non-physiological steroid, is added as an internal standard 
(IS) after saponification and before extraction with MtBE. The organic extracts are dried 
over anhydrous sodium sulfate, as any residual sodium hydroxide solution from the 
hydrolysis step might severely damage the GC column and diminish derivatization 
efficiency. Furthermore, our method uses a dispersive solid-phase extraction (dSPE) step, 
using a mixture of the ‘primary secondary amine’ (PSA) reagent and anhydrous sodium 
sulfate48. This step is not critical to the approach and is hence optional; it does, however, 
remove residual fatty acids, which results in much cleaner extracts and improved 
chromatograms. During longer sequences (>100 samples), we found the dSPE protocol 
quite useful in limiting pollution of the GC inlet. 
 
Fig. 3 | Workflow for target identification (and IC50 determination) in distal cholesterol biosynthesis. 
Derivatization and GC–MS analysis 
Although underivatized sterols can, in principle, be analyzed using GC–MS, we found that 
derivatization leads to increased sensitivity as well as sharper and more symmetric peak 
shapes. Sterol TMS ethers show characteristic fragmentations in MS, which allows distinct 
identification of closely related analytes. Sterols, being secondary alcohols, can present 
some difficulties during derivatization because of incomplete conversion. Although many 
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procedures for sterol derivatization have been described34,49,50, in our experience, the most 
straightforward one remains trimethylsilylation. We tested several reagents and 
combinations and found a combination of N-methyl-N-trimethylsilyl-trifluoroacetamide 
(MSTFA) and 10% (vol/vol) N-trimethylsilyl-imidazole (TSIM) most effective, even at 
room temperature (22 °C). Generally, MSTFA can be used alone; however, in this case, 
small amounts of pyridine should be used in order to prevent incomplete derivatization. 
Care must be taken here to ensure that dry and high-purity pyridine is applied. For the 
determination of squalene epoxide (which is analyzed in its underivatized form), a mixture 
of MSTFA/TSIM (1:1) is recommended; when using other silylation reagents, analyte 
breakdown can occur (data not shown). 
Many different stationary phases have been applied in the GC-based separation of 
sterols. However, we make use of a highly inert 5% (vol/vol) phenylmethyl polysiloxane 
column. This stationary phase is broadly applicable and allows high flexibility. Particularly 
in combination with pre-column derivatization and mass spectrometric detection, the use 
of polyethylene glycol–based columns is not advisable. For a detailed discussion of the 
advantages and disadvantages of certain column types, we refer to the work of Gerst et al.51 
and Giera et al.34. 
In principle, GC–MS analysis of sterols can be carried out in combination with 
quadrupole or ion trap (IT)-type mass analyzers. However, IT-type instruments tend to 
result in better quality of the obtained spectra, particularly in the full-scan mode. We 
observed that quadrupoles can lead to an increased intensity of low-mass fragments (m/z 
<200), which in the case of polyunsaturated sterols can lead to a loss of the molecular ion, 
especially when analytes are present in minute amounts. Nevertheless, the use of an IT-type 
mass analyzer is not a requirement, and we have run our assay on both types of instruments, 
including triple-quadrupoles. 
The choice for GC–MS analysis 
LC–MS has become the most prominent technique for the analysis of certain classes of 
steroids, such as bile acids52,53, conjugated sterols54, hormones55,56 and oxysterols57,58. 
However, GC–MS analysis is still the most common technique for the analysis of neutral 
sterols21,51,53,59, such as cholesterol60–64 and its precursors51,60–69. Nevertheless, some LC-
based approaches are described with17,65 or even without derivatization70,71 of neutral sterols. 
With respect to the different detection possibilities, MS-based detection is the most used 
technique in sterolomics53,72,73. Both LC and GC have some advantages and disadvantages 
(which we summarize in Supplementary Table 4). As can be seen, the two techniques are 
highly complementary35. Krone et al.74 have presented a comparison of the performance of 
GC–MS and LC–MS/MS for steroid analysis. The approach we present here aims to use 
GC–MS analysis to produce a screening assay based on determination of patterns of neutral 
sterols50. A decade ago, when we started our research in the field of distal CB, we argued 
that most available knowledge described the GC–MS-based analysis of sterols, including 
retention time data and detailed descriptions of the EI-MS fragmentation patterns75. Taken 
together, these facts let us choose GC–MS rather than LC–MS analysis as the method of 
choice for establishing the protocol presented here. 
Biochemical evaluation and target identification 
On the basis of sterol pattern analysis of the accumulation of cholesterol precursors, the 
target enzyme in distal CB of different low-molecular-weight inhibitors can be deduced. 
The accumulating precursors, in most cases, represent the target enzymes’ substrates (Fig. 
1 and Table 1). However, inhibiting an enzyme in distal CB does not simply stop the 
cascade; rather, the accumulating sterols might become substrates of downstream enzymes, 
resulting in the formation of non-physiological, yet very characteristic, marker sterols. One 
such example is cholesta-8,14-dien-3β-ol (19), a nonphysiological sterol resulting from the 
inhibition of sterol C14-reductase (E) and sterol C8-isomerase (G), typically found when 
high (10 µM) concentrations of AY-9944 are used33. A list of all enzymes involved in distal 
CB, corresponding marker sterols and selective inhibitors can be found in Table 1. 
Cerqueira et al.76 and Nes1 have presented excellent overviews of the enzymes involved in 
CB. 
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Validation of the test system with established enzyme inhibitors 
To calibrate target identification in a certain cell line or type, we recommend evaluating the 
described procedure in-house with well-established and selective enzyme inhibitors as 
outlined in Tables 1 and 3. 
Quantitative assay 
To allow a quantitative assessment of a test substance’s effects on distal CB, we opted for 
the use of sodium 2-13C-acetate. Of course, one could argue that the accumulating precursor 
could be quantified and used for the construction of IC50 curves as described for DHCR24 
(ref. 77). However, when evaluating the entire distal CB, we rationalized that multiple 
enzyme inhibition might occur, rendering the assessment of the quantitative effect on a 
specific enzyme rather complicated. Upstream blockage of the biosynthetic pathway 
normally limits downstream substrate accessibility in a concentration-dependent manner, 
thereby causing multiple enzyme inhibitions to be intertwined, influencing each other. In 
turn, we argued that for our purposes of comparing the efficiency of novel inhibitors of 
distal CB, we would prefer a single nominal value. Therefore, we evaluated the quantitation 
of 2-13C-acetate incorporation into the target molecule cholesterol. To prevent deuterium 
effects, carbon labeling was applied. Considering that cholesterol (11) is biosynthesized 
entirely from the acetate source acetyl-coenzyme A, a total of fifteen 2-13C-acetate units 
could be incorporated into the molecule1 (Fig. 4). To keep this quantification as simple as 
possible, we decided to quantify all the 13C-labeled cholesterol. 
 
Fig. 4 | Quantitation of 2-13C-acetate incorporation. a–c, Structure of sodium 2-13C-acetate (a), black number 1 = 12C, red number 2 = 13C; 
incorporation of unlabeled acetate into cholesterol and its characteristic MS spectrum (b); incorporation of labeled acetate under control 
conditions into cholesterol and its corresponding MS spectrum (c). Internal standard cholestane (26), cholesterol (11) TMS ether. Int., 
intensity; Rel. int., relative intensity. 
To achieve this, we validated our system and applied mass ranges of m/z 372–379 and 462–
469, referring to the most abundant isotope fraction of incorporated 2-13C-acetate units that 
has a sufficient mass distance from naturally occurring isotopes. Preventing overlap with 
the isotopes of unlabeled cholesterol is important; otherwise, these might interfere with the 
analysis. Although isotopolog or flux analysis might give a more accurate view, we argued 
that for the purposes of substance comparison within a group of inhibitors, an easy-to-
apply, facile and robust approach would be preferred and still fulfill our requirements. We 
tested this by evaluating the intra- and interday repeatability of the method as applied to 
two test substances over several days and obtained highly repeatable results18. Importantly, 
for this assessment, we needed to adopt a correction for the overall biomass in each 
experiment. As manual cell counting of dozens of samples can be very tedious, we decided 
to apply determination of total protein content for correction. For this purpose, we adopted 
the Bradford78 method, which can be directly applied to the hydrolyzed samples just before 
sterol extraction. As only a very small aliquot is required for this determination, this does 
not result in a noteworthy influence on the outcome of the sterol assay. Importantly, the 
applied quantification of 2- 13C-acetate incorporation does ultimately quantify a substances’ 
effect on the entire CB pathway but does not allow the determination of individual IC50 
values for specific enzymes. We chose this approach because it allows the comparison of 
IC50 values based on a common denominator, total CB. Such an approach allows a more 
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facile adaptation of the described protocol, as it omits tedious validation procedures for 
each accumulating sterol. Moreover, when multiple enzyme inhibition occurs, 
accumulation of precursors might influence upstream and/or downstream enzymatic 
reactions, thereby making the comparison of multiple enzyme inhibition very challenging. 
Nevertheless, use of our described protocol’s alternative strategies for selectively 
investigating specific enzymatic conversions might include the following examples. First, 
quantification of the accumulating precursor(s) or area ratio analysis compared to those of 
total cholesterol could be of value. Second, quantification of 2-13C-acetate incorporation 
into accumulating precursors might be an alternative as well. As can be seen from 
Supplementary Tables 5–7 (experimental data for three inhibitors of distal CB) and the 
corresponding MS data (some exemplary data are presented in Supplementary Figs. 1–3), 
as well as the recorded IC50 curves (Supplementary Figs. 4–6), such analysis is in principle 
possible, and indications about specific enzyme inhibitions can be obtained. Another 
possible approach for investigating specific enzymatic activities lies in the use of labeled 
substrates as, for example, recently shown by Prabhu et al.77, who studied the activity of 
DHCR24. Taken together, several possibilities for deciphering multi-enzyme inhibition 
and obtaining enzyme-specific IC50 values exist. However, when applying our protocol for 
more than a decade, we had positive experiences quantifying total CB and here focus on 
our proven approach, quantifying 2-13C-acetate incorporation into cholesterol. 
 
Testing of alternative materials 
The presented protocol can also be applied to the characterization of physiological 
cholesterol precursors in blood samples20,26, feces45, tissues45 and other matrices. The 
quantitative aspect of 2-13C-acetate incorporation is not limited to inhibitors of distal CB, 
but also allows a rapid assessment of if, and to what extent, a test substance affects overall 
CB, even for compounds inhibiting enzymes in the proximal (pre-squalene) part of CB. 
Limitations of the protocol 
We list some imitations below: 
• Metabolomics approaches are usually designed to study hundreds of metabolites in a single 
analytical run. However, these approaches are usually not designed to differentiate between 
analytes showing only minute structural differences79. We describe here an approach selectively 
aimed at the analysis of intermediates of distal CB. In turn, our approach can identify only drug 
targets within this pathway. As we wanted to keep the assay as simple and focused as possible, 
we omitted additional derivatization steps for other classes of steroids (lacking relevance in 
CB), for example, oxime or imine functionalization of oxosteroids (e.g., using methoxyamine 
in pyridine)49. 
• If full blockage of an early enzyme in the pathway occurs, inhibitory effects of the same 
inhibitor on downstream enzymes might be occluded. We account for this by recommending 
that the screening always be undertaken using both a high and a low inhibitor concentration 
(e.g., 1 and 50 µM). See, for example, Horling et al.22. 
• This protocol has been set up as a screening tool for medicinal chemistry purposes. In turn, we 
focused our attention on the main metabolites in CB and marker sterols. Hence, the approach 
might not give full coverage of all (minute) intermediates possible. For an in-depth analysis, 
several sterol analysis approaches should be applied. Excellent sources of such protocols are, 
for example, book chapters by Goad and Akihisa50 and Nes80. For a recent example, 
impressively showing an in-depth analysis of a sterol metabolome, see ref. 81. 
• Most of the sterols described here have been identified using synthetic reference materials34. 
However, some intermediates, mainly of the Bloch pathway, were identified only on the basis 
of characteristic retention time differences as compared to those of their Δ24-saturated 
counterparts from the Bloch pathway and characteristic fragmentations patterns matching those 
previously published (Supplementary Table 1). For these components, some care should be 
taken when assigning identity. 
Our quantitative approach using 2-13C-acetate incorporation does not allow enzymes to be 
assigned to specific IC50 values and might be jeopardized by substances inhibiting enzymes in 
distal as well as proximal CB 





• HL-60 cells (DSMZ, cat. no. ACC 3) !CAUTION Handle cell lines according to your 
institutional regulations and inform yourself about necessary bacterial and viral testing. 
!CAUTION The cell lines used in your research should be regularly checked to ensure they are 
authentic and are not infected with mycoplasma. 
Reagents 
!CAUTION Use gloves and a lab coat and ensure that work using organic solvents is carried out 
in a fume hood. 
Cell culture 
• Dimethyl sulfoxide (DMSO; >99.9% (vol/vol); Sigma-Aldrich, cat. no. D8418) 
• Ethanol, absolute (for analysis; Sigma-Aldrich, cat. no. 1009831011) 
• FBS (Sigma-Aldrich, cat. no. F7524) 
• Lipoprotein-deficient serum (LPDS; Sigma Aldrich, cat. no. S5394) 
• Medium for HL-60 cells without cholesterol (PAN Biotech, cat. no. P04-00800); 
alternatively, RPMI1640 can be used (see below) 
• PBS (Sigma-Aldrich, cat. no. P4417) 
• RPMI1640 (with phenol red; Sigma Aldrich, cat. no. R6504) 
• Sterile purified water (Sigma-Aldrich, cat. no. W3500) 
• Clotrimazole (as reference inhibitor; Sigma-Aldrich, cat. no. C6019) 
• AY-9944 (as reference inhibitor; Cayman Chemicals, cat. no. 14611) 
• Butylated hydroxytoluene (Sigma Aldrich, cat. no. W218405) 
• Triphenylphosphine (Sigma Aldrich, cat. no. T84409) 
(Optional) For the quantitative assay, 2-13C-acetate incorporation 
• Sodium 2-13C-acetate (Sigma-Aldrich, cat. no. 279315) 
• Sterile purified water (Sigma-Aldrich, cat. no. W3500) 
Workup 
• 5α-Cholestane (≥97% (HPLC); Sigma-Aldrich, cat. no. C8003) 
• Helium (99.999%; Air Liquide, cat. no. P0251S10R2A001) !CAUTION Helium is an 
asphyxiant. Use in a well-ventilated area. 
• Methyl tert-butyl ether, HPLC Plus, for GC (MtBE; Sigma-Aldrich, cat. no. 650560) 
!CAUTION Use MtBE in a chemical hood and wear protective gloves, safety glasses and 
suitable protective clothing. MtBE is flammable, is acutely toxic and causes skin and eye 
irritation. 
• Nitrogen (99.999%; Air Liquide, cat. no. P0271L50R2A001) !CAUTION Nitrogen is an 
asphyxiant. Use in a well-ventilated area. 
• N-Methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA; Macherey-Nagel, cat. no. 
701270.201) !CAUTION Wear protective gloves, safety glasses and suitable protective 
clothing. MSTFA is flammable and is acutely toxic. 
• N-Trimethylsilyl-imidazole (TSIM; Macherey-Nagel, cat. no. 701310.201) !CAUTION Wear 
protective gloves, safety glasses and suitable protective clothing. TSIM is flammable, 
corrosive and acutely toxic. 
• Sodium hydroxide solution (NaOH; 1 M, reagent grade, European. Pharmacopoeia; Sigma 
Aldrich, cat. no. 1091371000) !CAUTION Wear protective gloves, safety glasses and suitable 
protective clothing. 
• Sodium hydroxide is corrosive and causes serious eye damage. 
(Optional) For dSPE 
• Agilent SPE bulk sorbent, primary secondary amine (PSA; Agilent, cat. no. 5982-8382) 
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• Sodium sulfate, anhydrous (≥99.0%; Sigma-Aldrich, cat. no. 239313)    CRITICAL Make sure 
that this reagent is dry by heating it in a laboratory cabinet to >125 °C for at least 1 h. 
(Optional) For the quantitative assay, 2-13C-acetate incubation 
• BSA (Albumin Fraction V, ≥98%, powdered; Carl Roth, cat. no. 8076.2) 
• 96-well plate (polystyrene; Greiner Bio-One; VWR, cat. no. 391-3605) 
• Hydrochloric acid (1 M; bioreagent; Sigma-Aldrich, cat. no. H9892) !CAUTION Wear 
protective gloves, safety glasses and suitable protective clothing. Hydrochloric acid is 
corrosive and causes serious eye damage. 
• Roti-Quant Bradford reagent (Carl Roth, cat. no. K015.2) 
Equipment 
Cell culture 
• Flow cabinet (Thermo, cat. no. 51029701) 
• Centrifuge tubes (50 ml, polypropylene, sterile; VWR, cat. no. 521-1890) 
• Centrifuge, benchtop (Heraeus Megafuge 8; VWR, cat. no. 525-0156) 
• CO2 incubator (37°C, 5% CO2; Binder C series; VWR, cat. no. 390-0925) 
• Plastic microcentrifuge Safe-Lock tube (2 ml; Eppendorf; VWR, cat. no. 20901-540) 
• Fuchs–Rosenthal counting chamber (chamber depth: 0.2 mm; VWR, cat. no. 631-1171) 
• Culture flask (250 ml, 75 cm2, polystyrene, sterile; Greiner Bio-One; VWR, cat. no. 391-
3106) 
• Plate (24-well; polystyrene, sterile; Greiner Bio-One; VWR, cat. no. 82050-892) 
• Microscope (Zeiss Axio Observer 3; Zeiss, cat. no. 491915-0001-000) 
• Serological pipette (10 ml, polystyrene, sterile; VWR, cat. no. 612-3700) 
Workup 
• Plastic microcentrifuge Safe-Lock tube (2 ml; Eppendorf; VWR, cat. no. 20901-540)    
CRITICAL Only the highest-quality plastic material should be used. 
• Benchtop microcentrifuge (Eppendorf, model no. 5415 with rotor F-45-24-11; Sigma-
Aldrich, cat. no. Z604062) 
• GC glass vial with screw neck (N9, amber, flat bottom, scale, wide opening (Macherey-Nagel, 
cat. no.702284) 
• Glass vial (4 ml, VWR screw-thread vial; VWR, cat. no. 66010-562) 
• Hamilton gas-tight syringe (no. 1750 LT, 500 µl; VWR, cat. no. 549-1184) 
• Laboratory drying cabinet (Binder ED23; VWR, cat. no. 466-3251) 
• Polypropylene top, screw-cap, polypropylene, white silicone septa for 4-ml glass vials (VWR, 
cat. no. 46610-706) 
• Screw cap, N9 polypropylene (blue, center hole, silicone white/polytetrafluoroethylene red, 
hardness: 
• 45° shore A, thickness: 1.0 mm; Macherey-Nagel, cat. no. 702287.1) 
• Ultrasonic bath (Bandelin Sonorex, model no. RK100; Bandelin, cat. no. 301) 
GC–MS analysis 
• GC–MS instrument (Varian, model nos. GC 3800 and MS 2200 IT) 
• GC injector (Varian, model no. 1177 with split/splitless option) 
• GC inlet liner (2 mm i.d., split/splitless, gooseneck; Agilent, part. no. 8004-0119) 
• GC column (Agilent, model no. VF-5MS; 30-m length plus 10-m EZ-Guard, 0.25-mm i.d., 
0.25-µm film thickness; Agilent, part. no. CP9013)    CRITICAL The retention times of sterol 
TMS ethers can strongly depend on the manufacturer of the column. The use of a column 
from the same type and manufacturer is recommended. If a column from a different 
manufacturer is used, (relative) retention times might differ from the values described here. 
• GC autosampler (CTC Analytics, Combi PAL model)  
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Quantitative assay, 2-13C-acetate incubation 
• Greiner Bio-One 96-well plate (polystyrene; VWR, cat. no. 391-3605) 
• Plate reader (ELISA reader; Dynex Technologies, model no. MRX II) or similar 
Software 
• NIST MS search v.2.0 (or higher) if use of the presented database is intended (Supplementary 
Data) (https://chemdata.nist.gov/mass-spc/ms-search/) 
• Prism v.7 (GraphPad: https://www.graphpad.com/scientific-software/prism/) 
Reagent setup 
RPMI1640 medium containing 10% FBS (cultivation medium) 
In a flow cabinet under sterile conditions, add 50 ml of FBS to 500 ml of RPMI1640, mix it 
well and store at 5 °C. The solution can be stored for 2 weeks.    CRITICAL Sterile conditions 
are mandatory. 
Check the sterility of the medium before use. 
Medium for HL-60 cells or RPMI1640 (test medium) containing 1% LPDS 
In a flow cabinet under sterile conditions, add 5 ml of LPDS to 500 ml of medium for HL-
60 cells or RPMI1640, mix well and store at 5 °C. The solution can be stored for 2 weeks. 
CRITICAL Sterile conditions are mandatory. Check the sterility of the medium before use. 
Preparation of test compound solution 
The test compound must be dissolved in either RPMI1640, sterile purified water, ethanol or 
DMSO. The final concentrations of the test compound should be 1 µM and 50 µM. Prepare 
a 50 µM test compound solution and dilute 1:50 to obtain the 1 µM test compound solution. 
CRITICAL For ethanol and DMSO, a maximum final concentration of 1.0% (vol/vol) in the test 
well is allowed. Prepare the test compound solution on the day of experiment. 
Cholestane IS solution (10 µg/ml) for workup 
Prepare a 10 µg/ml solution of 5α-cholestane in MtBE, mix it well and store it in a glass 
volumetric flask at 5 °C. The solution can be stored up to 6 months. !CAUTION MtBE is 
flammable and toxic. See notes above. 
PBS (pH 7.4, 0.01 M phosphate buffer, 0.0027 M potassium chloride, 0.137 M sodium 
chloride)  
In a flow cabinet under sterile conditions, dissolve one tablet in 200 ml of sterile water. 
(Optional) Dispersive solid-phase adsorbent (40 mg per tube) 
Mix anhydrous sodium sulfate (if necessary, dried at >125 °C for 1 h) and Agilent SPE bulk 
sorbent in a ratio of 7:1. The weight per tube can vary between 35 and 45 mg. This mixture 
should be freshly prepared on a weekly basis, ensuring dryness of the sodium sulfate used. 
Bulk preparations can be stored in a closed Falcon tube for up to 1 week. 
Silylation reagent mixture 
Add 100 µl of TSIM with a Hamilton syringe to one vial of MSTFA (1,000 µl). Shake it 
carefully. Keep at 5 °C. The mixture can be stored for up to 1 week. !CAUTION TSIM and 
MSTFA are flammable and toxic. See notes above.    CRITICAL The mixture is sensitive to water. 
It can be stored refrigerated for 1 week. 
BSA calibration standards for quantitative assay, 2-13C-acetate incubation 
Prepare the calibration standards at a concentration range of 0–140 µg/ml (0, 40, 60, 80, 
100, 120, 140 µg/ml) BSA. Prepare a stock solution of 140 µg/ml in sterile water and 
serially dilute to reach the other concentrations. The solutions can be stored for up to 3 
months at −20 °C. 
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Roti-Quant solution (Bradford reagent) 
Mix 5 ml of Roti-Quant with 13.75 ml of water and shake the solution well in a 50-ml 
centrifuge tube. This volume allows pipetting into 84 wells.    CRITICAL Prepare the solution 
immediately before use and mix it well. 
Sodium acetate-2-13C solution (6.25 mg/ml) 
In a flow cabinet, prepare a 6.25 mg/ml solution of sodium 2-13C-acetate in sterile water 
and mix it well. The solution can be stored for up to 3 months at −20 °C.    CRITICAL Prepare 
the solution under sterile conditions. 
Equipment setup 
Injection parameters for GC–MS analysis of squalene, squalene epoxide and sterol TMS 
ethers 
Inject 1 µl of the sample (splitless). After 1 min, set the injector to a split ratio of 1:25. Hold 
the inlet at 250 °C. 
Chromatographic parameters for GC–MS analysis of squalene, squalene epoxide and sterol 
TMS ethers 
In our labs, the column we most often use for this analysis is an inert 5% phenylmethyl 
polysiloxane column (e.g., the VF-5MS from Agilent). Use the carrier gas helium at a 
constant flow rate of 1.4 ml/ min. After injection, hold the column oven at 50 °C for 1 min, 
then ramp up at a rate of 50 °C/min to 260 °C, followed by a ramp rate of 4 °C/min to the 
final temperature of 310 °C, and then hold for 0.3 min. The total run time is 18.0 min. 
Mass spectrometer settings for (qualitative) analysis 
Set the solvent delay at 9 min. Operate the mass spectrometer in scan mode from m/z 50 to 
450 for between 9 and 12 min, and implement a second segment from 12 to 18 min with a 
scan range from m/z 100 to 600. Sterol TMS ethers start eluting at ~13 min. Hold the MS 
transfer line at 270 °C. Set the manifold temperature to 50 °C and the trap temperature to 
200 °C.     CRITICAL The first scan segment is required only for detecting squalene and squalene 
epoxide. The chromatogram might be polluted with low-molecular-weight substances, 
especially in the first segment. If there is no interest in detecting squalene and/or squalene 
epoxide, set the solvent delay to 11 min and the scan range to m/z 100–600 during the whole 
run. It is advisable to obtain full spectral data for each sterol TMS ether in scan mode. For 
identifying the sterol TMS ethers, the use of the single-ion monitoring (SIM) mode in 
combination with relative retention time (RRT) is not sufficient, as this would, in particular, not 
allow detection of possible co-elutions of critical peak pairs. 
Mass spectrometer settings for IC50 analysis (quantitative assay) 
Quantify 13C-labeled cholesterol by analyzing the ions’ m/z 372–379 and 462–469 values 
corresponding to carbon-labeled cholesterol TMS ether (11). Plot the percentage inhibition 
(see equation for the calculation in Box 1, step 16) relative to untreated control samples 
(0% inhibition) against the logarithmic inhibitor Normalize all samples to their protein 
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Box 1 | Optional additional assays 
Quantitative assay: 2-13C-acetate incubation ● Timing 1–2 h hands-on time for 21 samples  
1 Carry out Steps 1–11 as described in the main Procedure. 
2 Calculate the required volume of medium. Use the following equation: 
1,000 µl – (volume 1 × 106 cell  10 µl test compound solution  10 µl 13C – acetate solution) 
 necessary volume of medium. 
3 Add the calculated volume of medium for HL-60 cells to 21 wells of a 24-well plate. 
CRITICAL STEP Do not reverse the mixing steps. If the test compound solution is placed first in each 
24-well plate, the solvent of the solution can evaporate. In addition, the cell suspension should not be mixed 
with the test compound solution to avoid temporarily increased concentrations of test compound, ethanol 
or DMSO. 
4 Add 10 µl of the test compound solution in six appropriate concentrations with each concentration in 
triplicate. 
5 Add 10 µl of the test compound solvent in triplicate; use the test compound solvent in triplicate as control 
samples. 
6 Add the calculated volume of cell suspension. 
7 Carry out Steps 17–32 as described in the main procedure. 
Quantitative assay: Bradford protein assay ● Timing 1–2 h hands-on time for 21 samples 
8 Pipette 50 µl of the calibration standards at 0, 40, 60, 80, 100, 120, 140 µg/ml (in triplicates) into a 96-well 
plate. 
9 Pipette 25 µl (in triplicates) of each sample into a 96-well plate. 
10 Add 25 µl of 1 M hydrochloric acid. 
!CAUTION Wear protective gloves, goggles and suitable protective clothing. Hydrochloric acid is corrosive 
and causes serious eye damage. 
    CRITICAL STEP Hydrochloric acid is added only to the sample wells, not the calibration standard wells. 
This is to neutralize the sodium hydroxide stemming from the hydrolysis step. 
11 Add 200 µl of Roti-Quant solution (Bradford reagent) to each well. 
12 Incubate the plate for 5 min at room temperature. 
    CRITICAL STEP Timing is essential for this step. Make sure that you measure your samples within 5–15 
min after you added the reagent. 
13 Measure the plate with the plate reader (ELISA reader) at OD595. Determine the concentration of each 
sample by plotting the OD595 values of the calibration curve and construct the calibration function. Use the 
calibration function in order to calculate the protein content of your samples. !CAUTION The 
concentration of the samples must be multiplied by two. 
Quantification of 2-13C-acetate incorporation and construction of IC50 curves ● Timing 0.5–1 h per sample 
14 Carry out Steps 33–54 as described in the main Procedure. 
15 Integrate the peak areas of cholestane (26) and labeled cholesterol (11) TMS ether. For cholestane, use 
m/z 217 and 357; for cholesterol, use m/z 372–379 + 462–469. 
16 Calculate the amount of newly synthesized cholesterol by using the following equation, where As is the 
area of labeled cholesterol TMS ether in the samples, aISc the average of the area of the IS in the control 
sample (no inhibitor added), aPCc the average of the protein content of the control sample, aAc the 
average area of labeled cholesterol TMS ether in the control sample, ISs the area of the IS in the sample 
and PCs the protein content of the sample. 
%Inhibition = 1  ×  ×   ×  ×  
17 Plot the results in a sigmoidal curve-fitting model and calculate the IC50 value. We usually carry out this 
step using the GraphPad Prism software. Also calculate R2 values to obtain an estimate of the goodness of 
fit. Usually R2 values >0.90–0.95 are obtained. The calculation of the 95% confidence intervals can be 
useful for comparing compound activities. 
Procedure  
    CRITICAL When working with lipids, laboratory glassware should be used wherever possible. 
In cases in which, for example, high centrifugal forces are applied, plastic cannot be 
circumvented. In such cases, we explicitly specify the plastic material to use. 
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Incubation of test organisms with test substances ● Timing 26 h; 1–2 h hands-on 
time for 24 samples 
1 Cultivate HL-60 cells in 25 ml of RPMI1640 medium containing 10% FBS without 
antibiotics (Reagent setup) at 37 °C in a humidified atmosphere containing 5% CO2. 
    CRITICAL STEP All cell-handling steps must be carried out under sterile conditions in 
a flow cabinet. 
2 Maintain the cells at 0.5–1.0 × 106 cells/ml and split the cells every 2–3 d. The residual 
cells can be used for incubation with test substances. Normally, split cells 1:2 –1:5. 3 
Transfer the residual cell culture to a 50-ml centrifuge tube.     CRITICAL STEP Transfer 
all the cells. 
4 Centrifuge the tube at 1,500g for 5 min at room temperature. 
5 Discard the supernatant, and resuspend the pellet in 10 ml of medium for HL-60 cells 
(or RPMI1640) with 1% LPDS. 
6 Transfer 100 µl of the resuspended cell pellet to a 2-ml microcentrifuge Safe-Lock tube. 
7 Add 900 µl of cold PBS, close the tube and manually swirl gently. 
8 Transfer 20 µl to a Fuchs–Rosenthal counting chamber. 
9 Count the cells. 
       CRITICAL STEP We recommend counting two big squares of a hemocytometer, each 
equaling 0.2 µl (verify the size of your own counting chamber). 
10 Calculate the number of cells in 10 ml. One big square of the recommended counting 
chamber equals 0.2 µl (0.2 mm3); hence, the average of the two counted big squares 
must be multiplied by a factor of 500,000. 
11 Calculate the volume containing an absolute number of 1.0 × 106 cells. 
12 Calculate the volume of medium necessary to make up each well to 1,000 µl. Use the 
following equation: 
1,000 µl – volume 1 × 106 cell + 10 µl test compound solution  
= necessary volume of medium 
13 Add the calculated volume of medium to each well of a 24-well plate. 
14 Add 10 µl of the test compound solution to reach final concentrations of 1 µM and 50 
µM, both for each test compound. Perform each experiment in duplicate for screening 
purposes and triplicate in the case of IC50 determination. 
15 Add the calculated volume of medium containing 1.0 × 106 cells from Step 11. 
     CRITICAL STEP Do not invert when mixing in Steps 13–15. If the test compound 
solution is placed first in each 24-well plate, the solvent of the solution can evaporate. 
In addition, the cell suspension should not be mixed with the test compound solution, 
as this might temporarily increase the concentration of the test compound, ethanol or 
DMSO. 
? TROUBLESHOOTING 
16 Always use two control wells; to these, add the same amount of solvent as used for 
dissolving the test compound(s). These wells represent the untreated controls. 
       CRITICAL STEP In addition, we also advise using a well-established inhibitor as a 
positive control 
(e.g., clotrimazole, AY-9944 or NB-598; see Table 1 and Supplementary Table 3 for 
additional inhibitors). 
17 Manually swirl the plate carefully. 
    CRITICAL STEP The test compound solution should be mixed with the test culture 
without splashing into other wells or onto the cover. 
18 Incubate the 24-well plate for 24 ± 2 h at 37 °C in a humidified atmosphere containing 
5% CO2. 
19 After incubation, check all wells under a suitable light microscope. Check for 
bacterial or fungal contamination (i.e., the presence of smaller, frequently rapidly 
moving, cells) and note the morphology of the HL-60 cells. Healthy HL-60 cells 
should be seen in the control wells and should have a round shape.  
? TROUBLESHOOTING 
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Transfer of cells and preparation for cell lysis and extraction ● Timing 0.5–1 h total 
time for 24 samples 
20 Pipette the cells from all incubations into individual 2-ml plastic microcentrifuge Safe-
Lock tubes. One tube per well. 
21 Wash each well of the 24-well plate with 1 ml of cold PBS and combine with the cell 
suspension from Step 20. 
22 Centrifuge the tubes at 540g for 5 min at room temperature. 
23 Discard the supernatants, and resuspend the pellets in 1 ml of cold PBS. 
24 Centrifuge the tubes at 540g for 5 min at room temperature. 
25 Discard the supernatants and resuspend the pellets in 1 ml of 1 M NaOH. 
!CAUTION Wear protective gloves, goggles and suitable protective clothing. Sodium 
hydroxide is corrosive and causes serious eye damage. 
26 Close the tubes. 
!CAUTION Close the tube tightly. Otherwise, there is a danger of loss of material and a 
health risk in case of spilling. 
27 Vortex the tubes for 10 s. 
!CAUTION Wear protective goggles. 
    CRITICAL STEP The pellets must be fully resuspended in sodium hydroxide solution. 
28 Transfer the solutions to 4-ml glass vials. 
    CRITICAL STEP Only glass vials are suitable for cell lysis and saponification. Using 
glass avoids the extraction of leachables and extractables from the plastic tubes and 
overcomes loss of analytes due to adsorption to the plastic material. 
29 Flood the glass vials with nitrogen (alternatively argon) and close the vials tightly with 
a PTFE screw cap. 
    CRITICAL STEP Nitrogen (or argon) prevents the oxidation of sterols. However, if 
oxysterols are detected, autoxidation should be considered. If autoxidation is observed, 
the addition of antioxidants such as butylated hydroxytoluene and triphenylphosphine 
should be considered. 
 ? TROUBLESHOOTING 
    PAUSE POINT At this point, the samples can be stored at 5 °C for up to 24 h. 
Cell lysis, lipid extraction and detection of squalene, squalene epoxide and sterol 
TMS ethers ● Timing 2–3 h total time for 24 samples 
30 Place the glass vial at 60 °C in a laboratory drying 
cabinet or water bath for 1 h. Vortex the vial for 
10 s occasionally during the incubation (at least 
twice). 
31 Allow the suspension to cool to room 
temperature. !CAUTION Wear protective goggles. 
    CRITICAL STEP Do not add MtBE to the hot mixture, as the MtBE might evaporate 
because its boiling point is 55 °C. 
? TROUBLESHOOTING 
 32 Transfer the lysed cell suspension to a 2-ml plastic microcentrifuge Safe-
Lock tube. 
    CRITICAL STEP Plastic must be used because high centrifugal forces will be required. 
In the presence of MtBE, notable diffusion of lipids into the plastic walls is not 
observed. Use only high-quality plastic, ideally the tubes from Eppendorf in the 
Equipment list. 
    CRITICAL STEP For quantification of de novo synthesized cholesterol, also carry out 
protein quantification according to Bradford as described in Box 1.  
33 Add 650 µl of MtBE. 
? TROUBLESHOOTING 
 34 Add 100 µl of IS solution (10 µg/ml). 
? TROUBLESHOOTING 
35 Close the tube. 
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!CAUTION The tube must be tightly closed. Otherwise, part of the suspension will be 
lost during shaking or centrifugation. 36 For the first extraction step, shake the tube 
vigorously for 1 min by hand. 
!CAUTION Wear protective goggles. 
37 Centrifuge the tube at 10,000g for 5 min at room temperature. 
38 Use a glass pipette to transfer ~550 µl of the organic upper layer to a glass GC vial. 
!CAUTION Avoid transferring any of the aqueous layer. Sodium hydroxide damages the 
GC column. 
    CRITICAL STEP If dSPE is to be applied, transfer the 550 µl of the organic upper layer 
to a 2-ml plastic microcentrifuge Safe-Lock tube containing the dispersive solid-phase 
adsorbent. ? TROUBLESHOOTING 
39 Add 750 µl of MtBE to the 2-ml plastic microcentrifuge Safe-Lock tube containing the 
lysed cell suspension. 
? TROUBLESHOOTING 
40 Close the tube. 
!CAUTION The tube must be tightly closed. Otherwise, part of the suspension will be 
lost during shaking or centrifugation. 
41 For the second extraction step, shake the tube vigorously for 1 min by hand. 
42 Centrifuge the tube at 10,000g for 5 min at room temperature. 
43 Use a glass pipette to combine the organic extracts by transferring ~650 µl of the 
organic upper layer to the GC glass vial. 
!CAUTION Avoid transfer of any of the aqueous layer. Sodium hydroxide damages the 
stationary phase of the GC column. 
   PAUSE POINT At this point, the sample can be stored at −20 °C for up to 24 h in the 
dark. 
(Optional) Dispersive solid-phase extraction ● Timing 15 min for 24 samples 
    CRITICAL Steps 44–47 are optional and are required only if performing dSPE. Otherwise, 
proceed directly to Step 48. 
44 Combine the organic extracts by transferring 650 µl of the organic upper layer to the 2-
ml plastic microcentrifuge Safe-Lock tube, which already contains 550 µl of extract 
plus dSPE sorbent from Step 38. 
45 Shake the tube vigorously for 1 min by hand. 
!CAUTION The tube must be tightly closed. Otherwise, a part of the suspension will be 
lost during shaking or centrifugation. 
46 Centrifuge the tube at 10,000g for 5 min at room temperature. 
47 Transfer 1,000 µl of the (cleaned) extract to a GC glass vial (as in Step 43). 
!CAUTION Pipette carefully, making sure to aspirate only the organic phase; avoid 
pipetting solid particles. Particles can plug the GC syringe or the GC column. 
    PAUSE POINT At this point, the sample can be stored at −20 °C for up to 24 h in the 
dark. 
Sterol derivatization ● Timing 1–2 h for 24 samples 
48 Evaporate the extract to dryness under a gentle stream of nitrogen at room 
temperature. 
!CAUTION Evaporate in a fume hood. MtBE is flammable and acutely toxic. 
    CRITICAL STEP Avoid splashing the organic phase out of the vial. If the sample cannot 
be evaporated to dryness, it is probable that some aqueous phase was transferred during 
the extraction step. Such a sample is not suitable for GC–MS analysis and should be 
discarded. 
? TROUBLESHOOTING 
    PAUSE POINT At this point, the sample can be stored at −20 °C for up 
to 24 h.  
49 Dissolve the dried lipid fraction in 950 µl of MtBE. 
? TROUBLESHOOTING 
50 Use a Hamilton glass syringe to add 50 µl of the silylation reagent mixture. 
!CAUTION The silylation reagent mixture is flammable and toxic. See notes above. 
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    CRITICAL STEP The mixture is sensitive to water (humidity). 
51 Close the GC glass vial with a screw cap. 
52 Mix the vial with a vortex mixer for 10 s. 
!CAUTION Wear protective glasses and work in a fume hood. The silylation mixture is 
corrosive and causes severe eye damage. 
53 Maintain the vial at room temperature for at least 30 min for complete silylation. 
GC–MS analysis and identification of CB intermediates ● Timing ~23 min per 
sample 
54 Transfer the silylated sample to the GC–MS autosampler for analysis (Equipment 
setup). Analyze using the described settings. 
Data analysis: identification and semi-quantitative assessment of CB 
intermediates  
● Timing ~5 min per sample 
55 For each peak in the GC–MS trace, calculate the RRT, i.e., the retention time relative 
to that of the IS. Compare the obtained RRT and mass spectra with the data in 
Supplementary Table 1 and the supplied mass spectral library (Supplementary Data or 
Supplementary Table 8, PDF of database entries). 
    CRITICAL STEP The sterol database gives MS spectra of sterol TMS ethers and can be 
run using the NIST MS search program. A free downloadable version of the NIST MS 
search program with which our library can be browsed is available at 
http://chemdata.nist.gov/mass-spc/ms-search/. Install the program and extract the 
Supplementary Data S1_substance library.7z into the NISTDEMO/MSSEARCH 
folder. The library should now be visible. To use it for search queries, use the ‘options’ 
> ‘library search options’ tab. All spectra should be visible under the ‘Names’ tab. The 
NIST MS search program usually allows searching for mass spectra directly out of raw 
data files. For further information, refer to http://www.chemdata.nist.gov/mass-spc/ms-
search/. The MS search program also allows other search terms, such as name, 
molecular weight and several other options, which can be found under the ‘search’ 
menu. Alternatively, use our spectra catalog (Supplementary Table 8). 
    CRITICAL STEP Both the mass spectrum and the RRT must match in order to achieve 
an unambiguous identification. Empirically, no more than a 0.5% RRT shift is tolerated. 
Some mass spectra of sterol TMS ether isomers, especially pairs of Δ7- and Δ8-isomers, 
are very similar (Fig. 2, Supplementary Data, or Supplementary Table 8). 
? TROUBLESHOOTING 
Identification of the target enzyme in CB ● Timing ~10 min per sample 
56 Compare the obtained peak patterns for the identified squalene, squalene epoxide or 
sterol TMS ethers between sample and control. 
57 Evaluate the differences between the two chromatograms, looking, for example, for any 
intermediates that accumulate only in the treated sample. Usually only cholesterol (11) 
can be found at significant levels in the control samples. 
? TROUBLESHOOTING 
58 Plot your accumulated sterols in the biosynthesis scheme (Fig. 1). The inhibited enzyme 
can now be evaluated. In addition, you can use Table 1 (marker sterols). 
? TROUBLESHOOTING 
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Steps 1–19, incubation of HL-60 cells with test compounds: 26 h; 1–2 h hands-on time for 24 samples 
Steps 20–29, transfer and preparation for cell lysis and extraction: 0.5–1 h for 24 samples 
Steps 30–47, cell lysis, lipid extraction, preparation: 2–3 h for 24 samples 
Steps 48–53, sterol derivatization procedure: 1–2 h for 24 samples 
Step 54, GC–MS separation and detection of intermediates: 23 min per sample 
Step 55, data analysis: identification and semi-quantitative assessment of CB intermediates: ~5 min per 
sample for experienced users 
Steps 56–58, identification of the target enzyme in CB: ~10 min per sample for experienced users 
Box 1, steps 1–7, optional quantitative assay: 1–2 h for 21 test samples 
Box 1, steps 8–13, Bradford protein assay: 1–2 h hands-on time for 21 samples 
Box 1, steps 14–17, quantification of 2-13C-acetate incorporation and construction of IC50 curves: 
0.5–1 h per sample 





Figure 5 shows typical test results for target identification, as well as IC50 determination. As can be 
seen from the upper left plot (blue), treatment of HL-60 cells using an inhibitor of proximal CB 
 
Fig. 5 | Anticipated results. The left panels show the total ion current (TIC) chromatograms obtained after incubation with the three listed inhibitors. 
From the chromatographic traces, the interaction with distal CB can be elucidated. No interaction with distal CB is observed for the HMG CoA-reductase 
inhibitor simvastatin, as no substrate of an enzyme of distal CB is detected. Inhibition of sterol C8-isomerase (G), characterized by an accumulation of 
zymostenol (8), is detected for Koe-12129, and inhibition of DHCR24 (C), characterized by the accumulation of desmosterol (18), is observed for SH-4226. 
On the right side, the corresponding IC50 curves as obtained with the described 2-13C-acetate incorporation assay are shown (n = 3 for each data point; 
error bars show ±1 s.d.). 
(simvastatin) does not lead to a detectable accumulation of CB precursors. Nevertheless, the approach 
presented here can still be used to assess the overall effect of simvastatin on the incorporation of 2-
13C-acetate into the target molecule cholesterol (11). The middle (green) and lower (yellow) panels 
show the selective inhibition of distal CB by Koe-121 and SH-42, respectively. Koe-121 leads to an 
accumulation of zymostenol (8), which is characteristic for an inhibition of sterol C8-isomerase (G). 
SH-42 causes a selective accumulation of desmosterol (18), indicating inhibition of DHCR24 (C). 
Following these observations, 2-13C-acetate incorporation analysis allows the assessment of the 
inhibitory potential of these components. These were found to be 15 and 4 nM, respectively. 
Identification of the accumulating sterols should be done on matching RRTs relative to the IS (26) 
and the full-scan MS spectrum (see Table 1 and Supplementary Table 8). Further examples in which 
the in vivo activity of SH-42 has subsequently also been established can be found in ref. 26. 
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Reporting Summary 
Further information on research design is available in the Nature Research Reporting Summary linked 
to this article. 
Data availability 
The datasets generated and analyzed during the current study are available from the corresponding 
author on reasonable request. 
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4  C  
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3β-ol  
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4,10  
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5,7-dien-3β-ol    C29H48O  412.4  
53296-
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10  
Supplementary Table S1, Analytical details of cholesterol biosynthesis intermediates. RRT relative retention time, C, commercial source, MS mass spectral analysis, OS organic synthesis, (I) 
incubation of Aspergillus fumigatus13, (II) incubation of Aspergillus fumigatus13, (III) incubation of HL-60 cells with experimental inhibitor (ethyl side chain) see reference14, (IV) incubation of HL-60 
cells with DR 2586, (V) incubation of HL-60 cells with AY-9944, and experimental inhibitor14, (VI) incubation of HL-60 cells with aminotriazole6, (VII) incubation of HL-60 cells with aminotriazole, 
AY9944, MGI-2115 (VIII) incubation of HL-60 cells with experimental inhibitor15, Isol. Isolated from yeast fat.  
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Supplementary table S2 Linear regression, LOD, and LOQ of prominent sterols The limit of 
detection (LOD) was determined at a signal/noise ratio of 3 in the total ion chromatogram. The 
limit of quantification (LOQ) was set where the RSD (n=6) was < 20% using the base peak 
chromatograms. All compounds were linear in a range between LOQ and 1.40 µg/mL.  
No.  IUPAC Name  Trivial Name  Base 
peak  
[m/z]  
Slope  Y -
intercept  




















Lanosterol  393  0.6388  -0.0500  0.979  0.01  0.02  20  
4  
4,4,14- 
Trimethylcholest-8en-3β-ol  Dihydrolanosterol  395  1.342  -0.0127  0.996  0.02  0.02  20 All   
5  
4,4-Dimethylcholesta- 
8,14-dien-3β-ol    379  0.5721  -0.0606  0.991  0.05  0.10  100  
6  
4,4-Dimethylcholest- 
8-en-3β-ol    486  0.1762  -0.0007  0.996  0.02  0.02  20  
8  Cholest-8-en-3β-ol  Zymostenol  458  0.1762  -0.0007  0.996  0.02  0.02  20  





Dehydrocholesterol  351  0.6525  -0.0574  0.979  0.02  0.20  200  
11  Cholest-5-en-3β-ol  Cholesterol  368  0.3788  0.0077  0.998  0.02  0.02  20  
15  
Cholesta-8,24-dien3β-ol  
Zymosterol  351  0.2560  -0.0015  0.989  0.05  0.05  50  
18  
Cholesta-5,24-dien3β-ol  
Desmosterol  253  0.3159  -0.0433  0.990  0.10  0.20  200  
19  
Cholesta-8,14-dien3β-ol  





Dehydrocholesterol  351  0.8237  -0.0227  0.998  0.05  0.05  50  
25  
4,4-Dimethylcholesta- 










 Inhibited enzymes  
Inhibitor  CAS-Number  Distributor  Item Number    
AY-9944  
BM 15766 sulfate1,2  
366-93-8  
86621-94-5  




C 3,4, E 5,6, G 3, I 1,2,4,7  
Haloperidol  52-86-8  Sigma-Aldrich  H1512  E 8, G 8, I 8,   
SR 31747  132173-06-9  MuseChem  I013540  C 9, G 3,6,9  
Tamoxifene  10540-29-1  Sigma-Aldrich  T5648  C6,10,11, G6,10,11  
Trifluoperazine 
dihyrochloride  
440-17-5  Sigma-Aldrich  T8516  C 4,12, H 12  
Triparanol  78-41-1  Sigma-Aldrich  T5200  C1,6,12, G12, H12  
U18666A  3039-71-2  Sigma-Aldrich  U3633  B1,13, C1,6,13, G13  
Supplementary Table S3  
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   LC-MS/MS   GC-EI-MS (scan mode)  




Short analysis times1,2, favored for 
high throughput analysis3 but 
long run time for cholesterol 
precursors after derivatization  
(40 min)4  
Analysis of non-hydrolysable and 
derivatization-resistant 
metabolites1,3,5  
Sensitive and specific technique 
for clinical steroid analysis6 (e.g. 
cortisol precursors, hormonal 
3oxo-Δ4 steroids1,2) and 
cholesterol precursors (LOD < 1pg 
on-column  
after derivatization)4  
Suited to commercial routine 










Minimal matrix effects1 
Derivatized sterols can be 
subjected to untarget and/or 
targeted analysis1,2  
Comparable MS spectra (libaries) 
are available7 (see Supporting 
information)  
Fragmentation of derivatized 
sterols allowes characterization 
of unexpected or novel  
compounds1,3,5   
  




Authentic reference material 
should be available1  
Analysis of steroids without 3oxo-
Δ4 unconjugated ring system, by 
ESI sources is challenging1,4 
Derivatzation step is necessary for 
the high sensitivity analysis 
cholesterol precursors4  
Lower sensitivites are achieved 






Extensive sample workup1, 
conjugated sterols (sulfates and 
glucuronides) require a hydrolysis  
step1,3,5-7  
Sterols with Δ5,7-diene structure 
may be labile under basic 
conditions (saponification step)5 
Derivatization step is necessary to 
improve steroid volatility and 
stability 1  
Scan mode lacks sensitivity for 
identifying and quantifying minor 
sterols1  
Supplementary Table S4  
1 Shackleton, C., Pozo, O. J. & Marcos, J. GC/MS in Recent Years Has Defined the Normal and 
Clinically Disordered Steroidome: Will It Soon Be Surpassed by LC/Tandem MS in This Role? 
Journal of the Endocrine Society 2, 974-996, doi:10.1210/js.2018-00135 (2018).  
2 Krone, N. et al. Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent 
discovery tool in clinical steroid investigations even in the era of fast liquid chromatography 
tandem mass spectrometry (LC/MS/MS). The Journal of Steroid Biochemistry and Molecular 
Biology 121, 496-504, doi:https://doi.org/10.1016/j.jsbmb.2010.04.010 (2010).  
3 Griffiths, W. J. & Wang, Y. Analysis of oxysterol metabolomes. Biochimica et Biophysica Acta 
(BBA) - Molecular and Cell Biology of Lipids 1811, 784-799, 
doi:https://doi.org/10.1016/j.bbalip.2011.05.012 (2011).  
4 Honda, A. et al. Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS. 
Journal of Lipid Research 49, 2063-2073, doi:10.1194/jlr.D800017-JLR200 (2008).  
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Supplementary Table S8 - Spectral database 
Compound No.  1  
IUPAC Name  (6E,10E,14E,18E)-2,6,10,15,19,23-Hexamethyltetracosa- 
2,6,10,14,18,22-hexaene  
Trival Name  Squalene  











RRT TMS ether  
(Cholestane)  
0.95  
RRT TMS ether  
(Cholesterol)  
0.76  
MS spectrum   
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Compound No.  2  
IUPAC Name  (3S)-2,2-Dimethyl-3-((3E,7E,11E,15E)-
3,7,12,16,20pentamethylhenicosa-3,7,11,15,19-pentaenyl)-oxirane  
Trival Name  Squalene epoxide  











RRT TMS ether  
(Cholestane)  
1.05  
RRT TMS ether  
(Cholesterol)  
0.83  
MS spectrum   
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Compound No.  3  
IUPAC Name  4,4,14-Trimethylcholesta-8,24-dien-3β-ol  
Trival Name  Lanosterol  











RRT TMS ether  
(Cholestane)  
1.44  
RRT TMS ether  
(Cholesterol)  
1.16  
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Compound No.  4  
IUPAC Name  4,4,14-Trimethylcholest-8-en-3β-ol  
Trival Name  Dihydrolanosterol  











RRT TMS ether  
(Cholestane)  
1.40  
RRT TMS ether  
(Cholesterol)  
1.12  
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Compound No.  5  
IUPAC Name  4,4-Dimethylcholesta-8,14-dien-3β-ol  
Trival Name    











RRT TMS ether  
(Cholestane)  
1.42  
RRT TMS ether  
(Cholesterol)  
1.13  
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Compound No.  6  
IUPAC Name  4,4-Dimethylcholest-8-en-3β-ol  
Trival Name    











RRT TMS ether  
(Cholestane)  
1.43  
RRT TMS ether  
(Cholesterol)  
1.14  
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Compound No.  7  
IUPAC Name  4α-Methylcholest-8-en-3β-ol  
Trival Name  4-Methylzymostenol  











RRT TMS ether  
(Cholestane)  
     
RRT TMS ether  
(Cholesterol)  
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Compound No.  8  
IUPAC Name  Cholest-8-en-3β-ol  
Trival Name  Zymostenol  











RRT TMS ether  
(Cholestane)  
1.27  
RRT TMS ether  
(Cholesterol)  
1.02  
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Compound No.  9  
IUPAC Name  Cholest-7-en-3β-ol  
Trival Name  Lathosterol  











RRT TMS ether  
(Cholestane)  
1.31  
RRT TMS ether  
(Cholesterol)  
1.04  
MS spectrum TMS ether  
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Compound No.  10  
IUPAC Name  Cholesta-5,7-dien-3β-ol  
Trival Name  7-Dehydrocholesterol  











RRT TMS ether  
(Cholestane)  
1.29  
RRT TMS ether  
(Cholesterol)  
1.03  
MS spectrum TMS ether  
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Compound No.  11  
IUPAC Name  Cholest-5-en-3β-ol  
Trivial Name  Cholesterol  











RRT TMS ether  
(Cholestane)  
1.26  
RRT TMS ether  
(Cholesterol)  
1.00  
MS spectrum TMS ether  
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Compound No.  12  
IUPAC Name  4,4-Dimethylcholesta-8,14,24-trien-3β-ol  
Trivial Name  FF-MAS  











RRT TMS ether  
(Cholestane)  
1.47  
RRT TMS ether  
(Cholesterol)  
1.17  
MS spectrum TMS ether  
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Compound No.  13  
IUPAC Name  4,4-Dimethylcholesta-8,24-dien-3β-ol  
Trivial Name  T-MAS  











RRT TMS ether  
(Cholestane)  
1.48  
RRT TMS ether  
(Cholesterol)  
1.18  
MS spectrum TMS ether  
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Compound No.  14  
IUPAC Name  4α-Methylcholesta-8,24-dien-3β-ol  
Trivial Name  4-Methylzymosterol  











RRT TMS ether  
(Cholestane)  
  
RRT TMS ether  
(Cholesterol)  
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Compound No.  15  
IUPAC Name  Cholesta-8,24-dien-3β-ol  
Trivial Name  Zymosterol  











RRT TMS ether  
(Cholestane)  
1.32  
RRT TMS ether  
(Cholesterol)  
1.06  
MS spectrum TMS ether  
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Compound No.  16  
IUPAC Name  Cholesta-7,24-dien‑3β-ol  
Trivial Name    











RRT TMS ether  
(Cholestane)  
1.34  
RRT TMS ether  
(Cholesterol)  
1.09  
MS spectrum TMS ether  
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Compound No.  17  
IUPAC Name  Cholesta-5,7,24‑trien‑3β-ol  
Trivial Name  7-Dehydrodesmosterol  











RRT TMS ether  
(Cholestane)  
1.33  
RRT TMS ether  
(Cholesterol)  
1.06  
MS spectrum TMS ether  
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Compound No.  18  
IUPAC Name  Cholesta-5,24-dien-3β-ol  
Trivial Name  Desmosterol  











RRT TMS ether  
(Cholestane)  
1.29  
RRT TMS ether  
(Cholesterol)  
1.03  
MS spectrum TMS ether  
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Compound No.  19  
IUPAC Name  Cholesta-8,14-dien-3β-ol  
Trivial Name    











RRT TMS ether  
(Cholestane)  
1.27  
RRT TMS ether  
(Cholesterol)  
1.02  
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Compound No.  20  
IUPAC Name  Cholesta-8,14,24-trien-3β-ol  
Trivial Name    











RRT TMS ether  
(Cholestane)  
1.31  
RRT TMS ether  
(Cholesterol)  
1.05  
MS spectrum TMS ether  
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Compound No.  21  
IUPAC Name  4α-Methylcholest-7-en-3β-ol  
Trivial Name  Lophenol  











RRT TMS ether  
(Cholestane)  
1.37  
RRT TMS ether  
(Cholesterol)  
1.09  
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Compound No.  22  
IUPAC Name  4α-Methylcholesta-7,24-dien-3β-ol  
Trivial Name    











RRT TMS ether  
(Cholestane)  
1.40  
RRT TMS ether  
(Cholesterol)  
1.12  
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Compound No.  23  
IUPAC Name  Cholesta-5,8-dien-3β-ol  
Trivial Name  8-Dehydrocholesterol  











RRT TMS ether  
(Cholestane)  
1.26  
RRT TMS ether  
(Cholesterol)  
1.01  
MS spectrum TMS ether  
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Compound No.  24  
IUPAC Name  Cholesta-5,8,24-trien-3β-ol  
Trivial Name    











RRT TMS ether  
(Cholestane)  
1.30  
RRT TMS ether  
(Cholesterol)  
1.04  





5. Characterization of inhibitors of cholesterol biosynthesis 
145 
Compound  25  
IUPAC Name  4,4-Dimethylcholesta-5,7-dien-3β-ol  
Trivial Name    











RRT TMS ether  
(Cholestane)  
1.43  
RRT TMS ether  
(Cholesterol)  
1.14  
MS spectrum TMS ether  
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Compound No.  26  
IUPAC Name  Cholestane  
Trivial Name    











RRT TMS ether  
(Cholestane)  
1.00  
RRT TMS ether  
(Cholesterol)  
0.80  








5. Characterization of inhibitors of cholesterol biosynthesis 
148 
 













6. Traceless isoprenylation 
152 
6. Traceless isoprenylation 
 
D. Heerdegen, J. Junker, S. Dittrich, P. Mayer, F. Bracher, Traceless Isoprenylation of 
Aldehydes via N-Boc-N-(1,1-dimethylallyl)hydrazones, European Journal of Organic 
Chemistry, 24 (2020) 3680-3687. 
 
6.1. Summary 
Isoprenylation is a typical biological process which takes place in posttranslational 
modifications of proteins [92] and in the biosynthesis of terpenes like sterols by addition of 
isopentenyl diphosphate building blocks as shown in Figure 2 (Chapter 1.2.1) [13]. In this 
article, a new approach for the introduction of an isoprenyl group into organic molecules is 
presented. Using the traceless bond construction developed by Thomson et al. [93] N-Boc-N-
allylhydrazines were used, which after condensation with appropriate aldehydes undergo [3,3]-
sigmatropic rearrangement leading to the desired isoprenylated compounds. The 
rearrangement here is named traceless bond construction, since only gaseous by-products 
(N2, iso-butylene (C4H8) and CO2) were formed during the C-C bond formation and the product 
does not contain any retron, which could reveal the used synthetic pathway [93]. The required 
N-Boc-N-allylhydrazone was synthesized from a novel N-Boc-N-allyl-hydrazine building block 
by condensation with the appropriate aldehyde. The resulting hydrazone underwent the [3,3] 
sigmatropic in the presence of catalytic amounts of the superacid triflimide.  
 
Figure 11 Graphical abstract of the article showing the condensation of the N-Boc-N-allylhydrazine with an 
aldehyde leading to a N-Boc-N-allylhydrazone. After [3,3]- sigmatropic rearrangement the desired isoprenylated 
product is formed 
This article describes the synthesis of the required N-Boc-N-allyl-hydrazine building block, the 
condensation reactions with various aldehydes and the subsequent rearrangement. It was 
crucial, to first optimize the [3,3]-sigmatropic rearrangement by changing the solvent, acid, 
temperature and reaction times by using a model compound. All in all, 33 optimization 
reactions were performed for one model product. This high number of experiments could be 
achieved using GC-MS monitoring, which was the ideal method to analyze the very volatile 
model product ((4-methylpent-3-en-1-yl)cyclohexane). As the cumbersome preparative 
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cleanup and weighting of the product could be avoided, the optimization reactions could be 
performed much faster and in smaller synthesis approaches. 
 
6.2. Personal contribution 
Conceptualization of the project, as well as planning and implementation of the synthesis was 
done by Dr. Desiree Heerdegen. In addition, she wrote the original draft and also the 
preliminary investigations and experiments were part of her contribution to the article.  
My contribution to this article were the development of the GC-MS method for the analysis of 
the prenylated products. The conceptualization of the analytical procedure for the optimization 
experiments, the performance of the respective GC-MS measurements and the analysis of the 
measurement data (see Chapter 6.4) was also part of my contribution to this article. This GC-
MS based method was crucial for the screening of multiple different reaction conditions without 
time consuming workup. 
The crystallization experiments were done by Dr. Peter Mayer. 
The project based on previously developed traceless bond constructions, that were published 
by Dr. Sebastian Dittrich and Prof. Dr. Franz Bracher [94, 95]. Both supported the 
conceptualization of this project and further contributed in editing and reviewing of the original 
draft. Dr. Sebastian Dittrich was further involved in parts of the synthesis. Prof. Dr. Franz 
Bracher further contributed by providing the necessary resources.  
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6.3. Article 
The following article is printed in the original wording. The formatting may vary slightly 
compared to the original article. 
Traceless Isoprenylation 
Traceless Isoprenylation of Aldehydes via N-Boc-N-(1,1-
dimethylallyl)hydrazones 
Desirée Heerdegen,[a] Julia Junker,[a] Sebastian Dittrich,[a] Peter Mayer,[b] and Franz 
Bracher*[a] 
Abstract: A short isoprenylation protocol starting from 
nonconjugated N-Boc-N-(1,1-dimethylallyl)hydrazones was 
developed utilising Thomson's traceless bond construction. 
This type of [3,3]-sigmatropic rearrangement is catalysed by 
the Brønsted acid triflimide and liberates only gaseous by-
products. The required N-Boc-N-allylhydrazine precursor is 
available in three steps strating from a known diazene using  
Introduction 
The [3,3]-sigmatropic rearrangement is a common but 
impressive tool for the formation of new C–C-bonds in 
synthetic chemistry.[1] In 1973 Stevens showed that N-
allylhydrazones undergo such a rearrangement under 
release of N2 as well, but due to very harsh reaction 
conditions (300 °C) and low yields, this reaction was limited 
in its applicability.[2] For several decades, synthetic chemists 
did not see any real benefit of this unique rearrangement, 
until 2010, when Thomson and co-workers published the 
traceless bond construction (TBC), an improved variant of 
Stevens' [3,3]-sigmatropic rearrangement, working with N-
Boc-N-allylhydrazones (A, Scheme 1a) and catalytic amounts 
of the Brønsted superacid triflimide (HNTf2).[3] It was now 
possible to lower the temperature of the rearrangement to 
125 °C and the yields of the products could be increased. This 
pioneering work of Thomson allowed the synthesis of 
various 1,2disubstituted olefins (B) and one 1,1-
disubstituted olefin (Scheme 1a). Mono-substituted olefins 
could not be obtained by this way. Later our group extended 
the scope to the synthesis of 1,1-disubstituted olefins (D, 
Scheme 1b), bearing an isopropyl group in 1-position, which 
resulted in a methylene branched end, a motif which is found 
in the side chains of steroidal natural products, e.g. 
episterol.[4] In the same year we reportet the synthesis of  
[a] D. Heerdegen, J. Junker, Dr. S. Dittrich, Prof. Dr. F. Bracher 
Department of Pharmacy - Center for Drug Research, Ludwig-Maximilians University, 
Butenandtstr. 5-13, 81377 Munich, Germany 
https://bracher.cup.uni-muenchen.de/ 
[b] Dr. P. Mayer 
Department of Chemistry, Ludwig-Maximilians University, 
Butenandtstr. 5-13, 81377 Munich, Germany 
Supporting information and ORCID(s) from the author(s) for this article are available 
on the WWW under https://doi.org/10.1002/ejoc.202000382.  
© 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. · This is an 
open access article under the terms of the Creative Commons Attribution License, 
which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited. 
biocatalytic aldol addition and Tebbe olefination as key 
steps. Allylhydrazones are prepared via condensation with 
appropriate aldehydes. Scope and limitations of the [3,3]-
sigmatropic rearrangements are analysed. 
 
 
terminal vinylsilanes (F, Scheme 1c) using TBC, which 
opened a new route to diversely substituted olefins.[5] 
 
In this work we present a protocol for the introduction of 
an isopentenyl (isoprenyl) residue to aldehydes (Scheme 1d). 
The isoprenyl function is a common structural element in 
terpenoid biomolecules and natural secondary 
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metabolites.[6] The natural isoprene building block in 
terpenoid biosynthesis is dimethylallyl pyrophosphate 
(DMAPP).[7,8] Steroids like cholesterol as a membrane 
component,[9] pigments like -carotene,[10] or cortisone or 
progesterone to name a few hormones,[11] are naturally 
occurring terpenoid derivatives, derived from DMAPP. 
At the biological level, protein prenyltransferases attach 
terpenoid residues like farnesyl (C15) or geranylgeranyl (C20) 
groups to cysteinyl residues of proteins in posttranslational 
modifications. Due to the introduction of this hydrophobic 
group, the proteins can anchor in biomembranes resulting in 
altered biological activities.[12] In synthetic chemistry, 
organometallic building blocks like 3-methyl-2-
butenylmagnesium chloride are commonly used for the 
introduction of an isoprenyl group.[13] Utilising inverse 
reactivities, 3,3-dimethylallyl bromide can be applied as an 
electrophilic isoprenyl building block,[14] as exemplified by 
the total syntheses of natural products, e.g. (±)-eldanolide[15] 
and (±)-fumagillin.[16] Besides direct isoprenylation, 
eliminations can lead to the isoprenyl function by forming 
the thermodynamically most stable double bond, e.g. from 
tertiary alcohols by dehydration.[17] An intramolecular 
isoprenylation, in which the group is constructed during a 
rearrangement, is to the best of our knowledge, not 
described in literature yet. 
A further centrepiece of this work is the synthesis of the 
required, hitherto unknown, N-Boc-N-(1,1-
dimethylallyl)hydrazine building block (G, Scheme 1d), 
bearing two geminal methyl groups in α-position to the 
hydrazine moiety to receive the desired isoprenylated 
products (I, Scheme 1d) via N-Boc-N-allylhydrazones (H, 
Scheme 1d). In our previous investigations leading to 1,1-
disubstituted olefins,[4] undesired subsequent acidcatalysed 
isomerisations of the formed olefinic double bond were 
observed,[18] which led occasionally to isomeric mixtures of 
product alkenes. In the present case this is not expected to 
happen, since the resulting trisubstituted olefin should be 
the thermodynamically most stable isomer. An additional 
benefit of the two geminal methyl groups in precursor G is 
on the one hand that product I cannot be formed as mixture 
of E/Z isomers and on the other hand it is expected to 
facilitate the rearrangement due to the Thorpe-Ingold effect 
(gem-dimethyl effect).[19] As a result, less drastic reaction 
temperatures and shortened reaction times may be 
employable.[20] 
Results and Discussion 
The synthesis of the required N-Boc-N-(1,1-
dimethylallyl)hydrazine building block 8a (Scheme 2; G in 
Scheme 1d) started with the two-step synthesis of known N-
Troc-N-Boc-protected diazene 2.[21] Conversion into 
aldehyde 6a was performed on two different routes. Route 
A used commercially available silyl enol ether 3, which was 
activated by LiOTf and TBAF. The idea was to achieve a 
controlled O-Si-bond cleavage in 3 by slow addition of the 
fluoride source. Simultaneously, the presence of significant 
amounts of lithium ions should lead to an immediate 
formation of the lithium enolate. However, the addition of 3 
to 2 did not proceed in a regioselective manner, and a 50:50 
mixture of the isomeric aldehydes 6a and its regioisomer 6b 
was obtained. It is noteworthy, that the regioselectivity of 
this reaction could not be measured in this step, hence, it 
was determined retrospectively after conversion into 8a/8b 
after the last step. Both isomers showed identical 
chromatographic behaviour and no distinct signals enabling 
quantification of the ratio of regioisomers could be observed 
by NMR spectroscopy until reaching 8a/8b. Because of the 
lack of regioselectivity, an alternative approach to 
intermediate 6a utilising organocatalysis[22,23] was worked 
out (route B). For this Aldol-type reaction with 
isobutyraldehyde (4), three catalysts were explored: L-
proline,[24] L-phenylalanine,[25] and Ley's (S)-5-(pyrrolidin-2-
yl)1H-tetrazole (5).[21,26] Tetrazole catalyst 5 gave the best 
result with 68 % yield and the isomeric ratio could be 
improved to 91:9 (determined retrospectively by 1H NMR 
spectroscopy) of the desired aldehyde 6a and its 
regioisomer 6b. Methylenation of the aldehyde function of 
6a/6b gave the olefins 7a and 7b. Different methods like 
Wittig,[27] Nysted-Takai[28] and Tebbe[29] olefination were 
tested, whereby the first two methods did not result in any 
product. Under Tebbe conditions the desired terminal olefin 
7a and its regioisomer 7b were obtained in an acceptable 
yield of 48 % as an inseparable mixture. 
 
Scheme 2. Route A leading to an equimolar mixture of 8a/8b starting 
from silyl enolether 3. Route B provides 8a, contaminated with 9 % of 
isomer 6b starting from aldehyde 4. *The ratios of the isomers were 
determined retrospectively by NMR spectroscopy of the product 8a/8b. 
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The X-ray crystal structure of the desired isomer 8a is shown on the left. 
Diazene 2 was synthesised according to literature.[21] 
Chemoselective reductive Troc cleavage with zinc powder 
gave a still inseparable mixture of the desired olefin 8a and 
its constitutional isomer 8b in excellent yield. However, at 
this stage NMR spectroscopy enabled determination of the 
ratio of isomers (route A 50:50, route B 91:9). The structure 
of the desired N-Boc-N-allylhydrazine 8a was 
unambiguously confirmed by X-ray crystal structure analysis 
(see Supporting Information). The enriched isomeric mixture 
of building block 8a and 8b could be used for the next step 
without further purification, since exclusively 8a undergoes 
condensation with the employed aldehydes to give the N-
Boc-N-allylhydrazones 9, whereas the isomer 8b remains 
unreacted. Scheme 3 shows the prepared allylhydrazones 
9a–q. Aliphatic (9a-d, 9f, 9g, 9p), allylic (9h, 9q) and 
aromatic (9i–9o) and ester-bearing (9e) allylhydrazones 
were synthesised by reacting the appropriate aldehydes 
with building block mixture 8a/b in ethanol (yields 33 – 95 
%). Especially non-conjugated allylhydrazones slowly 
decomposed during the purification process, which is 
reflected in the yields. Before we studied the capability of 
our N-Boc-N-allylhydrazine building block 8a, we identified 
the optimum reaction conditions for the rearrangement 
utilising cyclohexanecarboxaldehyde-derived hydrazone 9g 
as a model compound. Overall, 33 test reactions were 
performed with variations of temperature (23 to 125 °C), 
time (15 to 75 min) and solvents (THF and diglyme) (see 
Supporting Information). Significant rearrangement was 
only accomplished at temperatures of 75 °C and above. 
Besides HNTf2 (pKa –12.0, measured in DCE),[30] triflic acid 
(TfOH, pKa –11.3, measured in DCE)[30] and trifluoroacetic 
acid (TFA, pKa 0.23)[31] were tested. All in all, the hitherto 
used conditions of Thomson[3] (HNTf2, diglyme, 125 °C) gave 
the best results for this conversion, closely followed by the 
rearrangement with triflic acid in diglyme at 125 °C, which 
would be a rewarding alternative to HNTf2, which 
decomposes immediately in air and requires extremely dry 
reaction conditions. As the main side product, and even right 
at the beginning of the reaction, the corresponding Boc-
deprotected allylhydrazone was observed, a compound 
which does not undergo the rearrangement. This is in 
accordance with the observations of Thomson and could not 
be prevented.[3] This prompted us to further investigate an 
alternative carbamate residue, which might be less prone to 
premature acidic cleavage. We prepared the ethyl 
carbamate analogue S5a of 8a starting from ethyl carbazate 
on a route analogous to route B shown in Scheme 2 (for 
details, see Supporting Information). Two N-Boc-N-
allylhydrazones S6g and S6i derived thereof were subjected 
to the previously determined best reaction conditions for 
rearrangement (HNTf2, diglyme, 125 °C), but though the 
starting materials were fully consumed, none of the 
expected rearrangement products could be identified by 
GC/MS analysis. Consequently, the Boc group cannot be 
replaced in this protocol by the smaller ethoxycarbonyl 
group. 
 
Scheme 3. N-Boc-N-allylhydrazones 9a–q prepared via condensation 
reaction between N-Boc-N-allylhydrazine 8a and appropriate 
aldehydes. The yields refer to the content of N-Boc-N-allylhydrazine 8a 
in the applied 8a/8b mixture. 
Scheme 4 shows the following rearrangement of substrates 
9. The allylhydrazones 9a–c derived from n-alkanals 
underwent sigmatropic rearrangement providing the 
appropriate olefins 10a–c in 20–21 % isolated yields. The 
poor yields are in part due to the high volatility of the olefinic 
products, as demonstrated by an increased yield (25 %) of 
10g on a larger scale (3 mmol). The rearrangement product 
10d of isobutyraldehydederived N-allylhydrazone 9d could 
be detected by GC/MS, but could not be isolated due to its 
very high volatility (b.p. 135– 136 °C[32]). Ester 9e did not 
undergo rearrangement to the corresponding olefin and 
only the Boc-deprotected allylhydrazone was found. 
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Scheme 4. Successful rearrangements of N-Boc-N-allyhydrazones using 
the standard conditions of the TBC. The reactions were performed at 
least in a 0.5 mmol scale. Isolated yields are given. 
N-Allylhydrazones derived from cycloalkane 
carboxaldehydes (9f, 9g) underwent rearrangement to 
olefins 10f and 10g with a yield of 20 % for both compounds 
(Scheme 4). In contrast, allylhydrazone 9h derived from an 
α,β-unsaturated aldehyde did not undergo rearrangement 
and again only Boc-deprotected allylhydrazone was isolated. 
The attempted rearrangements of variously substituted 
arylidene hydrazones failed as well (9i–m). During the 
purification process of the attempted rearrangements of 9i 
and 9j crystalline solids were obtained, which were 




Scheme 5. Attempted rearrangements of allylhydrazones 9i and 9j 
leading to deprotected allylhydrazons 11a/b and bis-hydrazones 
12a/b. 
Obviously, acid-mediated removal of both the Boc and the 
dimethylallyl residue took place in these experiments. Next 
to those, once again Boc-deprotected allylhydrazones 11a/b 
were formed. Introduction of both electron-donating 
(methoxy compound 9l) and electron-withdrawing groups 
(nitro compound 9m) did not lead to successful 
rearrangements, and the same holds for hydrazones derived 
from heteroaromatic aldehydes (thiophene 9n and pyridine 
9o). After these experiments it became evident which type 
of allylhydrazones would undergo the attempted acid-
catalysed rearrangement. Non-conjugated allylhydrazones, 
like aliphatic systems 9a-d, 9f, and 9g form the 
corresponding olefins, in contrast to allylhydrazones 
conjugated with aryl or ester groups, which do not show any 
rearrangement. The following experiments supported this 
assumption: Non-conjugated N-allylhydrazone 9p derived 
from phenylpropanal showed a successful rearrangement 
with 19 % yield, whereas its cinnamaldehyde-derived 
congener 9q did not give the desired alkene 10q and only 
Boc-deprotected allylhydrazone was obtained. Thomson 
also reported on problems during the development of 
methods for hydrazone rearrangements, but with aliphatic 
systems,[3,33] which resulted in unidentified decomposition 
products. However, the rearrangement of aryl-substituted 
allylhydrazones worked well in his setup. Boc-deprotected 
allylhydrazones were observed in every reaction as by-
products by GC/MS analysis, but no rearrangement takes 
place with these deprotected forms under our conditions. 
The deprotection reaction outcompetes the rearrangement 
and is a possible reason for the observed yields. This finding 
validates computational studies towards the mechanism of 
the triflimidecatalysed [3,3]-sigmatropic rearrangement by 
Gutierrez et al. indicating that conversion of deprotected 
allylhydrazones does not proceed well or not at all.[34] 
Conclusion 
In summary, we present a unique method for traceless 
isoprenylation of aliphatic aldehydes via triflimide-catalysed 
[3,3]-sigmatropic rearrangement of N-Boc-N-
allylhydrazones. The central N-Boc-N-allylhydrazine building 
block 8a is available in four steps utilising organocatalysis 
and Tebbe methylenation. This method opens a new route 
to isoprenyl compounds. This novel protocol is compromised 
by poor yields in the final step and its limitation to non-
conjugated systems. Nevertheless, it broadens the scope of 
Stevens-type traceless bond constructions and represents 
the first example of a TBC for the introduction of an isoprenyl 
group into readily available aliphatic aldehydes. Therefore, 
this work extends the repertoire of methods for the total 
synthesis of isoprenoid natural products. 
Experimental Section 
General Information: All reactions were carried out in 
oven-dried Schlenk flasks equipped with a septum and a 
magnetic stirring bar which were evacuated and back filled 
with dry nitrogen. Solvents were dried ac cording to standard 
methods by distillation over drying agents. Thin layer 
chromatography (TLC) was performed using polyester sheets 
polygram SIL G/UV254 covered with SiO2 (layer thickness 0.2 
mm, 40 × 80 mm) from Macherey-Nagel. Spots were 
visualized with a CAM (ceric ammonium molybdate) solution 
followed by heating. Flash column chromatography was 
performed using SiO2 60 (0.040–0.063 mm, 230–400 mesh 
ASTM) from Merck. For chromatography distilled solvents 
were used. NMR spectra were recorded on JNM-Eclipse 400 
(400 MHz), JNM-Eclipse 500 (500 MHz), Avance III HD 400 
MHz Bruker Biospin (400 MHz) and 
Avance III HD 500 MHz Bruker Biospin (500 MHz) with 
CryoProbe™ Prodigy. Chemical shifts δ are reported as δ 
values in ppm relative to the deuterated solvent peak. The 
chemical shifts are reported in parts per million [ppm] and 
refer to the δ scala. Coupling constants J are indicated in 
Hertz [Hz]. For the characterization of the observed signal 
multiplicities the following abbreviations were applied: s 
(singlet), d (doublet), dd (doublet of doublet), dt (doublet of 
triplet), t (triplet), q (quartet), quint (quintet), m (multiplet), 
br (broad). Infrared spectra were recorded from 4000–650 
cm–1 on a PERKIN ELMER Spectrum BX-59343 FT-IR 
instrument. For detection a Smiths Detection DuraSamp IR II 
Diamond ATR sensor was used. The absorption bands are 
reported in wave numbers (cm–1). High resolution mass 
spectra (HRMS) were recorded on a Jeol Mstation 700 (Fa. 
Jeol, Peabody, USA) or JMS GCmate II Jeol instrument for 
electron impact ionisation (EI) equipped with a quadrupole 
doublet based lens system. Thermo Finnigan LTQ FT (Fa. 
Thermo Electron Corporation, Bremen, Germany) was used 
for electrospray ionization (ESI) equipped with an ion trap. 
Melting points were measured with a Büchi apparatus B-540 
(Büchi, Flawill, Switzerland) and are reported in °C and are 
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not corrected. Gas chromatography (GC) was performed on 
a Varian 3800 gas chromatograph coupled to a Saturn 2200 
ion trap from Varian (Darmstadt, Germany). The 
autosampler was from CTC Analytics (Zwingen, Switzerland) 
and the split/splitless injector was a Varian 1177 (Darmstadt, 
Germany). Instrument control and data analysis were carried 
out with Varian Workstation 6.9 SP1 software (Darmstadt, 
Germany). A Varian VF-5ms capillary column of 30 m length, 
0.25 mm i.d. and 0.25 μm film thickness (Darmstadt, 
Germany) was used at a constant flow rate of 1.4 mL/min. 
Carrier gas was helium 99.999 % from Air Liquide 
(Düsseldorf, Germany). The inlet temperature was kept at 
300 °C and injection volume was 1 μL with splitless time 1.0 
min. The initial column temperature was 50 °C and was held 
for 1.0 min. Then the temperature was ramped up to 250 °C 
with 50 °C/min. Then the products were eluted at a rate of 5 
°C/min until 310 °C (hold time 3 min). Total run time was 20 
min. Transfer line temperature was 300 °C and the ion trap 
temperature was 150 °C. The ion trap was operated with 
electron ionization (EI) at 70 eV in scan mode (m/z 50–650) 
with a solvent delay of 6.3 min. 
Crystallography: All X-ray intensity data were measured 
on a Bruker D8 Venture TXS system equipped with a 
multilayer mirror optics monochromator and a Mo Kα 
rotating-anode X-ray tube (λ = 0.71073 Å). The data 
collections were performed at 103 K. The frames were 
integrated with the Bruker SAINT Software package.[35] Data 
were corrected for absorption effects using the Multi-Scan 
method (SADABS).[36] The structures were solved and refined 
using the Bruker SHELXTL Software Package.[37] All C-bound 
hydrogen atoms were calculated in positions having ideal 
geometry riding on their parent atoms. 
Deposition Number(s) 1907495 (for 8a) contain(s) the 
supplementary crystallographic data for this paper. These 
data are provided free of charge by the joint Cambridge 
Crystallographic Data Centre and Fachinformationszentrum 
Karlsruhe Access Structures service 
www.ccdc.cam.ac.uk/structures. 
Synthesis of Compounds 
Diazene 2 was synthesised according to a literature 
protocol[21] in two steps and a total yield of 81 %. 
1-(tert-Butyl) 2-(2,2,2-Trichloroethyl) 1-(2-Methyl-
1-oxopropan2-yl)hydrazine-1,2-dicarboxylate (6a) 
and 2-(tert-Butyl) 1-(2,2,2Trichloroethyl) 1-(2-
Methyl-1-oxopropan-2-yl)hydrazine-1,2-
dicarboxylate (6b): Route A: A suspension of LiOTf (875 
mg, 5.61 mmol, 1.52 equiv.) in dry CHCl3 (20 mL) was cooled 
to - 50 °C. A solution of diazene 2 (1.70 g, 5.56 mmol, 1.5 
equiv.) in CHCl3 (10 mL), 2-methyl-1-(trimethylsilyloxy)-1-
propene (3) (533 mg, 3.70 mmol, 1.0 equiv.) in CHCl3 (10 mL) 
was added, followed by TBAF (1 M in THF, 3.7 mL, 3.7 mmol, 
1.0 equiv.). The resulting reaction mixture was warmed to 
room temperature and stirred for 16 h. The reaction was 
stopped with aq. sat. NH4Cl solution (10 mL) and the layers 
were separated. The organic layer was washed with aq. sat. 
NaHCO3 solution (10 mL), dried with MgSO4, filtered and the 
solvent was removed in vacuo. The title compound was 
purified by flash column chromatography (hexanes/EtOAc, 
8:1). An inseparable mixture of aldehydes 6a/6b (911 mg, 
2.43 mmol, 66 %) were obtained as a colourless solid in an 
isomeric mixture of 50:50 (determined retrospectively via 1H 
NMR). Route B: Diazene 2 (690 mg, 2.26 mmol, 1.0 equiv.) 
and (S)-5-(pyrrolidin-2-yl)-1H-tetrazole (5) (31.4 mg, 0.226 
mmol, 10 mol-%) were dissolved in dry dichloromethane (15 
mL) and the solution was cooled to 0 °C. Isobutyraldehyde 
(4) (0.25 mL, 2.71 mmol, 1.2 equiv.) was added slowly and 
the reaction mixture was warmed to room temperature. 
After completion of the reaction, the solvent was removed 
in vacuo and the product was purified by flash column 
chromatography (hexanes/ EtOAc, 8:1). An inseparable 
mixture of aldehydes 6a/6b (580 mg, 1.53 mmol, 68 %) were 
obtained as a colourless solid in an isomeric mixture of 91:9 
(determined retrospectively via 1H NMR): Rf = 0.17 
(hexanes/EtOAc, 8:1); m.p. 128–129 °C; 1H NMR (500 MHz, 
[D]chloroform) δ/ppm = 9.49 (s, 1H), 6.70 (s, 1H), 4.93–4.51 
(m, 2H), 1.44 (s, 9H), 1.36 (s, 3H), 1.29 (s, 3H); 13C NMR (101 
MHz, [D]chloroform δ/ ppm = 198.1, 155.4, 154.3, 94.9, 84.3, 
75.2, 67.4, 28.2, 20.5; IR (ATR) ν˜ = /cm–1 = 3255, 3013, 2980, 
2936, 1771, 1723, 1694, 1528, 1457, 1391, 1380, 1365, 1358, 
1287, 1254, 1220, 1161, 1108, 1054, 992, 945, 916, 882, 858, 
834, 817, 799, 763, 750, 724, 709, 658; HRMS (ESI): m/z 
calcd. For C12H18Cl3N2O5 [M – H]– 375.0287, found 375.0287. 
1-(tert-Butyl) 2-(2,2,2-Trichloroethyl) 1-(2-
Methylbut-3-en-2yl)hydrazine-1,2-di-carboxylate 
(7a) and 2-(tert-Butyl) 1-(2,2,2Trichloroethyl) 1-(2-
Methylbut-3-en-2-yl)hydrazine-1,2-dicarboxylate 
(7b): The isomeric mixture of aldehydes 6a/6b (569 mg, 
1.51 mmol, 1.0 equiv.) and pyridine (0.22 mL, 2.7 mmol, 1.8 
equiv.) were added to a flame dried flask and the mixture 
was blended to a gel via ultrasound bath. The suspension 
was cooled to –80 °C and Tebbe reagent (0.5 M in toluene, 
3.92 mL, 1.96 mmol, 1.3 equiv.) was added carefully by 
adding it along the flask. The reaction mixture was warmed 
to 0 °C and stirred 48 h. The reaction was quenched with a 
saturated aqueous NaHCO3 solution (6 mL) at –80 °C and 
extracted with dichloromethane (3 × 10 mL). The combined 
organic layers were dried with MgSO4, filtered and the 
solvent was removed in vacuo. Purification by flash column 
chromatography (hexanes/EtOAc, 9:1) gave an inseparable 
mixture of olefins 7a/7b (270 mg, 0.719 mmol, 48 %) as a 
colourless solid in an isomeric mixture of 91:9 (determined 
retrospectively via 1H NMR): Rf = 0.29 (hexanes/EtOAc, 9:1); 
m.p. 103–104 °C; 1H NMR (500 MHz, [D]chloroform) δ/ppm 
= 6.68 (s, 1H), 6.10 (dd, 3JH,H = 17.4, 11.0 Hz, 1H), 5.08 (d, 3JH,H 
= 17.1 Hz, 1H), 5.00 (d, 3JH,H = 10.9 Hz, 1H), 4.87 (d, 2JH,H = 11.5 
Hz, 1H), 4.68 (d, 2JH,H = 11.8 Hz, 1H), 1.50 (s, 3H), 1.44 (s, 9H), 
1.42 (s, 3H); 13C NMR (126 MHz, [D]chloroform) δ/ppm = 
155.4, 154.5, 144.6, 111.2, 95.2, 82.1, 75.1, 62.9, 28.4, 26.6, 
26.4; IR (ATR) ν˜ = /cm–1 = 3323, 2924, 2854, 1733, 1706, 
1644, 1522, 1456, 1414, 1386, 1359, 1274, 1253, 1233, 1156, 
1101, 1078, 1044, 1011, 990, 967, 922, 907, 851, 815, 759, 
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741, 724, 688; HRMS (ESI): m/z calcd. for C13H20O4N2Cl3 [M – 
H]– 373.0494, found 373.0499. 
tert-Butyl 1-(2-Methylbut-3-en-2-yl)hydrazine-1-
carboxylate (8a) and tert-Butyl 2-(2-Methylbut-3-
en-2-yl)hydrazine-1-carboxylate (8b): The mixture of 
olefins 7a/7b (95.6 mg, 0.254 mmol, 1.0 equiv.) was 
dissolved in a mixture of ethanol (0.3 mL), water (0.3 mL) and 
acetic acid (0.3 mL). Zinc powder (582 mg, 8.91 mmol, 35.0 
equiv.) was added and the reaction mixture was stirred for 
10 minutes at room temperature. After filtration of the 
reaction mixture, the filtrate was extracted with 
dichloromethane (3 × 3 mL) and the residue was extracted. 
The combined organic layers were washed was saturated 
aqueous NaHCO3 solution (5 mL) and the organic layer was 
dried with MgSO4, filtered and the solvent was removed in 
vacuo. The product was used without purification. 8a/8b 
(57 mg, 0.28 mmol, quantitative) was obtained as a 
colourless oil in an isomeric mixture of 91:9: Rf = 0.15 
(hexanes/EtOAc, 8:2); 1H NMR (8a) (400 MHz, [D6]DMSO) 
δ/ppm = 6.00 (dd, 3JH,H = 17.5, 10.7 Hz, 1H), 4.87 (dd, 3JH,H = 
17.5, 10.8, 2H), 4.24 (s, 2H), 1.38 (s, 9H), 1.33 (s, 6H); 13C 
NMR (8a) (126 MHz, [D6]DMSO) δ/ppm = 156.4, 146.2, 
108.8, 79.3, 60.6, 28.1, 26.5; 1H NMR (8b) (500 MHz, 
[D6]DMSO) δ/ppm = 7.95 (s, 1H), 5.81 (dd, 3JH,H = 17.6, 10.8 
Hz, 1H), 5.08–4.92 (m, 2H), 4.07 (s, 1H), 1.38 (s, 9H), 1.03 (s, 
6H); 13C NMR (8b) (126 MHz, [D6]DMSO) δ/ppm = 155.6, 
145.0, 112.2, 78.1, 57.8, 28.2, 24.8; IR (ATR) ν˜ = /cm–1 = 
3334, 2977, 2932, 1679, 1477, 1455, 1412, 1365, 1249, 1163, 
1101, 1005, 994, 948, 907, 868, 766, 724, 687; HRMS (ESI): 
m/z calcd. for C10H21N2O2 [M + H]+ 201.1597, found 
201.1597. 
General Procedure 1 (GP1) for the Synthesis of N-
Boc-N-(1,1Dimethylallyl)hydrazones 9a–q: The 
mixture of N-(1,1-dimethylallyl)hydrazines 8a/8b (1.0 
equiv.) was dissolved in absolute EtOH and the appropriate 
aldehyde (1.0 equiv.) was added. The reaction mixture was 
stirred at room temperature for 15 h, then the solvent was 
removed in vacuo and the crude product was purified by 
flash column chromatography. Isolated yields are correlated 
to the amount of 8a in the isomeric mixture 8a/8b. 
tert-Butyl 1-(2-methylbut-3-en-2-yl)-2-
octylidenehydrazine-1carboxylate (9a): Mixture of 
allylhydrazines 8a/8b (250 mg, 
1.75 mmol  1.59 mmol of isomer 8a) and octanal (0.298 mL, 
1.75 mmol) gave N-Boc-N-allylhydrazone 9a (178 mg, 0.576 
mmol, 36 % referred to isomer 8a) as colourless oil via GP1: 
Rf = 0.58 (hexanes/EtOAc, 9:1); 1H NMR (400 MHz, 
[D]chloroform) δ/ppm = 7.71 (t, 3JH,H = 5.6 Hz, 1H), 6.11 (dd, 
3JH,H = 17.5, 10.8 Hz, 1H), 5.07– 4.86 (m, 2H), 2.35 (td, 3JH,H = 
5.6 Hz, 2H), 1.59–1.50 (m, 2H), 1.42 (s, 9H), 1.39 (s, 6H), 
1.34–1.24 (m, 8H), 0.87 (m, 3H); 13C NMR (101 MHz, 
[D]chloroform) δ/ppm = 169.5, 154.3, 146.3, 109.4, 80.9, 
61.7, 33.0, 31.9, 29.5, 29.2, 28.6, 26.7, 26.2, 22.8, 14.3; IR 
(ATR) ν˜ = /cm–1 = 3084, 3004, 2972, 2958, 2927, 2857, 1698, 
1641, 1455, 1412, 1391, 1366, 1302, 1244, 1157, 1101, 1003, 
991, 901, 855, 757, 724, 686; HRMS (ESI): m/z calcd. for 
C18H35N2O2 [M + H]+ 311.2693, found 311.2694. 
tert-Butyl 1-(2-Methylbut-3-en-2-yl)-2-
nonylidenehydrazine-1carboxylate (9b): Mixture of 
allylhydrazines 8a/8b (404 mg, 2.02 mmol  1.83 mmol of 
isomer 8a) and nonanal (0.346 mL, 2.02 mmol) gave N-Boc-
N-allylhydrazone 9b (284 mg, 0.877 mmol, 48 % referred to 
isomer 8a) as colourless oil via GP1: Rf = 0.58 
(hexanes/EtOAc, 9:1); 1H NMR (500 MHz, [D]chloroform) 
δ/ppm = 7.71 (t, 3JH,H = 5.6 Hz, 1H), 6.11 (dd, 3JH,H = 17.5, 10.8 
Hz, 1H), 5.05–4.89 (m, 2H), 2.34 (td, 3JH,H = 5.6 Hz, 2H), 1.55 
(m, 2H), 1.42 (s, 9H), 1.39 (s, 6H), 1.36–1.21 (m, 10H), 0.89–
0.85 (m, 3H); 13C NMR (101 MHz, [D]chloroform) δ/ppm = 
169.4, 154.3, 146.3, 109.4, 80.9, 61.7, 33.0, 31.9, 29.5, 29.4, 
29.3, 28.5, 26.7, 26.2, 22.8, 14.2; IR (ATR) ν˜ = /cm–1 = 3086, 
2972, 2956, 2926, 2856, 1698, 1640, 1455, 1412, 1390, 1366, 
1302, 1244, 1157, 1100, 1003, 992, 900, 874, 857, 783, 756, 
723, 687, 599; HRMS (ESI): m/z calcd. for C19H37N2O2 [M + 
H]+ 325.2849, found 325.2849. 
tert-Butyl 2-Decylidene-1-(2-methylbut-3-en-2-
yl)hydrazine-1carboxylate (9c): Mixture of 
allylhydrazines 8a/8b (115 mg, 0.574 mmol  0.522 mmol of 
isomer 8a) and decanal (0.108 mL, 0.574 mmol) gave N-Boc-
N-allylhydrazone 9c (56 mg, 0.17 mmol, 33 % referred to 
isomer 8a) as colourless oil via GP1: Rf = 0.56 
(hexanes/EtOAc, 9:1). 1H NMR (500 MHz, [D]chloroform) 
δ/ppm = 7.71 (t, 3JH,H = 5.6 Hz, 1H), 6.11 (dd, 3JH,H = 17.5, 10.8 
Hz, 1H), 5.01 (dd, 3JH,H = 17.5, 2JH,H = 0.7 Hz, 1H), 4.92 (dd, J 
3JH,H = 10.8, 2JH,H = 0.7 Hz, 1H), 2.35 (td, 3JH,H = 5.6 Hz, 2H), 
1.57–1.54 (m, 2H), 1.42 (s, 9H), 1.39 (s, 6H), 1.26 (m, 12H), 
0.89–0.86 (m, 3H). 13C NMR (126 MHz, [D]chloroform) 
δ/ppm = 169.5, 154.3, 146.3, 109.4, 80.9, 61.7, 33.0, 32.0, 
29.6, 29.5, 29.5, 29.4, 28.6, 26.7, 26.2, 22.8, 14.3. IR (ATR) ν˜ 
= /cm–1 = 2924, 2853, 1696, 1458, 1407, 1368, 1310, 1245, 
1158, 1101, 990, 903, 852, 754, 719, 665. HRMS (ESI): m/z 
calcd. for C20H39N2O2 [M + H]+ 339.3006, found 339.3011. 
tert-Butyl 1-(2-Methylbut-3-en-2-yl)-2-(2-
methylpropylidene)hydrazine-1-carboxylate (9d): 
Mixture of olefins 8a/8b (519 mg, 2.59 mmol  2.36 mmol of 
isomer 8a) and isobutyraldehyde (4) (0.237 mL, 2.59 mmol) 
gave N-Boc-N-allylhydrazone 9d (262 mg, 1.03 mmol, 44 % 
referred to isomer 8a) as colourless oil via GP1: Rf = 0.55 
(hexanes/EtOAc, 9:1); 1H NMR (400 MHz, [D]chloroform) δ/ 
ppm = 7.61 (d, 3JH,H = 5.9 Hz, 1H), 6.11 (dd, 3JH,H = 17.6, 10.8 
Hz, 1H), 5.03–4.90 (m, 2H), 2.66–2.56 (m, 1H), 1.42 (s, 9H), 
1.39 (s, 6H), 1.13 (s, 3H), 1.12 (s, 3H). 13C NMR (101 MHz, 
[D]chloroform) δ/ppm = 173.2, 154.1, 146.3, 109.4, 80.9, 
61.9, 32.2, 28.6, 26.6, 19.6. IR (ATR) ν˜ = /cm–1 = 3086, 3008, 
2973, 2930, 2872, 1698, 1641, 1456, 1412, 1390, 1366, 1304, 
1289, 1244, 1156, 1092, 1058, 992, 970, 902, 879, 856, 756, 
686, 599, 588. HRMS (ESI): m/z calcd. for C14H27N2O2 [M + 
H]+ 255.2067, found 255.2066. 
 




Mixture of olefins 8a/8b (200 mg, 0.990 mmol,  0.901 mmol 
of isomer 8a) and ethyl glyoxalate solution (ca. 50 % in 
toluene, 0.198 mL, 0.990 mmol) gave NBoc-N-
allylhydrazone 9e (108 mg, 0.380 mmol, 42 % referred to 
isomer 8a) as colourless oil via GP1: Rf = 0.44 
(hexanes/EtOAc, 9:1); 1H NMR (400 MHz, [D]chloroform) 
δ/ppm = 8.41 (s, 1H), 6.05 (dd, 3JH,H = 17.5, 10.8 Hz, 1H), 5.07–
4.93 (m, 2H), 4.26 (q, 3JH,H = 7.1 Hz, 2H), 1.52 (s, 6H), 1.48 (s, 
9H), 1.31 (t, 3JH,H = 7.1 Hz, 3H); 13C NMR (101 MHz, 
[D]chloroform) δ/ppm = 164.9, 151.9, 145.5, 135.7, 110.6, 
83.6, 65.9, 60.9, 28.3, 27.7, 14.4; IR (ATR) ν˜ = /cm–1 = 1742, 
1708, 1585, 1477, 1456, 1369, 1339, 1288, 1242, 1206, 1181, 
1148, 1113, 1093, 1044, 911, 848, 798, 759, 744, 576; HRMS 




Mixture of olefins 8a/8b. (430 mg, 2.15 mmol  1.96 mmol of 
isomer 8a) and cyclopentane carboxaldehyde (0.229 mL, 
2.15 mmol) gave N-Boc-N-allylhydrazone 9f (245 mg, 0.874 
mmol, 45 % referred to isomer 8a) as colourless oil via GP1: 
Rf = 0.57 (hexanes/EtOAc, 9:1); 1H NMR (400 MHz, 
[D]chloroform) δ/ppm = 7.62 (d, 3JH,H = 6.8 Hz, 1H), 6.11 (dd, 
3JH,H = 17.5, 10.8 Hz, 1H), 5.08–4.82 (m, 2H), 2.87–2.71 (m, 
1H), 1.95–1.79 (m, 2H), 1.73–1.54 (m, 6H), 1.42 (s, 9H), 1.38 
(s, 6H); 13C NMR (101 MHz, [D]chloroform) δ/ppm = 172.6, 
154.2, 146.2, 109.4, 80.8, 61.8, 42.9, 30.3, 28.6, 28.5, 26.6, 
25.7; IR (ATR) ν˜ = /cm–1 = 3084, 2968, 2956, 2869, 1697, 
1639, 1476, 1454, 1412, 1390, 1366, 1304, 1244, 1156, 1101, 
1061, 1003, 992, 900, 877, 856, 783, 757, 687; HRMS (ESI): 




Mixture of olefins 8a/8b (91.6 mg, 0.686 mmol  0.624 mmol 
of isomer 8a) and cyclohexanecarboxaldehyde (55.4 μL, 
0.686 mmol) gave N-Boc-N-allylhydrazone 9f (63.3 mg, 
0.215 mmol, 34 % referred to isomer 8a) as colourless oil via 
GP1: Rf = 0.64 (hexanes/EtOAc, 9:1); 1H NMR (500 MHz, 
[D]chloroform) δ/ppm = 7.58 (d, 3JH,H = 6.0 Hz, 1H), 6.11 (dd, 
3JH,H = 17.5, 10.8 Hz, 1H), 5.01 (dd, 3JH,H = 17.5, 2JH,H = 0.9 Hz, 
1H), 4.92 (dd, 3JH,H = 10.8, 2JH,H = 0.9 Hz, 1H), 2.42–2.25 (m, 
1H), 1.89–1.80 (m, 2H), 1.80–1.73 (m, 2H), 1.70–1.64 (m, 
1H), 1.41 (s, 9H), 1.39 (s, 6H), 1.35– 1.28 (m, 4H), 1.27–1.18 
(m, 1H). 13C NMR (101 MHz, [D]chloroform) δ/ppm = 172.6, 
154.3, 146.3, 109.4, 80.8, 61.8, 41.5, 29.9, 28.6, 26.7, 26.1, 
25.5; IR (ATR) ν˜ = /cm–1 = 2929, 2854, 1709, 1366, 1308, 
1244, 1160; HRMS (ESI): m/z calcd. for C17H31N2O2: 295.2380 
[M + H]+, found 295.2385. 
tert-Butyl 2-(Cyclohex-1-en-1-ylmethylene)-1-(2-
methylbut-3en-2-yl)hydrazine-1-carboxylate (9h): 
Mixture of olefins 8a/8b (200 mg, 0.999 mmol  0.909 mmol 
of isomer 8a) and 1-cyclohexene-1-carboxaldehyde (0.114 
mL, 0.990 mmol) gave N-Boc-N-allylhydrazone 9h (135 mg, 
0.460 mmol, 51 % referred to isomer 8a) as colourless oil via 
GP1: Rf = 0.52 (hexanes/EtOAc, 9:1); 1H NMR (400 MHz, 
[D]chloroform) δ/ppm = 7.99 (s, 1H), 6.18–6.05 (m, 2H), 
5.05–4.85 (m, 2H), 2.37–2.12 (m, 4H), 1.70–1.61 (m, 4H), 
1.43 (s, 9H), 1.41 (s, 6H); 13C NMR (101 MHz, [D]chloroform) 
δ/ppm = 163.9, 153.9, 146.6, 138.2, 136.3, 109.1, 81.2, 62.7, 
28.6, 26.9, 26.3, 23.4, 22.5, 22.1; IR (ATR) ν˜ = /cm–1 = 2976, 
2931, 2859, 1697, 1639, 1596, 1366, 1291, 1243, 1152, 1107, 
902, 881, 754, 699; HRMS (ESI): m/z calcd. for C17H29N2O2 [M 
+ H]+ 293.2224, found 293.2223. 
tert-Butyl 2-Benzylidene-1-(2-methylbut-3-en-2-
yl)hydrazine-1carboxylate (9i): Mixture of olefins 
8a/8b (580 mg, 2.90 mmol  2.64 mmol of isomer 8a) and 
benzaldehyde (0.294 mL, 2.90 mmol) gave N-Boc-N-
allylhydrazone 9i (312 mg, 1.08 mmol, 41 % referred to 
isomer 8a) as colourless oil via GP1: Rf = 0.64 
(hexanes/EtOAc, 9:1); 1H NMR (400 MHz, [D]chloroform) 
δ/ppm = 8.65 (s, 1H), 7.74–7.68 (m, 2H), 7.43–7.34 (m, 3H), 
6.17 (dd, 3JH,H = 17.5, 10.8 Hz, 1H), 5.11–4.90 (m, 2H), 1.52 (s, 
6H), 1.47 (s, 9H); 13C NMR (101 MHz, [D]chloroform) δ/ppm 
= 157.1, 153.6, 146.4, 135.4, 130.2, 128.7, 127.7, 109.4, 81.8, 
63.6, 28.5, 27.2; IR (ATR) ν˜ = /cm–1 = 3083, 3062, 2976, 2932, 
1697, 1642, 1574, 1476, 1449, 1412, 1391, 1366, 1289, 1243, 
1149, 1109, 1071, 992, 947, 898, 856, 784, 753, 692, 659, 
563; HRMS (ESI): m/z calcd. for C17H25N2O2 [M + H]+ 
289.1910, found 289.1909. 
tert-Butyl 2-(4-Bromobenzylidene)-1-(2-methylbut-
3-en-2-yl)hydrazine-1-carboxylate (9j): Mixture of 
olefins 8a/8b (243 mg, 1.21 mmol  1.10 mmol of isomer 8a) 
and 4-bromobenzaldehyde (224 mg, 1.21 mmol) gave N-
Boc-N-allylhydrazone 9j (356 mg, 0.971 mmol, 88 % referred 
to isomer 8a) as colourless oil via GP1: Rf = 0.64 
(hexanes/EtOAc, 9:1); 1H NMR (500 MHz, [D]chloroform) δ/ 
ppm = 8.68 (s, 1H), 7.56 (d, 3JH,H = 8.4 Hz, 2H), 7.50 (d, 3JH,H = 
8.3 Hz, 2H), 6.14 (dd, 3JH,H = 17.5, 10.8 Hz, 1H), 5.07–4.92 (m, 
2H), 1.51 (s, 6H), 1.47 (s, 9H); 13C NMR (126 MHz, 
[D]chloroform) δ/ppm = 153.9, 153.5, 146.3, 134.7, 131.9, 
128.9, 124.1, 109.6, 82.1, 63.9, 28.5, 27.3; IR (ATR) ν˜ = /cm–
1 = 3086, 2979, 2932, 1696, 1643, 1591, 1564, 1487, 1455, 
1412, 1392, 1367, 1289, 1244, 1148, 1115, 1098, 1069, 1044, 
1009, 992, 953, 929, 901, 856, 819, 786, 752, 708, 691, 667; 




Mixture of olefins 8a/8b (100 mg, 0.499 mmol  0.454 mmol 
of isomer 8a) and 4-dimethylaminobenzaldehyde (74.5 mg, 
0.499 mmol) gave N-Boc-N-allylhydrazone 9k (143 mg, 
0.431 mmol, 95 % referred to isomer 8a) as white crystalline 
solid via GP1: Rf = 0.35 (hexanes/EtOAc, 9:1); m.p. 73–75 °C; 
1H NMR (400 MHz, [D]chloroform) δ/ppm = 8.30 (s, 1H), 7.61 
(d, 3JH,H = 8.9 Hz, 2H), 6.69 (d, 3JH,H = 8.9 Hz, 2H), 6.19 (dd, 3JH,H 
= 17.5, 10.8 Hz, 1H), 5.08–4.90 (m, 2H), 3.01 (s, 6H), 1.47 (s, 
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6H), 1.44 (s, 9H); 13C NMR (101 MHz, [D]chloroform) δ/ppm 
= 162.4, 154.2, 152.2, 146.6, 129.4, 122.4, 111.8, 109.2, 80.9, 
62.6, 40.4, 28.6, 26.9; IR (ATR) ν˜ = /cm–1 = 2976, 2930, 1693, 
1616, 1601, 1528, 1477, 1455, 1363, 1300, 1237, 1155, 1100, 
1060, 894, 859, 816, 755, 731; HRMS (ESI): m/z calcd. for 
C19H30N3O2 [M + H]+ 332.2333, found 332.2333. 
tert-Butyl 2-(4-Methoxybenzylidene)-1-(2-
methylbut-3-en-2-yl)hydrazine-1-carboxylate (9l): 
Mixture of olefins 8a/8b (150 mg, 0.749 mmol  0.682 mmol 
of isomer 8a) and 4-anisaldehyde (102 mg, 91.1 μL, 0.749 
mmol) gave N-Boc-N-allylhydrazone 9l (151 mg, 0.475 
mmol, 70 % referred to isomer 8a) as colourless oil via GP1: 
Rf = 0.42 (hexanes/EtOAc, 9:1); 1H NMR (400 MHz, 
[D]chloroform) δ/ppm = 8.48 (s, 1H), 7.66 (d, 3JH,H = 8.8 Hz, 
2H), 6.91 (d, 3JH,H = 8.9 Hz, 2H), 6.17 (dd, 3JH,H = 17.5, 10.8 Hz, 
1H), 5.08–4.92 (m, 2H), 3.84 (s, 3H), 1.49 (s, 6H), 1.45 (s, 9H); 
13C NMR (101 MHz, [D]chloroform) δ/ppm = 161.5, 159.0, 
153.9, 146.5, 129.3, 127.8, 114.1, 109.3, 81.4, 63.1, 55.5, 
28.6, 27.0; IR (ATR) ν˜ = /cm–1 = 2975, 2932, 1693, 1606, 
1512, 1456, 1366, 1293, 1245, 1150, 1104, 1031, 900, 859, 
831, 75; HRMS (ESI): m/z calcd. for C18H27N2O3 [M + H]+ 
319.2016, found 319.2015. 
tert-Butyl 1-(2-Methylbut-3-en-2-yl)-2-(4-
nitrobenzylidene)hydrazine-1-carboxylate (9m): 
Mixture of olefins 8a/8b (250 mg, 1.25 mmol  1.14 mmol of 
isomer 8a) and 4-nitrobenzaldehyde (0.126 mL, 1.25 mmol) 
gave N-Boc-N-allylhydrazone 9m (233 mg, 0.698 mmol, 61 
% referred to isomer 8a) as yellow solid via GP1: Rf = 0.51 
(hexanes/EtOAc, 9:1); m.p. 67–69 °C; 1H NMR (400 MHz, 
[D]chloroform) δ/ppm = 9.02 (s, 1H), 8.24–8.19 (m, 2H), 
7.82–7.75 (m, 2H), 6.12 (dd, J = 17.5, 10.8 Hz, 1H), 5.10–4.93 
(m, 2H), 1.56 (s, 6H), 1.50 (s, 9H); 13C NMR (101 MHz, 
[D]chloroform) δ/ppm = 152.9, 148.1, 147.7, 145.9, 142.7, 
127.6, 124.0, 110.1, 82.9, 65.0, 28.5, 27.6; IR (ATR) ν˜ = /cm–
1 = 1699, 1598, 1572, 1518, 1368, 1343, 1286, 1246, 1146, 
1107, 907, 849, 832, 729, 692, 647; HRMS (EI): m/z calcd. for 
C17H23N3O4 [M˙]+ 333.1683, found 333.1710. 
tert-Butyl 1-(2-Methylbut-3-en-2-yl)-2-(thiophen-
2-ylmethylene)hydrazine-1-carboxylate (9n): 
Mixture of olefins 8a/8b (150 mg, 0.749 mmol  0.681 mmol 
of isomer 8a) and 2-thiophenecarboxaldehyde (70 μL, 0.749 
mmol) gave N-Boc-N-allylhydrazone 9n (104 mg, 0.352 
mmol, 52 % referred to isomer 8a) as light yellow oil via GP1: 
Rf = 0.60 (hexanes/EtOAc, 9:1); 1H NMR (400 MHz, 
[D]chloroform) δ/ppm = 8.85–8.83 (m, 1H), 7.32 (dt, 3JH,H = 
5.0, 1.0 Hz, 1H), 7.24 (dd, 3JH,H = 3.6, 1.2 Hz, 1H), 7.04 (dd, 
3JH,H = 5.1, 3.6 Hz, 1H), 6.14 (dd, 3JH,H = 17.5, 10.8 Hz, 1H), 
5.08–4.91 (m, 2H), 1.49 (s, 6H), 1.47 (s, 9H); 13C NMR (101 
MHz, [D]chloroform) δ/ppm = 153.6, 150.2, 146.3, 140.9, 
129.7, 127.9, 127.4, 109.5, 81.9, 63.7, 28.5, 27.2; IR (ATR) ν˜ 
= /cm–1 = 2985, 2938, 1742, 1708, 1585, 1369, 128, 1242, 
1181, 1148, 1113, 1093, 1044, 911, 848, 759, 744, 576; 
HRMS (EI): m/z calcd. for C15H22N2O2S [M]˙+ 294.1396, found 
294.1392. 
tert-Butyl 1-(2-Methylbut-3-en-2-yl)-2-(pyridin-4-
ylmethylene)hydrazine-1-carboxylate (9o): Mixture 
of olefins 8a/8b (350 mg, 1.75 mmol  1.59 mmol of isomer 
8a) and 4-pyridinecarboxaldehyde (0.165 mL, 1.75 mmol) 
gave N-Boc-N-allylhydrazone 9o (342 mg, 1.18 mmol, 74 % 
referred to isomer 8a) as light yellow oil via GP1: Rf = 0.12 
(hexanes/EtOAc, 9:1); 1H NMR (400 MHz, [D]chloroform) 
δ/ppm = 8.90 (s, 1H), 8.65–8.55 (m, 2H), 7.50 (dd, 3JH,H = 6.1, 
0.4 Hz, 2H), 6.11 (dd, 3JH,H = 17.5, 10.8 Hz, 1H), 5.11–4.90 (m, 
2H), 1.54 (s, 6H), 1.49 (s, 9H); 13C NMR (101 MHz, 
[D]chloroform) δ/ppm = 152.9, 150.3, 147.7, 146.0, 143.8, 
121.1, 109.9, 82.8, 64.9, 28.5, 27.6; IR (ATR) ν˜ = /cm–1 = 
2977, 2933, 1698, 1590, 1367, 1287, 1246, 1147, 989, 903, 
859, 814, 755, 732, 656; HRMS (ESI): m/z calcd. for 
C16H24N3O2 [M + H]+ 290.1863, found 290.1862. 
tert-Butyl 1-(2-Methylbut-3-en-2-yl)-2-(3-
phenylpropylidene)hydrazine-1-carboxylate (9p): 
Mixture of olefins 8a/8b (237 mg, 1.18 mmol  1.07 mmol of 
isomer 8a) and 3-phenylpropionaldehyde (0.157 mL, 1.18 
mmol) gave N-Boc-N-allylhydrazone 9p (141 mg, 0.446 
mmol, 42 % referred to isomer 8a) as colourless oil via GP1: 
Rf = 0.46 (hexanes/EtOAc, 9:1); 1H NMR (400 MHz, 
[D6]DMSO) δ/ppm = 7.75 (t, 3JH,H = 5.3 Hz, 1H), 7.31–7.22 (m, 
4H), 7.18 (m, 1H), 5.99 (dd, 3JH,H = 17.5, 10.8 Hz, 1H), 4.94 (dd, 
3JH,H = 17.5, 2JH,H = 1.1 Hz, 1H), 4.86 (dd, 3JH,H = 10.8, 2JH,H = 1.1 
Hz, 1H), 2.83 (t, 3JH,H = 7.3 Hz, 2H), 2.59 (ddd, 3JH,H = 7.3, 5.3 
Hz, 2H),1.36 (s, 9H), 1.25 (s, 6H); 13C NMR (101 MHz, 
[D6]DMSO) δ/ppm = 166.7, 153.2, 145.7, 140.9, 128.3, 128.3, 
125.9, 109.4, 80.1, 61.1, 33.9, 31.3, 27.9, 26.4; IR (ATR) ν˜ = 
/cm–1 = 2979, 2929, 1693, 1639, 1455, 1264, 1303, 1241, 
1155, 1101, 903, 870, 856, 748; HRMS (ESI): m/z calcd. for 
C19H29N2O2 [M + H]+ 317.2224, found 317.2229. 
tert-Butyl 1-(2-Methylbut-3-en-2-yl)-2-((E)-3-
phenylallylidene)hydrazine-1-carboxylate (9q): 
Mixture of olefins 8a/8b (250 mg, 1.25 mmol  1.13 mmol of 
isomer 8a) and cinnamaldehyde (0.157 mL, 1.25 mmol) gave 
N-Boc-N-allylhydrazone 9q (228 mg, 0.725 mmol, 64 % 
referred to isomer 8a) as yellow oil via GP1: Rf = 0.56 
(hexanes/EtOAc, 9:1); 1H NMR (500 MHz, [D]chloroform) δ/ 
ppm = 8.33 (dd, 3JH,H = 7.2, 1.5 Hz, 1H), 7.49–7.47 (m, 2H), 
7.38–7.33 (m, 2H), 7.32–7.28 (m, 1H), 6.96–6.93 (m, 2H), 
6.14 (dd, 3JH,H = 17.5, 10.8 Hz, 1H), 5.07–4.92 (m, 2H), 1.47 (s, 
6H), 1.46 (s, 9H); 13C NMR (101 MHz, [D]chloroform) δ/ppm 
= 161.7, 153.7, 146.2, 140.5, 136.2, 128.9, 128.9, 127.2, 
126.0, 109.5, 81.6, 62.9, 28.5, 26.9; IR (ATR) ν˜ = /cm–1 = 
1694, 1449, 1366, 1289, 1243, 1148, 1109, 1051, 973, 906, 
879, 850, 749, 689; HRMS (ESI): m/z calcd. for C19H27N2O2 [M 
+ H]+ 315.2067, found 315.2066. 
General Procedure for the Synthesis of Olefins via 
[3,3]-Sigmatropic Rearrangement (GP2): In an oven 
dried two-necked Schlenk flask HNTf2 (10 mol-%) was 
dissolved in dry diglyme (1 mL). A solution of the appropriate 
N-Boc-N-allylhydrazone 9 (1.0 equiv.) in dry diglyme (2 mL + 
1 mL rinse) was added at room temperature. The reaction 
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mixture was fitted with a N2 flashed reflux condenser and 
immediately heated to 125 °C in a pre-heated oil bath. After 
completion of the rearrangement detected by TLC (75 min), 
the reaction was immediately cooled to room temperature 
via water bath and then quenched with a sat. aq. NaHCO3 
solution (4 mL). Pentane (10 mL) was added and the organic 
layer was washed with at least 100 mL water. The solvent 
was removed in vacuo (30 °C, max. 700 mbar) and the crude 
product was purified by flash column chromatography. 
2-Methyldodec-2-ene (10a): Allylhydrazone 9a (155 mg, 
0.500 mmol) and HNTf2 (14 mg, 0.050 mmol) gave olefin 10a 
(18 mg, 0.099 mmol, 20 %) as colourless oil via GP2: Rf = 0.94 
(pentane); 1H NMR (400 MHz, [D]chloroform) δ/ppm = 5.15–
5.08 (m, 1H), 1.96 (q, 3JH,H = 7.1 Hz, 2H), 1.69 (d, 3JH,H = 1.4 Hz, 
3H), 1.60 (d, 3JH,H = 1.3 Hz, 3H), 1.26 (s, 14H), 0.88 (t, 3JH,H = 
2.9 Hz, 3H). 13C NMR (101 MHz, [D]chloroform) δ/ppm = 
131.3, 125.1, 32.1, 30.1, 29.8, 29.8, 29.5, 29.5, 28.2, 25.9, 
22.9, 17.8, 14.3. IR (ATR) ν˜ = /cm–1 = 2956, 2922, 2853, 1462, 
1376, 1094, 985, 886, 833, 722; HRMS (EI): m/z calcd. for 
C13H26 [M˙]+ 182.2029, found 182.2027. 
2-Methyltridec-2-ene(10b): Allylhydrazone 9b (162
mg, 0.500 mmol) and HNTf2 (14 mg, 0.050 mmol) gave olefin 
10b (19 mg, 0.10 mmol, 21 %) as colourless oil via GP2: Rf = 
0.88 (pentane/Et2O, 9:1); 1H NMR (400 MHz, [D]chloroform) 
δ/ppm = 5.12 (tdt, 3JH,H = 7.2, 1.5 Hz, 1H), 1.96 (q, 3JH,H = 6.8 
Hz, 2H), 1.69 (d, 3JH,H = 1.4 Hz, 3H), 1.60 (d, 3JH,H = 1.3 Hz, 3H), 
1.26 (s, 16H), 0.93–0.83 (m, 3H); 13C NMR (101 MHz, 
[D]chloroform) δ/ppm = 131.3, 125.1, 32.1, 30.1, 29.8, 29.8, 
29.8, 29.5, 29.5, 28.2, 25.9, 22.9, 17.8, 14.3; IR (ATR) ν˜ = 
/cm–1 = 2955, 2922, 2853, 1456, 1376, 1094, 984, 886, 832, 
721, 593, 556; HRMS (EI): m/z calcd. for C14H28 [M˙]+ 
196.2185, found 196.2183. 
2-Methyltetradec-2-ene (10c): Allylhydrazone 9c (169 
mg, 0.500 mmol) and HNTf2 (14 mg, 0.050 mmol) gave olefin 
10c (21 mg, 0.099 mmol, 20 %) as colourless oil via GP2: Rf = 
0.98 (pentane); 1H NMR (400 MHz, [D]chloroform) δ/ppm = 
5.12 (ddt, 3JH,H = 7.1 Hz, 1H), 1.96 (q, 3JH,H = 6.9 Hz, 2H), 1.69 
(s, 3H), 1.60 (s, 3H), 1.26 (br, 18H), 0.88 (t, 3JH,H = 6.8 Hz, 3H); 
13C NMR (101 MHz, [D]chloroform) δ/ppm = 131.3, 125.1, 
34.3, 32.1, 30.1, 29.9, 29.8, 29.8, 29.5, 28.2, 25.9, 22.9, 22.5, 
17.8, 14.3; IR (ATR) ν˜ = /cm–1 = 2958, 2921, 2850, 1461, 
1372, 1260, 1090, 1022, 881, 806, 723; HRMS (EI): m/z calcd. 
for C15H30 [M˙]+ 210.2342, found 210.2347. 
(4-Methylpent-3-en-1-yl)cyclopentane (10f): 
Allylhydrazone 9f (140 mg, 0.500 mmol) and HNTf2 (14 mg, 
0.050 mmol) gave olefin 10f (15 mg, 0.099 mmol, 20 %) as 
colourless oil via GP2: Rf = 0.95 (pentane); 1H NMR (500 MHz, 
[D]chloroform) δ/ppm = 5.15–5.10 (m, 1H), 2.01–1.95 (m, 
2H), 1.77–1.73 (m, 2H), 1.69 (d, 3JH,H = 1.4 Hz, 3H), 1.60 (d, 
3JH,H = 1.2 Hz, 3H), 1.52–1.46 (m, 2H), 1.34–1.30 (m, 2H), 
1.11–1.05 (m, 2H), 0.91–0.86 (m, 3H); 13C NMR (126 MHz, 
[D]chloroform) δ/ppm = 131.1, 125.2, 39.9, 36.6, 32.8, 27.4, 
25.9, 25.4, 17.8; IR (ATR) ν˜ = /cm–1 = 2983, 2950, 2922, 2857, 
1452, 1376, 1105, 985, 907, 830, 735, 650, 574, 560; HRMS 
(EI): m/z calcd. for C11H20 [M˙]+ 152.1559, found 152.1558. 
(4-Methylpent-3-en-1-yl)cyclohexane (10g): 
Allylhydrazone 9g (147 mg, 0.500 mmol) and HNTf2 (14 mg, 
0.050 mmol) gave olefin 10g (17 mg, 0.10 mmol, 20 %) as 
colourless oil via GP2. (4-Methylpent-3-en-1-
yl)cyclohexane (10g, 30 mol-% HNTf2). Allylhydrazone 
9g (127 mg, 0.433 mmol) and HNTf2 (37 mg, 0.13 mmol) 
gave olefin 10g (18 mg, 0.11 mmol, 22 %) as colourless oil 
via GP2. (4-Methylpent-3-en-1-yl)cyclohexane (10g, 
3.00 mmol scale). Allylhydrazone 9g (822 mg, 3.00 mmol) 
and HNTf2 (84 mg, 0.30 mmol) gave olefin 10g (129 mg, 
0.759 mmol, 25 %) as colourless oil via GP2: Rf = 0.91 
(pentane); 1H NMR (500 MHz, [D]chloroform) δ/ppm = 5.15–
5.00 (m, 1H), 2.03–1.91 (m, 2H), 1.75–1.57 (m, 11H), 1.25–
1.15 (m, 6H), 0.92–0.83 (m, 2H); 13C NMR (126 MHz, 
[D]chloroform) δ/ppm = 131.1, 125.3, 37.8, 37.5, 33.5, 26.9, 
26.6, 25.9, 25.5, 17.8; IR (ATR) ν˜ = /cm–1 = 2923, 2852, 1694, 
1448, 1376; HRMS (EI): m/z calcd. for C12H22 [M˙]+ 166.1722, 
found 166.1720. 
(6-Methylhept-5-en-1-yl)benzene (10p): 
Allylhydrazone 9p (217 mg, 0.686 mmol) and HNTf2 (14 mg, 
0.068 mmol) gave olefin 10p (25 mg, 0.13 mmol, 19 %) as 
colourless oil via GP2: Rf = 0.48 (pentane); 1H NMR (400 MHz, 
dichloromethane-d2) δ/ppm = 7.29–7.23 (m, 2H), 7.20–7.13 
(m, 3H), 5.12 (tdt, 3JH,H = 7.2, 1.5 Hz, 1H), 2.60 (t, 3JH,H = 7.7 
Hz, 2H), 2.01 (q, 3JH,H = 7.3 Hz, 2H), 1.68 (d, 3JH,H = 1.4 Hz, 3H), 
1.64–1.58 (m, 5H), 1.41–1.33 (m, 2H); 13C NMR (101 MHz, 
dichloromethane-d2) δ/ppm = 143.6, 131.8, 128.9, 128.7, 
126.1, 125.2, 36.4, 31.8, 30.1, 28.4, 25.9, 17.9; IR (ATR) ν˜ = 
/cm–1 = 3026, 2922, 2853, 1602, 1494, 1451, 1378, 1108, 
1079, 1029, 741, 698, 571; HRMS (EI): m/z calcd. for C14H20 
[M˙]+ 188.1565, found 188.1565. 
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1 Optimisation of reaction conditions (monitoring with 
GC/MS)  
For the optimization of the acid-catalysed rearrangement different temperatures, reaction 
times and acids/solvents were tested. The reactions were monitored by GC/MS analysis.  
1.1 Instrument parameters  
Gas chromatography (GC) was performed on a Varian 3800 gas chromatograph coupled to a 
Saturn 2200 ion trap from Varian (Darmstadt, Germany). The autosampler was from CTC 
Analytics (Zwingen, Switzerland) and the split/splitless injector was a Varian 1177 (Darmstadt, 
Germany). Instrument control and data analysis were carried out with Varian Workstation 6.9 
SP1 software (Darmstadt, Germany). A Varian VF-5-ms capillary column of 30 m length, 0.25 
mm i.d. and 0.25 µm film thickness (Darmstadt, Germany) was used at a constant flow rate of 
1.4 mL/min. Carrier gas was helium 99.999% from Air Liquide (Düsseldorf, Germany). The 
inlet temperature was kept at 300 °C and injection volume was 1 µL with splitless time 1.0 min. 
The initial column temperature was 50 °C and was held for 1.0 min. Then the temperature was 
ramped up to 250 °C with 50 °C/min. Then the products were eluted at a rate of 5 °C/min until 
310 °C (hold time 3 min). Total run time was 20 min. Transfer line temperature was 300 °C 
and the ion trap temperature was 150 °C. The ion trap was operated with electron ionization 
(EI) at 70 eV in scan mode (m/z 50 - 650) with a solvent delay of 6.3 min.  
1.2 Experimental procedure  
In an oven-dried reaction tube the appropriate catalyst (10 mol %) was dissolved in the 
appropriate solvent (1.3 mL). A solution of the N-Boc-N-allylhydrazone 9g (14.7 mg, 0.050 
mmol, 1.0 eq) in dry diglyme was added. Further cholestane in dry diglyme was added as 
internal standard (IS, final concentration 5 µg/mL in the test tube) at room temperature. The 
reaction tube was purged with N2, closed and then immediately heated at the corresponding 
temperature. After 15, 45 and 75 min samples (3 x 60 µL) were taken. The reaction mixture 
was neutralised with sat. aq. NaHCO3 solution (60 µL) and water (1.0 mL) was added. The 
aqueous phase was extracted with methyl tert-butyl ether (MtBE) (1 x 500 µL). The organic 
layer was dried with Na2SO4 and 300 µL were transferred into an autosampler vial. After 
dilution with additional 300 µL MtBE the solution was analysed by GC/MS.  
1.3 Quantification  
For the quantification of the reaction product 10g, a standard curve with five levels (10-100 
µg/mL) of product 10g and a constant level of IS was used (n = 3; R² > 0.996). The 
corresponding standard curve was measured on the same day the samples were analysed.   
With this method only the concentration of product 10g can be measured, but not the 
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concentration of any side product, as these may have different ionisation properties. As a 
result, the complete mass balance of this reaction cannot be determined.  
  
1.4 Optimisation of reaction conditions for temperature and time  
To examine the effect of temperature and time on the yield of product 10g the reactions were 
carried out at five different temperatures (23 °C, 50 °C, 75 °C, 100 °C and 125 °C) in diglyme 
with HNTf2. The yield of 10g was determined via GC/MS as described above (see chapter 1.1- 
1.3) after 15, 45 and 75 min (n = 3). The results of this experiment are shown in Figure S1.  
 
  
Figure S1. Yields of the optimisation reactions at 23 °C, 50 °C, 75 °C, 100 °C, and 125 °C after 
different reaction times.   
  
The reaction proceeds best at 125 °C and after 75 min. Under these conditions a yield of 31% 
was observed. Longer reaction times were not tested, because at this time only 
Bocdeprotected allylhydrazone was observed, which does not undergo the desired 
rearrangement. Higher temperatures were not tested, because of a possible decomposition of 
the final products.  
    
1.5 Optimisation of reaction conditions for different solvents and catalysts   
To examine the effect of different solvents and catalysts on the yield of product 10g the 
reactions were carried out in THF (70 °C) and diglyme (125 °C). Each solvent was tested with 
three different catalysts (HNTf2, TfOH and TFA). The yield of 10g was determined via GC/MS 
as described above (see chapter 1.1-1.3) after 15, 45 and 75 min (n = 3). The results of this 
experiment are shown in Figure S2.   
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Figure S2. Yields of the optimisation reactions under different conditions after different reaction times.  
The reaction proceeds best with HNTf2 in diglyme at 125 °C and after 75 min a yield of 24%, which 
varies slightly to the value in chapter 1.4, was obtained.  
  
1.6 Optimisation results of reaction conditions  
 









aThe reactions were performed with 0.05 mmol of 9g, entries 1-15: HNTf2 in diglyme with variation of 
the reaction, entries 16-33: variation of catalyst and solvent. bThe yields were determined by GC/MS 
using cholestane as internal standard (see Supporting Information). cEntries 1-15 were performed on 




2 Synthesis of the N-ethoxycarbonyl-N-allylhydrazine 
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Scheme S1. Synthesis of the N-ethoxycarbonyl-N-allylhydrazine building block S5a and two model 
allylhydrazones S6g and S6i  
  






To a solution of ethyl carbazate (5.2 g, 49 mmol, 1.0 eq) and N-methylmorpholine (5.5 mL, 49 
mmol, 1.0 eq) in THF, 2,2,2-trichloroethylchloroformat (6.9 mL, 49 mmol, 1.0 eq) was added 
at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 24 h. 
The suspension was filtered and the filtrate concentrated in vacuo. Purification by flash column 
chromatography (hexanes/EtOAc 7:3) gave hydrazine S1 (14 g, 49 mmol, quantitative) as a 
colourless oil: Rf = 0.28 (hexanes/EtOAc 7:3); 1H NMR (400 MHz, chloroform-d) δ/ppm = 7.10  
(s, 1H), 6.73 (s, 1H), 4.78 (s, 2H), 4.21 (q, 3JH,H = 7.2 Hz, 2H), 1.27 (t, 3JH,H = 7.1 Hz, 3H); 13C  
NMR (101 MHz, chloroform-d) δ/ppm = 156.6, 155.3, 94.9, 75.2, 62.7, 14.5; IR (ATR) ṽ/cm-1 = 
3258, 1762, 1735, 1697, 1524, 1441 1367, 1259, 1208, 1095, 1053, 1023, 978, 886, 824, 776, 
737, 707; HRMS (EI): m/z  = calcd for C6H9O4N2Cl3 [M]•+ 277.9622, found 277.9617.  
  
1-Ethyl 2-(2,2,2-trichloroethyl) diazene-1,2-dicarboxylate (S2)  
  
 
Hydrazine S1 (14.6 g, 52.2 mmol, 1.0 eq) was dissolved in toluene (120 mL), then pyridine 
(4.22 mL, 52.2 mmol, 1.0 eq) and NBS (9.30 g, 52.2 mmol, 1.0 eq) were added. The reaction 
mixture was stirred for 3 h at room temperature. The mixture was diluted with toluene (50 mL), 
washed with water (120 mL), sat. aq. Na2S2O3 solution (100 mL), 1M aq. HCl (100 mL), sat. 
aq. NaHCO3 solution (100 mL), water (100 mL) and brine (110 mL). The organic layer was 
dried over Na2SO4, filtered and the solvent was removed in vacuo. Azodicarboxylate S2 (13.4 
g, 48.3 mmol, 92%) was obtained as an orange oil and was used without further purification: 
Rf = 0.75 (hexanes/EtOAc 7:3); 1H NMR (400 MHz, chloroform-d) δ/ppm = 5.03 (s, 2H), 4.54 
(q, 3JH,H = 7.1 Hz, 2H), 1.47 (t, 3JH,H = 7.1 Hz, 3H); 13C NMR (101 MHz, chloroform- d) δ/ppm 
= 159.9, 159.0, 93.4, 76.9, 65.9, 14.2; IR (ATR) ṽ/cm-1 = 1770, 1370, 1200, 1097, 1059, 1015, 
854, 801, 718; HRMS (EI): m/z calcd for C6H7O4N2Cl3 [M]·+ 275.9466; found 275.9458.  
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 1-Ethyl 2-(2,2,2-trichloroethyl) 1-(2-methyl-1-oxopropan-2-yl)hydrazine-
1,2dicarboxylate (S3a) and 2-ethyl 1-(2,2,2-trichloroethyl) 1-(2-methyl-1-oxopropan-
2yl)hydrazine-1,2-dicarboxylate (S3b)  
  
 
Azodicarboxylate S2 (6.0 g, 22 mmol, 1.0 eq) and L-proline (249 mg, 2.16 mmol, 10 mol %) 
were disperged in dry methylene chloride (120 mL) and the suspension was cooled to 0 °C. 
Isobutyraldehyde (2.96 mL, 32.4 mmol, 1.5 eq) was added and the reaction mixture was 
allowed to warm to room temperature and stirred for 18 h. The solvent was removed in vacuo 
and the title compound was purified by flash column chromatography (hexanes/EtOAc 7:3). 
An inseparable mixture of aldehydes S3a/S3b (3.23 g, 9.24 mmol, 43%) were obtained as a 
colourless oil in an isomeric mixture of 85:15 (determined retrospectively via 1H NMR 
spectroscopy): Rf = 0.75 (hexanes/EtOAc 7:3); 1H NMR (400 MHz, chloroform-d) δ/ppm = 9.51 (s, 
1H), 7.02 – 6.57 (m, 1H), 4.78 (d, 2JH,H = 31.6 Hz, 2H), 4.20 (dd, 3JH,H = 7.1, 2JH,H = 2.4 Hz, 2H), 1.47 – 
1.20 (m, 9H); 13C NMR (101 MHz, chloroform-d) δ/ppm = 198.1, 155.6, 155.2, 95.0, 75.1, 67.7, 
63.6, 20.4, 14.4; IR (ATR) ṽ/cm-1 = 3306, 1733, 1707, 1514, 1469, 1407, 1379, 1342, 1216, 
1173, 1096, 1047, 818, 757, 719; HRMS (ESI): m/z calcd for C10H16O5N2Cl3 [M+H]+ 349.0119; 
found 349.0123.  
  
1-Ethyl 2-(2,2,2-trichloroethyl) 1-(2-methylbut-3-en-2-yl)hydrazine-1,2-dicarboxylate 
(S4a) and 2-ethyl 1-(2,2,2-trichloroethyl) 1-(2-methylbut-3-en-2-yl)hydrazine-
1,2dicarboxylate (S4b)  
 
  
The isomeric mixture of aldehydes S3a/S3b (3.1 g, 8.9 mmol, 1.0 eq) and pyridine (1.3 mL, 
16 mmol, 1.8 eq) were added to a flame dried flask and cooled to -80 °C.  Tebbe reagent (0.5M 
in toluene, 23.1 mL, 11.5 mmol, 1.3 eq) was added carefully by adding it along the flask. The 
reaction mixture was allowed to warm up to 0 °C and stirred 24 h. The reaction was quenched 
with a saturated aqueous NaHCO3 solution (6 mL) at -80 °C and extracted with methylene 
chloride (3 x 30 mL). The combined organic layers were dried over MgSO4, filtered and the 
solvent was removed in vacuo. Purification by flash column chromatography (hexanes/EtOAc 
9:1 → 8:2) gave an inseparable mixture of olefines S4a/S4b (556 mg, 1.60 mmol, 18%) as a 
colourless oil in an isomeric mixture of 85:15 (determined retrospectively via 1H NMR 
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spectroscopy): Rf = 0.39 (hexanes/EtOAc 8:2); 1H NMR (400 MHz, chloroform-d) δ/ppm = 6.63 
(s, 1H), 6.10 (dd, 3JH,H = 17.5, 10.7 Hz, 1H), 5.10 (dd, 3JH,H = 17.9, 2JH,H = 6.7 Hz, 1H), 5.03 
(dd, 3JH,H = 10.7, 2JH,H = 6.7 Hz, 1H), 4.90 – 4.68 (m, 2H), 4.19 – 4.09 (m, 2H), 1.52 (s, 3H), 
1.45 (s, 3H), 1.25 – 1.20 (m, 3H); 13C NMR (101 MHz, chloroform-d) δ/ppm = 155.4, 155.2, 
143.8, 111.8, 74.9, 63.2, 62.4, 26.3, 26.1, 23.9, 14.5; IR (ATR) ṽ/cm-1 = 3291, 2985, 1749, 
1695, 1517, 1403, 1375, 1338, 1251, 1216, 1181, 1096, 1051, 915, 821, 765, 739, 719; HRMS 
(ESI): m/z calcd for C11H16O4N2Cl3 [M-H]- 345.0181; found 345.0182.  
  
Ethyl 1-(2-methylbut-3-en-2-yl)hydrazine-1-carboxylate (S5a) and ethyl 2-(2-




The mixture of olefins S4a/S4b (550 mg, 1.58 mmol, 1.0 eq) was dissolved in a mixture of 
ethanol (1.0 mL), water (1.0 mL) and acetic acid (1.0 mL). Zinc powder (3.62 g, 55.4 mmol, 
35.0 eq) was added and the reaction mixture was stirred for 10 min at room temperature. After 
filtration of the reaction mixture, the filtrate was extracted with methylene chloride (3 x 10 mL).  
The combined organic layers were washed was saturated aqueous NaHCO3 solution (15 mL) 
and dried over MgSO4, filtered and the solvent was removed in vacuo. S5a/S5b (167 mg, 
0.970 mmol, 61%) was obtained as a colourless oil in an isomeric mixture of 85:15 (determined 
via 1H NMR spectroscopy). This mixture was used for the next step without purification.  Rf = 
0.47 (hexanes/EtOAc 8:2); 1H NMR (S5a) (500 MHz, chloroform-d) δ/ppm = 6.05 (dd, 3JH,H = 
17.5, 10.7 Hz, 1H), 5.01 – 4.92 (m, 2H), 4.13 (q, 3JH,H = 7.2 Hz, 2H), 3.80 (s, 2H), 1.44 (s, 6H), 
1.25 (t, 3JH,H = 7.1 Hz, 3H); 13C NMR (S5a) (101 MHz, chloroform-d) δ/ppm = 157.9, 145.3, 
109.9, 61.9, 61.7, 26.5, 14.7; 1H NMR (S5b) (500 MHz, chloroform-d) δ/ppm = 5.97 (dd, 3JH,H 
= 17.4, 10.7 Hz, 1H), 5.14 – 5.05 (m, 2H), 4.10 – 4.04 (m, 2H), 1.39 (s, 6H), 1.23 – 1.20 (m, 
3H); 13C NMR (S5b) (101 MHz, chloroform-d) δ/ppm = 155.8, 144.2, 111.8, 61.5, 53.6, 26.5, 
14.5; IR (ATR) ṽ/cm-1 = 2980, 1686, 1465, 1400, 1374, 1318, 1246, 1181, 1081, 1007, 910, 
859, 769, 686; HRMS (ESI): m/z calcd for C8H17O2N2 [M+H]+ 173.1285; found 173.1283.  
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Ethyl 2-(cyclohexylmethylene)-1-(2-methylbut-3-en-2-yl)hydrazine-1-carboxylate (S6g)  
  
 
The mixture of allylhydrazines S5a/S5b (200 mg, 1.16 mmol  0.986 mmol of isomer S5a, 1.0 
eq) was dissolved in absolute EtOH (15 mL) and cyclohexane carboxaldehyde (130 mg, 1.16 
mmol, 1.0 eq) was added. The reaction mixture was stirred at room temperature for 18 h. The 
solvent was removed in vacuo and the crude product was purified by flash column 
chromatography (pentane/Et2O 9:1). N-CO2Et-N-allylhydrazone S6g was isolated as 
colourless oil (115 mg, 0.432 mmol, 44% referred to isomer S5a).   
Rf = 0.32 (pentane/Et2O 9:1); 1H NMR (400 MHz, chloroform-d) δ/ppm = 7.60 (d, 3JH,H = 6.0 
Hz, 1H), 6.11 (dd, 3JH,H = 17.5, 10.8 Hz, 1H), 5.10 – 4.90 (m, 2H), 4.07 (q, 3JH,H = 7.1 Hz, 2H), 
2.42 – 2.32 (m, 1H), 1.89 – 1.62 (m, 6H), 1.41 (s, 6H), 1.37 – 1.28 (m, 4H), 1.20 (t, 3JH,H = 7.1 
Hz, 3H); 13C NMR (101 MHz, chloroform-d) δ/ppm = 173.9, 154.9, 145.4, 110.1, 61.9, 61.4, 
41.4, 29.7, 26.5, 26.1, 25.4, 14.5; IR (ATR) ṽ/cm-1 =2979, 2927, 2853, 1699, 1448, 1369, 1281, 
1240, 1177, 1097, 1004, 911, 758, 684; HRMS (EI): m/z calcd for C15H26O2N2 [M]·+ 266.1989; 
found 266.1989.  
  
Ethyl 2-benzylidene-1-(2-methylbut-3-en-2-yl)hydrazine-1-carboxylate (S6b)  
  
 
The mixture of allylhydrazines S5a/S5b (200 mg, 1.16 mmol  0.986 mmol of isomer S5a,  
1.0 eq) was dissolved in absolute EtOH (15 mL) and benzaldehyde (123 mg, 1.16 mmol, 1.0 
eq) was added. The reaction mixture was stirred at room temperature for 17 h. The solvent 
was removed in vacuo and the crude product was purified by flash column chromatography 
(pentane/Et2O 9:1). N-CO2Et-N-allylhydrazone S6i was isolated as colourless oil (234 mg, 
0.899 mmol, 91% referred to isomer S5a).   
Rf = 0.38 (pentane/Et2O 9:1); 1H NMR (500 MHz, chloroform-d) δ/ppm = 8.60 (s, 1H), 7.74 –  
7.70 (m, 2H), 7.44 – 7.38 (m, 3H), 6.18 (dd, 3JH,H = 17.5, 10.8 Hz, 1H), 5.11 – 4.96 (m, 2H), 
4.17 (q, 3JH,H = 7.1  Hz, 2H), 1.53 (s, 6H), 1.25 (t, 3JH,H = 7.1 Hz, 3H); 13C NMR (101 MHz, 
chloroform-d) δ/ppm = 159.0, 154.6, 145.7, 134.9, 130.5, 128.7, 127.8, 110.0, 63.6, 61.7, 26.9, 
14.5; IR (ATR) ṽ/cm-1 = 1698, 1597, 1455, 1368, 1282, 1202, 1166, 1098, 1073, 1015, 906, 
827, 743, 687; HRMS (ESI): m/z calcd for C15H21O2N2 [M+H]+ 261.1597; found 261.1596.  
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3 Crystallographic data  
  
3.1. Sample preparation  
To receive crystals out of the oily isomeric mixture of 8a and 8b, 80 mg of the neat mixture 
were placed in a 5 mL round bottom flask and cooled to - 20 °C. After seven days, crystals of 
8a were grown as colourless needles. The crystals are stable at room temperature for one 
day.   
  
3.2. Crystallographic information of 
8a  
Table S2. Crystallographic information of 8a  
Compound 8a 
 CCDC 1907495 
net formula C10H20N2O2 
Mr/g mol−1  200.28  
crystal size/mm  0.100 × 0.060 × 0.050  
T/K  103.(2)  
radiation  MoKα  
diffractometer  'Bruker D8 Venture TXS'  
crystal system  triclinic  
space group  'P -1'  
a/Å  5.9860(5)  
b/Å  9.0630(7)  
c/Å  11.4665(9)  
α/°  105.616(3)  
β/°  99.965(3)  
γ/°  97.087(3)  
V/Å3  580.52(8)  
Z  2  
calc. density/g cm−3  1.146  
μ/mm−1  0.080  
absorption correction  Multi-Scan  
transmission factor range  0.95–1.00  
refls. measured  5785  
Rint  0.0312  
mean σ(I)/I  0.0416  
θ range  3.444–26.370  
observed refls.  1982  
x, y (weighting scheme)  0.0299, 0.2047  
hydrogen refinement  H(C) constr, H(N) refall  
refls in refinement  2368  
parameters  140  
restraints  0  
R(Fobs)  0.0411  
Rw(F2)  0.0961  
S  1.072  
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shift/errormax  0.001  
max electron density/e Å−3 0.242 min 





Figure S3. Mercury plot of the solid-state structure of compound 8a 
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4 NMR spectra   
 
Figure S4. 500 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 6a/6b in CDCl3.  
 
6. Traceless isoprenylation 
176 
 
Figure S5. 500 MHz 1H NMR spectrum (top) and 126 MHz 13C NMR spectrum (bottom) of 7a/7b in CDCl3.   
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Figure S6. 400 MHz 1H NMR spectrum (top) and 126 MHz 13C NMR spectrum (bottom) of 8a/8b (ratio 91:9) in 
DMSO-d6.




Figure S7. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 9a in CDCl3.   
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Figure S8. 500 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 9b in CDCl3.   
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Figure S9. 500 MHz 1H NMR spectrum (top) and 126 MHz 13C NMR spectrum (bottom) of 9c in CDCl3.   
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 Figure S10. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 9d 
in CDCl3.  
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Figure S11. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 9e 
in CDCl3 
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Figure S12. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 9f 
in CDCl3 
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Figure S13. 500 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
9g in CDCl3. 
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Figure S14. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
9h in CDCl3. 
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Figure S15. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
9i in CDCl3. 
6. Traceless isoprenylation 
187 
 
Figure S16. 500 MHz 1H NMR spectrum (top) and 126 MHz 13C NMR spectrum (bottom) of 9j 
in CDCl3. 
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Figure S17. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 9k 
in CDCl3. 
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Figure S18. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
9l in CDCl3. 
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Figure S19. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
9m in CDCl3. 
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Figure S20. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
9n in CDCl3. 
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Figure S21. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
9o in CDCl3. 
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Figure S22. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
9p in DMSO-d6 
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Figure S23. 500 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
9q in CDCl3 
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Figure S24. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
10a in CDCl3. 
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Figure S25. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
10b in CDCl3. 
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Figure S26. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
10c in CDCl3. 
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Figure S27. 500 MHz 1H NMR spectrum (top) and 126 MHz 13C NMR spectrum (bottom) of 
10f in CDCl3. 
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Figure S28. 500 MHz 1H NMR spectrum (top) and 126 MHz 13C NMR spectrum (bottom) of 
10g in CDCl3. 
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Figure S29. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
10p in CD2Cl2. 
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Figure S30. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
S1 in CDCl3. 
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Figure S31. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
S2 in CDCl3. 
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Figure S32. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
S3a/S3b in CDCl3. 
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Figure S33. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
S4a/S4b in CDCl3. 
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Figure S34. 500 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
S5a/S5b in CDCl3. 
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Figure S35. 400 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 
S6g in CDCl3. 
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Figure S36. 500 MHz 1H NMR spectrum (top) and 101 MHz 13C NMR spectrum (bottom) of 





Monitoring pathological changes of the steroid profile could lead to a better understanding of 
the progression of diseases like Alzheimer’s disease. So, the aim of this work was the 
development of a comprehensive analytical method that could provide a wide overview of the 
sterolome of a specific tissue or cultured cells. In the end, an effective sample preparation 
protocol was developed and validated for 37 steroidal compounds of five different steroid 
classes. The scope of this method includes cholesterol precursors, oxysterols, neurosteroids, 
steroid acids and sterol sulfates. While other published methods focus on one or two of these 
subgroups, this new method can give an extensive overview of the sterolome. The 
corresponding article (Chapter 4) was submitted for publication in the Journal of Steroid 
Biochemistry and Molecular Biology and currently the revised manuscript is under review. In 
order to achieve this goal, some obstacles had to be overcome. One problem was the GC-MS 
measurement of sterol sulfates. Especially for this steroid class, several different 
deconjugation and derivatization procedures were evaluated and finally, a new and 
straightforward protocol for direct MO-TMS derivatization was found and published (Chapter 
3). As sterol sulfates and unconjugated sterols were both measured as unconjugated MO-TMS 
derivatives, they had to be separated before deconjugation and derivatization. Also, the group 
of steroid acids needed to be separated due to different derivatization procedures. The 
necessary steroid group separation was accomplished by a newly developed SPE protocol 
that was included in the novel sample preparation procedure (Chapter 4). Another difficulty 
was the partly huge concentration difference of the analytes. Therefore, the processed 
samples needed to be analyzed on two different GC-MS systems in scan mode and in dMRM 
mode. This approach allowed untargeted screening as well as highly sensitive analysis of 
steroids of interest at trace levels. For scan analysis, a mass spectral library was created that 
contained mainly steroids of interest, defined by the group of Prof. Dr. Harald Steiner at DZNE. 
Additionally, cholesterol precursors could be integrated. Those had already been part of a 
previously published assay for cholesterol biosynthesis inhibitors in Nature Protocols, in which 
I contributed by creating the mass spectral library (Chapter 5). In addition to the creation of the 
mass spectral library, the transitions and collision energies for analysis in dMRM mode were 
optimized individually for each compound. This was the first method transfer from an IT-mass 
spectrometer (scan) to a qQq-mass spectrometer (dMRM) that was performed within our 
working group. Finally, the method was validated and applied to different biological samples 
including brain tissue, liver tissue and cultured cells. The levels of several endogenous 
compounds were measured and compared to literature data wherever possible. Some 
endogenous concentrations had never been reported before. Beside the analysis of biological 
samples, I contributed to a chemical synthesis article which demonstrated a new traceless 
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bond synthesis for isoprenylated products (Chapter 6). In this case I analyzed the synthesis 






AD Alzheimer’s disease 
APP Amyloid precursor protein 
Aβ amyloid β 
CHILD Congenital Hemidysplasia with Ichthyosiform nevus and Limb Defects 
CNS central nervous system  
CoA Coenzyme A 
CTX cerebrotendinous xanthomatosis  
dMRM dynamic multiple reaction monitoring 
DZNE Deutsches Zentrum für neurodegenerative Erkrankungen 
GABAA γ-aminobutyric acid 
GC-MS gas chromatography-mass spectrometry 
HDL high density lipoprotein  
HMG 3.Hydroxy-3-methylglutaryl 
IPP Isopentenyl diphosphate 
IT ion trap 
LC-MS liquid chromatography-mass spectrometry 
LDL low density lipoprotein 
LXR liver X receptor 
MO-TMS methyl oxime-trimethyl silyl 
MS mass spactrometry 
MS/MS tandem MS 
MSTFA N-methyl-N-trimethylsilyl acetamide 
MtBE methyl-tert-butyl ether 
NMDA N-methyl-D-aspartate 
NPC Niemann-Pick type C 
QqQ triple quadrupole 
RIA radioimmunoassays 
RRT relative retention time 
SFC-MS supercritical fluid chromatography- mass spectrometry 
SLOS Smith-Lemli-Opitz syndrome 
SPE solid phase extraction 
TFA trifluoroacetyl 
TFAA trifluoroacetic anhydride 
TMS trimethylsilyl 
TRPM melastatin-like transient receptor potential channels 
TSIM trimethylsilyl imidazole 
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